<!DOCTYPE html><html lang="en" class="bg-surface-base antialiased"><head><meta charSet="utf-8"/><meta name="viewport" content="width=device-width, initial-scale=1, interactive-widget=resizes-content"/><link rel="stylesheet" href="/_next/static/css/62c4caba71dfda84.css" nonce="ZTYwMmJhNmYtNzA2Mi00ODJjLTkyZWMtZTEyMjYyYjIxODZj" data-precedence="next"/><link rel="stylesheet" href="/_next/static/css/eb3d87f98fe1565f.css" nonce="ZTYwMmJhNmYtNzA2Mi00ODJjLTkyZWMtZTEyMjYyYjIxODZj" data-precedence="next"/><link rel="stylesheet" href="/_next/static/css/1b5e561215938d4d.css" nonce="ZTYwMmJhNmYtNzA2Mi00ODJjLTkyZWMtZTEyMjYyYjIxODZj" data-precedence="next"/><link rel="stylesheet" href="/_next/static/css/0227d069a630d414.css" nonce="ZTYwMmJhNmYtNzA2Mi00ODJjLTkyZWMtZTEyMjYyYjIxODZj" data-precedence="next"/><link rel="stylesheet" href="/_next/static/css/f87fff2ab93d05a7.css" nonce="ZTYwMmJhNmYtNzA2Mi00ODJjLTkyZWMtZTEyMjYyYjIxODZj" data-precedence="next"/><link rel="preload" as="script" fetchPriority="low" nonce="ZTYwMmJhNmYtNzA2Mi00ODJjLTkyZWMtZTEyMjYyYjIxODZj" href="/_next/static/chunks/webpack-e121ed42680f327e.js"/><script src="/_next/static/chunks/78a669d9-e7993486b22c4915.js" async="" nonce="ZTYwMmJhNmYtNzA2Mi00ODJjLTkyZWMtZTEyMjYyYjIxODZj"></script><script src="/_next/static/chunks/40c4a5a7-abdabb07419d1cfc.js" async="" nonce="ZTYwMmJhNmYtNzA2Mi00ODJjLTkyZWMtZTEyMjYyYjIxODZj"></script><script src="/_next/static/chunks/2230-f7c87dc9fa57c408.js" async="" nonce="ZTYwMmJhNmYtNzA2Mi00ODJjLTkyZWMtZTEyMjYyYjIxODZj"></script><script src="/_next/static/chunks/main-app-536d4b8fca62396a.js" async="" nonce="ZTYwMmJhNmYtNzA2Mi00ODJjLTkyZWMtZTEyMjYyYjIxODZj"></script><script src="/_next/static/chunks/63f0ec43-8ee6a76d70472249.js" async="" nonce="ZTYwMmJhNmYtNzA2Mi00ODJjLTkyZWMtZTEyMjYyYjIxODZj"></script><script src="/_next/static/chunks/7670-7326298c9856172b.js" async="" nonce="ZTYwMmJhNmYtNzA2Mi00ODJjLTkyZWMtZTEyMjYyYjIxODZj"></script><script src="/_next/static/chunks/282-691fffb366e24ca5.js" async="" nonce="ZTYwMmJhNmYtNzA2Mi00ODJjLTkyZWMtZTEyMjYyYjIxODZj"></script><script src="/_next/static/chunks/7515-336759ef5dad2b52.js" async="" nonce="ZTYwMmJhNmYtNzA2Mi00ODJjLTkyZWMtZTEyMjYyYjIxODZj"></script><script src="/_next/static/chunks/927-34e2a6da3e15e26b.js" async="" nonce="ZTYwMmJhNmYtNzA2Mi00ODJjLTkyZWMtZTEyMjYyYjIxODZj"></script><script src="/_next/static/chunks/5855-243eeca8f0e4cabd.js" async="" nonce="ZTYwMmJhNmYtNzA2Mi00ODJjLTkyZWMtZTEyMjYyYjIxODZj"></script><script src="/_next/static/chunks/4393-1c8dff25ec904469.js" async="" nonce="ZTYwMmJhNmYtNzA2Mi00ODJjLTkyZWMtZTEyMjYyYjIxODZj"></script><script src="/_next/static/chunks/2225-454cf9f44775e7ce.js" async="" nonce="ZTYwMmJhNmYtNzA2Mi00ODJjLTkyZWMtZTEyMjYyYjIxODZj"></script><script src="/_next/static/chunks/7618-43536a8fb0dd3bfe.js" async="" nonce="ZTYwMmJhNmYtNzA2Mi00ODJjLTkyZWMtZTEyMjYyYjIxODZj"></script><script src="/_next/static/chunks/app/page/%5Bslug%5D/layout-55a344716dd57c44.js" async="" nonce="ZTYwMmJhNmYtNzA2Mi00ODJjLTkyZWMtZTEyMjYyYjIxODZj"></script><script src="/_next/static/chunks/7720-3a1e7e411adba2d3.js" async="" nonce="ZTYwMmJhNmYtNzA2Mi00ODJjLTkyZWMtZTEyMjYyYjIxODZj"></script><script src="/_next/static/chunks/7086-1f1c4891d766e04f.js" async="" nonce="ZTYwMmJhNmYtNzA2Mi00ODJjLTkyZWMtZTEyMjYyYjIxODZj"></script><script src="/_next/static/chunks/app/page/%5Bslug%5D/not-found-69a3edc7db5749d6.js" async="" nonce="ZTYwMmJhNmYtNzA2Mi00ODJjLTkyZWMtZTEyMjYyYjIxODZj"></script><script src="/_next/static/chunks/app/global-error-4d07d20223cd4b4c.js" async="" nonce="ZTYwMmJhNmYtNzA2Mi00ODJjLTkyZWMtZTEyMjYyYjIxODZj"></script><script src="/_next/static/chunks/8208b75a-a48e5a4507a0de91.js" async="" nonce="ZTYwMmJhNmYtNzA2Mi00ODJjLTkyZWMtZTEyMjYyYjIxODZj"></script><script src="/_next/static/chunks/5497-ab85ef3ea59dd353.js" async="" nonce="ZTYwMmJhNmYtNzA2Mi00ODJjLTkyZWMtZTEyMjYyYjIxODZj"></script><script src="/_next/static/chunks/6281-c6e84786dade3614.js" async="" nonce="ZTYwMmJhNmYtNzA2Mi00ODJjLTkyZWMtZTEyMjYyYjIxODZj"></script><script src="/_next/static/chunks/2660-d983a7f287e89f18.js" async="" nonce="ZTYwMmJhNmYtNzA2Mi00ODJjLTkyZWMtZTEyMjYyYjIxODZj"></script><script src="/_next/static/chunks/5002-9735c25beda556ba.js" async="" nonce="ZTYwMmJhNmYtNzA2Mi00ODJjLTkyZWMtZTEyMjYyYjIxODZj"></script><script src="/_next/static/chunks/3655-6717081f7512305a.js" async="" nonce="ZTYwMmJhNmYtNzA2Mi00ODJjLTkyZWMtZTEyMjYyYjIxODZj"></script><script src="/_next/static/chunks/8945-e4e3cf487f5e27c7.js" async="" nonce="ZTYwMmJhNmYtNzA2Mi00ODJjLTkyZWMtZTEyMjYyYjIxODZj"></script><script src="/_next/static/chunks/9214-a10614844a67ba31.js" async="" nonce="ZTYwMmJhNmYtNzA2Mi00ODJjLTkyZWMtZTEyMjYyYjIxODZj"></script><script src="/_next/static/chunks/4789-2080f6497f78b5b6.js" async="" nonce="ZTYwMmJhNmYtNzA2Mi00ODJjLTkyZWMtZTEyMjYyYjIxODZj"></script><script src="/_next/static/chunks/app/layout-226f2bd71acf9f9e.js" async="" nonce="ZTYwMmJhNmYtNzA2Mi00ODJjLTkyZWMtZTEyMjYyYjIxODZj"></script><script src="/_next/static/chunks/24cf1b50-159cca90b09285e0.js" async="" nonce="ZTYwMmJhNmYtNzA2Mi00ODJjLTkyZWMtZTEyMjYyYjIxODZj"></script><script src="/_next/static/chunks/9ffa21ba-c069766d809bd4c7.js" async="" nonce="ZTYwMmJhNmYtNzA2Mi00ODJjLTkyZWMtZTEyMjYyYjIxODZj"></script><script src="/_next/static/chunks/600-9a9fcafaaa6c1c4c.js" async="" nonce="ZTYwMmJhNmYtNzA2Mi00ODJjLTkyZWMtZTEyMjYyYjIxODZj"></script><script src="/_next/static/chunks/5448-2a3cfd853d899c9a.js" async="" nonce="ZTYwMmJhNmYtNzA2Mi00ODJjLTkyZWMtZTEyMjYyYjIxODZj"></script><script src="/_next/static/chunks/8-8ca70ca619d8e099.js" async="" nonce="ZTYwMmJhNmYtNzA2Mi00ODJjLTkyZWMtZTEyMjYyYjIxODZj"></script><script src="/_next/static/chunks/app/page/%5Bslug%5D/page-540a27b6839afde5.js" async="" nonce="ZTYwMmJhNmYtNzA2Mi00ODJjLTkyZWMtZTEyMjYyYjIxODZj"></script><script src="/_next/static/chunks/app/error-4a29e9399afba038.js" async="" nonce="ZTYwMmJhNmYtNzA2Mi00ODJjLTkyZWMtZTEyMjYyYjIxODZj"></script><script src="/_next/static/chunks/app/not-found-dd95690acf732f18.js" async="" nonce="ZTYwMmJhNmYtNzA2Mi00ODJjLTkyZWMtZTEyMjYyYjIxODZj"></script><meta name="next-size-adjust" content=""/><title>Grokipedia</title><meta name="description" content="Grokipedia is an open source, comprehensive collection of all knowledge."/><link rel="icon" type="image/x-icon" href="/favicon.ico" sizes="48x48"/><link rel="icon" href="/images/icon-dark.png" media="(prefers-color-scheme: light)" type="image/png"/><link rel="icon" href="/images/icon-light.png" media="(prefers-color-scheme: dark)" type="image/png"/><link rel="apple-touch-icon" href="/icon-192x192.png"/><link rel="manifest" href="/manifest.webmanifest"/><meta name="robots" content="index, follow"/><meta name="googlebot" content="index, follow, max-snippet:-1"/><meta property="og:title" content="Grokipedia"/><meta property="og:description" content="Grokipedia is an open source, comprehensive collection of all knowledge."/><meta property="og:url" content="https://grokipedia.com"/><meta property="og:site_name" content="Grokipedia"/><meta property="og:locale" content="en_US"/><meta property="og:type" content="website"/><meta property="og:image" content="https://grokipedia.com/icon-512x512.png"/><meta property="og:image:width" content="512"/><meta property="og:image:height" content="512"/><meta property="og:image:alt" content="Grokipedia"/><meta name="twitter:card" content="summary"/><meta name="twitter:creator" content="@Grokipedia"/><meta name="twitter:title" content="Grokipedia"/><meta name="twitter:description" content="Grokipedia is an open source, comprehensive collection of all knowledge."/><meta name="twitter:image" content="https://grokipedia.com/icon-512x512.png"/><title>Cytokine release syndrome</title><meta name="description" content="In immunology, cytokine release syndrome (CRS) is a form of systemic inflammatory response syndrome (SIRS) that can be triggered by a variety of factors such as infections and certain drugs.[3] CRS is a type of cytokine storm syndrome (CSS)[4] and occurs when large numbers of white blood cells are activated and release inflammatory cytokines, which in turn activate yet more white blood cells. CRS is also an adverse effect of some monoclonal antibody medications, as well as adoptive T-cell..."/><meta name="author" content="system"/><link rel="manifest" href="/manifest.webmanifest"/><meta name="keywords" content="CRS, Cytokine storm"/><meta name="robots" content="index, follow"/><meta name="googlebot" content="index, follow, max-snippet:-1"/><link rel="canonical" href="https://grokipedia.com/page/Cytokine_release_syndrome"/><meta property="og:title" content="Cytokine release syndrome"/><meta property="og:description" content="In immunology, cytokine release syndrome (CRS) is a form of systemic inflammatory response syndrome (SIRS) that can be triggered by a variety of factors such as infections and certain drugs.[3] CRS is a type of cytokine storm syndrome (CSS)[4] and occurs when large numbers of white blood cells are activated and release inflammatory cytokines, which in turn activate yet more white blood cells. CRS is also an adverse effect of some monoclonal antibody medications, as well as adoptive T-cell..."/><meta property="og:url" content="https://grokipedia.com/page/Cytokine_release_syndrome"/><meta property="og:site_name" content="Grokipedia"/><meta property="og:locale" content="en"/><meta property="og:image" content="https://grokipedia.com/icon-512x512.png"/><meta property="og:image:width" content="512"/><meta property="og:image:height" content="512"/><meta property="og:image:alt" content="Cytokine release syndrome"/><meta property="og:type" content="article"/><meta property="article:modified_time" content="1970-01-21T09:19:12.986Z"/><meta name="twitter:card" content="summary"/><meta name="twitter:creator" content="@Grokipedia"/><meta name="twitter:title" content="Cytokine release syndrome"/><meta name="twitter:description" content="In immunology, cytokine release syndrome (CRS) is a form of systemic inflammatory response syndrome (SIRS) that can be triggered by a variety of factors such as infections and certain drugs.[3] CRS is a type of cytokine storm syndrome (CSS)[4] and occurs when large numbers of white blood cells are activated and release inflammatory cytokines, which in turn activate yet more white blood cells. CRS is also an adverse effect of some monoclonal antibody medications, as well as adoptive T-cell..."/><meta name="twitter:image" content="https://grokipedia.com/icon-512x512.png"/><link rel="icon" href="/favicon.ico" type="image/x-icon" sizes="16x16"/><meta name="sentry-trace" content="d1e1a797447bcc5febf320fc04c67f56-b9d5a45b5acd6063-1"/><meta name="baggage" content="sentry-environment=production,sentry-public_key=5f2258f71198ee26a355127af230c3a6,sentry-trace_id=d1e1a797447bcc5febf320fc04c67f56,sentry-org_id=4508179396558848,sentry-transaction=GET%20%2Fpage%2F%5Bslug%5D,sentry-sampled=true,sentry-sample_rand=0.8050297653012879,sentry-sample_rate=1"/><script src="/_next/static/chunks/polyfills-42372ed130431b0a.js" noModule="" nonce="ZTYwMmJhNmYtNzA2Mi00ODJjLTkyZWMtZTEyMjYyYjIxODZj"></script></head><body class="flex h-[100svh] w-full flex-col __variable_13c637 __variable_8a0ba0 __variable_779740 __variable_2484fd __variable_525cc3 __variable_13486b"><div hidden=""><!--$--><!--/$--></div><script nonce="ZTYwMmJhNmYtNzA2Mi00ODJjLTkyZWMtZTEyMjYyYjIxODZj">((a,b,c,d,e,f,g,h)=>{let i=document.documentElement,j=["light","dark"];function k(b){var c;(Array.isArray(a)?a:[a]).forEach(a=>{let c="class"===a,d=c&&f?e.map(a=>f[a]||a):e;c?(i.classList.remove(...d),i.classList.add(f&&f[b]?f[b]:b)):i.setAttribute(a,b)}),c=b,h&&j.includes(c)&&(i.style.colorScheme=c)}if(d)k(d);else try{let a=localStorage.getItem(b)||c,d=g&&"system"===a?window.matchMedia("(prefers-color-scheme: dark)").matches?"dark":"light":a;k(d)}catch(a){}})("class","theme","dark",null,["light","dark"],null,true,true)</script><header class="h-16 bg-surface-base fixed top-0 z-50 w-full"><div class="hidden h-full grid-cols-[1fr_3fr_1fr] items-center gap-4 !py-0 md:grid max-w-full py-6 px-4 w-full mx-auto"><div class="-ml-2 justify-self-start"><a class="cursor-pointer" href="/"><svg width="200" height="auto" viewBox="0 0 955 225" fill="none" xmlns="http://www.w3.org/2000/svg"><path d="M99.6937 159.214C90.008 159.214 81.5652 157.414 74.3652 153.814C67.1652 150.214 61.5509 144.986 57.5223 138.129C53.5794 131.271 51.608 123.043 51.608 113.443C51.608 103.843 53.5794 95.4857 57.5223 88.3714C61.5509 81.2572 67.1652 75.7286 74.3652 71.7857C81.6509 67.8429 90.1794 65.8714 99.9509 65.8714C103.208 65.8714 106.679 66.1286 110.365 66.6429C114.051 67.0714 117.222 67.6714 119.879 68.4429C121.508 68.8714 123.008 69.2572 124.379 69.6C125.751 69.9429 127.122 70.1143 128.494 70.1143C129.522 70.1143 130.551 69.9857 131.579 69.7286C131.751 73.5 131.922 77.4 132.094 81.4286C132.265 85.4572 132.522 89.6572 132.865 94.0286C131.065 94.2857 129.565 94.3714 128.365 94.2857C126.651 86.4 123.522 80.5714 118.979 76.8C114.437 72.9429 108.394 71.0143 100.851 71.0143C94.8509 71.0143 89.708 72.1286 85.4223 74.3572C81.2223 76.5 77.7937 79.4572 75.1366 83.2286C72.5652 87 70.6794 91.3714 69.4794 96.3429C68.2794 101.229 67.6794 106.457 67.6794 112.029C67.6794 120.171 68.9223 127.371 71.408 133.629C73.8937 139.886 77.6652 144.814 82.7223 148.414C87.8652 151.929 94.2937 153.686 102.008 153.686C104.408 153.686 107.065 153.471 109.979 153.043C112.894 152.529 115.679 151.757 118.337 150.729V134.529C118.337 131.871 118.208 129.814 117.951 128.357C117.779 126.814 117.222 125.7 116.279 125.014C115.422 124.329 114.008 123.857 112.037 123.6C110.151 123.257 107.537 122.957 104.194 122.7C103.937 121.329 103.937 119.957 104.194 118.586C105.994 118.586 108.179 118.629 110.751 118.714C113.322 118.714 115.894 118.757 118.465 118.843C121.122 118.843 123.308 118.843 125.022 118.843C127.679 118.843 130.722 118.8 134.151 118.714C137.665 118.629 140.665 118.586 143.151 118.586C143.322 119.871 143.322 121.2 143.151 122.571C139.637 123 137.108 123.429 135.565 123.857C134.022 124.286 133.079 125.143 132.737 126.429C132.394 127.714 132.222 129.9 132.222 132.986V137.1C132.222 141.129 132.308 144.514 132.479 147.257C132.737 150 132.951 151.971 133.122 153.171C121.208 157.2 110.065 159.214 99.6937 159.214ZM148.19 157.414C147.933 156.043 147.933 154.714 148.19 153.429C151.105 153.257 153.248 153 154.619 152.657C155.99 152.229 156.89 151.371 157.319 150.086C157.748 148.8 157.962 146.743 157.962 143.914V115.114C157.962 111.771 157.79 109.286 157.448 107.657C157.19 106.029 156.376 104.914 155.005 104.314C153.719 103.629 151.49 103.071 148.319 102.643C148.062 101.443 148.062 100.329 148.319 99.3C151.748 98.6143 155.09 97.8429 158.348 96.9857C161.605 96.0429 165.033 94.8429 168.633 93.3857L170.819 94.1572V105.471C176.819 97.8429 182.948 94.0286 189.205 94.0286C192.205 94.0286 194.433 94.8429 195.89 96.4714C197.348 98.0143 198.076 99.7714 198.076 101.743C198.076 104.057 197.305 105.857 195.762 107.143C194.219 108.343 192.462 108.943 190.49 108.943C188.862 108.943 187.233 108.514 185.605 107.657C184.062 106.8 182.905 105.471 182.133 103.671C179.219 103.671 176.605 104.829 174.29 107.143C172.062 109.371 170.948 111.986 170.948 114.986V142.629C170.948 145.971 171.119 148.371 171.462 149.829C171.89 151.286 172.919 152.229 174.548 152.657C176.262 153 179.005 153.257 182.776 153.429C182.948 154.629 182.948 155.957 182.776 157.414C179.862 157.414 176.862 157.371 173.776 157.286C170.69 157.2 167.519 157.157 164.262 157.157C161.09 157.157 158.262 157.2 155.776 157.286C153.376 157.371 150.848 157.414 148.19 157.414ZM229.285 158.829C223.028 158.829 217.542 157.5 212.828 154.843C208.199 152.1 204.599 148.371 202.028 143.657C199.457 138.857 198.171 133.371 198.171 127.2C198.171 120.514 199.499 114.686 202.157 109.714C204.899 104.743 208.714 100.886 213.599 98.1429C218.485 95.4 224.099 94.0286 230.442 94.0286C236.699 94.0286 242.142 95.4 246.771 98.1429C251.399 100.886 254.999 104.657 257.571 109.457C260.142 114.257 261.428 119.7 261.428 125.786C261.428 132.043 260.057 137.7 257.314 142.757C254.657 147.729 250.928 151.671 246.128 154.586C241.328 157.414 235.714 158.829 229.285 158.829ZM212.699 125.657C212.699 134.4 214.114 141.343 216.942 146.486C219.857 151.543 224.185 154.071 229.928 154.071C235.414 154.071 239.614 151.671 242.528 146.871C245.442 141.986 246.899 135.471 246.899 127.329C246.899 118.671 245.442 111.771 242.528 106.629C239.614 101.486 235.371 98.9143 229.799 98.9143C224.314 98.9143 220.071 101.271 217.071 105.986C214.157 110.7 212.699 117.257 212.699 125.657ZM267.394 157.414C267.308 157.071 267.265 156.729 267.265 156.386C267.265 156.043 267.265 155.7 267.265 155.357C267.265 155.014 267.265 154.714 267.265 154.457C267.265 154.114 267.308 153.771 267.394 153.429C270.308 153.257 272.451 153 273.822 152.657C275.194 152.229 276.094 151.371 276.522 150.086C276.951 148.8 277.165 146.743 277.165 143.914V79.5C277.165 76.8429 276.908 74.8714 276.394 73.5857C275.965 72.2143 274.979 71.2714 273.437 70.7572C271.979 70.1572 269.751 69.7286 266.751 69.4714C266.665 69.1286 266.622 68.8286 266.622 68.5714C266.622 68.3143 266.622 68.0572 266.622 67.8C266.622 67.4572 266.622 67.1572 266.622 66.9C266.622 66.6429 266.665 66.3429 266.751 66C270.179 65.5714 273.694 64.9286 277.294 64.0714C280.894 63.1286 284.579 61.8429 288.351 60.2143L290.537 60.9857C290.451 62.8714 290.365 65.0143 290.279 67.4143C290.279 69.8143 290.279 72.4286 290.279 75.2572V122.957C291.308 122.957 292.165 122.786 292.851 122.443C293.537 122.1 294.094 121.757 294.522 121.414C294.694 121.243 295.037 120.943 295.551 120.514C296.065 120 296.965 119.1 298.251 117.814C299.537 116.529 301.379 114.6 303.779 112.029C306.008 109.543 307.765 107.614 309.051 106.243C310.422 104.786 311.108 103.586 311.108 102.643C311.108 101.957 310.508 101.4 309.308 100.971C308.194 100.457 306.651 100.157 304.679 100.071C304.594 99.7286 304.551 99.3857 304.551 99.0429C304.551 98.7 304.551 98.3572 304.551 98.0143C304.551 97.6714 304.551 97.3286 304.551 96.9857C304.551 96.6429 304.594 96.3 304.679 95.9572C306.394 95.9572 308.537 96 311.108 96.0857C313.765 96.1714 316.122 96.2143 318.179 96.2143C319.208 96.2143 320.665 96.2143 322.551 96.2143C324.522 96.1286 326.494 96.0857 328.465 96.0857C330.437 96.0857 331.894 96.0857 332.837 96.0857C332.922 96.4286 332.965 96.7714 332.965 97.1143C333.051 97.4572 333.094 97.8 333.094 98.1429C333.094 98.4857 333.051 98.8286 332.965 99.1714C332.965 99.4286 332.922 99.7286 332.837 100.071C328.379 100.157 324.608 101.271 321.522 103.414C318.437 105.471 315.479 107.914 312.651 110.743L303.394 120L321.137 143.4C323.022 145.886 324.565 147.857 325.765 149.314C327.051 150.686 328.422 151.671 329.879 152.271C331.337 152.871 333.351 153.257 335.922 153.429C336.094 154.629 336.094 155.957 335.922 157.414C334.808 157.414 333.137 157.371 330.908 157.286C328.765 157.2 325.379 157.157 320.751 157.157C320.065 157.157 319.037 157.157 317.665 157.157C316.294 157.157 315.008 157.243 313.808 157.414C313.808 156.471 313.294 155.186 312.265 153.557C311.237 151.843 310.422 150.6 309.822 149.829C309.565 149.4 308.922 148.5 307.894 147.129C306.865 145.671 305.622 144 304.165 142.114C302.794 140.143 301.379 138.171 299.922 136.2C298.465 134.143 297.137 132.343 295.937 130.8C294.994 129.514 294.094 128.529 293.237 127.843C292.465 127.071 291.479 126.686 290.279 126.686V142.629C290.279 145.971 290.408 148.371 290.665 149.829C291.008 151.286 291.737 152.229 292.851 152.657C294.051 153 295.851 153.257 298.251 153.429C298.422 154.714 298.422 156.043 298.251 157.414C296.022 157.414 293.665 157.371 291.179 157.286C288.779 157.2 286.165 157.157 283.337 157.157C280.594 157.157 277.894 157.2 275.237 157.286C272.579 157.371 269.965 157.414 267.394 157.414ZM369.34 157.414C366.94 157.414 364.454 157.371 361.883 157.286C359.311 157.2 356.526 157.157 353.526 157.157C350.783 157.157 347.997 157.2 345.169 157.286C342.426 157.371 339.769 157.414 337.197 157.414C336.94 156.043 336.94 154.714 337.197 153.429C340.111 153.257 342.254 153 343.626 152.657C344.997 152.229 345.897 151.371 346.326 150.086C346.754 148.8 346.969 146.743 346.969 143.914V115.114C346.969 111.771 346.84 109.286 346.583 107.657C346.326 106.029 345.511 104.914 344.14 104.314C342.854 103.629 340.583 103.071 337.326 102.643C337.069 101.443 337.069 100.329 337.326 99.3C341.097 98.6143 344.697 97.7572 348.126 96.7286C351.554 95.7 354.854 94.5857 358.026 93.3857L360.211 94.1572C360.126 96.8143 360.04 99.3 359.954 101.614C359.954 103.929 359.954 106.114 359.954 108.171V142.629C359.954 145.971 360.126 148.371 360.469 149.829C360.897 151.286 361.754 152.229 363.04 152.657C364.411 153 366.511 153.257 369.34 153.429C369.597 154.714 369.597 156.043 369.34 157.414ZM343.626 71.5286C343.626 69.0429 344.483 66.9429 346.197 65.2286C347.997 63.5143 350.14 62.6572 352.626 62.6572C355.026 62.6572 357.083 63.5143 358.797 65.2286C360.597 66.9429 361.497 69 361.497 71.4C361.497 73.6286 360.64 75.6857 358.926 77.5715C357.211 79.3714 355.026 80.2714 352.369 80.2714C349.969 80.2714 347.911 79.4143 346.197 77.7C344.483 75.9857 343.626 73.9286 343.626 71.5286ZM372.678 188.914C372.592 187.543 372.592 186.214 372.678 184.929C375.678 184.757 377.864 184.457 379.235 184.029C380.607 183.6 381.464 182.743 381.807 181.457C382.235 180.257 382.45 178.286 382.45 175.543V115.114C382.45 111.771 382.278 109.286 381.935 107.657C381.678 106.029 380.864 104.914 379.492 104.314C378.207 103.629 375.978 103.071 372.807 102.643C372.635 101.443 372.635 100.329 372.807 99.3C376.321 98.6143 379.75 97.8 383.092 96.8572C386.435 95.9143 389.907 94.7572 393.507 93.3857L395.307 94.2857C395.221 96.4286 395.178 98.2714 395.178 99.8143C395.178 101.271 395.178 102.686 395.178 104.057C398.521 100.543 401.821 98.0143 405.078 96.4714C408.335 94.8429 411.807 94.0286 415.492 94.0286C420.892 94.0286 425.435 95.4429 429.121 98.2714C432.892 101.1 435.764 104.786 437.735 109.329C439.707 113.871 440.692 118.8 440.692 124.114C440.692 130.371 439.321 136.157 436.578 141.471C433.921 146.7 430.192 150.9 425.392 154.071C420.592 157.243 415.021 158.829 408.678 158.829C406.192 158.829 403.835 158.614 401.607 158.186C399.378 157.843 397.278 157.329 395.307 156.643V174C395.307 177.343 395.564 179.743 396.078 181.2C396.592 182.657 397.707 183.557 399.421 183.9C401.135 184.329 403.835 184.629 407.521 184.8C407.607 186.171 407.607 187.543 407.521 188.914C404.607 188.914 401.65 188.871 398.65 188.786C395.735 188.7 392.521 188.657 389.007 188.657C385.664 188.657 382.792 188.7 380.392 188.786C377.992 188.871 375.421 188.914 372.678 188.914ZM395.178 146.1C398.864 151.414 403.75 154.071 409.835 154.071C414.121 154.071 417.507 152.871 419.992 150.471C422.564 148.071 424.407 144.943 425.521 141.086C426.721 137.229 427.321 133.157 427.321 128.871C427.321 124.586 426.764 120.386 425.65 116.271C424.535 112.157 422.692 108.771 420.121 106.114C417.635 103.371 414.207 102 409.835 102C404.607 102 399.721 104.529 395.178 109.586V146.1ZM477.335 158.829C471.25 158.829 466.107 157.414 461.907 154.586C457.707 151.757 454.493 147.986 452.264 143.271C450.121 138.471 449.05 133.2 449.05 127.457C449.05 121.543 450.164 116.057 452.393 111C454.707 105.943 458.05 101.871 462.421 98.7857C466.793 95.6143 472.107 94.0286 478.364 94.0286C485.907 94.0286 491.778 96.3 495.978 100.843C500.264 105.3 502.407 111.086 502.407 118.2C502.407 119.057 502.364 119.829 502.278 120.514C502.278 121.114 502.235 121.629 502.15 122.057L461.65 121.671C461.65 122.014 461.65 122.314 461.65 122.571C461.65 130.971 463.578 137.571 467.435 142.371C471.293 147.171 476.693 149.571 483.635 149.571C489.464 149.571 495.207 147.686 500.864 143.914C501.721 144.943 502.364 145.929 502.793 146.871C495.507 154.843 487.021 158.829 477.335 158.829ZM462.035 116.914L488.65 116.4C488.735 116.229 488.778 116.014 488.778 115.757C488.778 115.414 488.778 115.2 488.778 115.114C488.778 110.486 487.75 106.629 485.693 103.543C483.721 100.457 480.764 98.9143 476.821 98.9143C473.135 98.9143 469.921 100.414 467.178 103.414C464.435 106.414 462.721 110.914 462.035 116.914ZM559.644 158.957L557.587 158.057L557.073 149.186C554.073 152.443 550.987 154.886 547.816 156.514C544.73 158.057 541.302 158.829 537.53 158.829C532.216 158.829 527.544 157.414 523.516 154.586C519.573 151.671 516.53 147.9 514.387 143.271C512.244 138.643 511.173 133.629 511.173 128.229C511.173 121.971 512.502 116.271 515.159 111.129C517.902 105.986 521.716 101.871 526.602 98.7857C531.573 95.6143 537.359 94.0286 543.959 94.0286C545.93 94.0286 547.987 94.2 550.13 94.5429C552.273 94.8 554.502 95.2714 556.816 95.9572V79.5C556.816 76.8429 556.559 74.8714 556.044 73.5857C555.53 72.2143 554.502 71.2714 552.959 70.7572C551.502 70.1572 549.273 69.7286 546.273 69.4714C546.016 68.3572 546.016 67.2 546.273 66C549.702 65.5714 553.216 64.9286 556.816 64.0714C560.416 63.1286 564.102 61.8429 567.873 60.2143L570.059 60.9857C569.973 62.8714 569.887 65.0143 569.802 67.4143C569.802 69.8143 569.802 72.4286 569.802 75.2572V139.029C569.802 142.286 569.93 144.729 570.187 146.357C570.445 147.986 571.216 149.143 572.502 149.829C573.787 150.429 575.973 150.986 579.059 151.5C579.316 152.614 579.316 153.771 579.059 154.971C575.63 155.486 572.287 156.043 569.03 156.643C565.773 157.243 562.644 158.014 559.644 158.957ZM556.944 106.886C553.259 101.829 548.416 99.3 542.416 99.3C536.502 99.3 532.044 101.486 529.044 105.857C526.044 110.143 524.544 116.1 524.544 123.729C524.544 128.186 525.144 132.471 526.344 136.586C527.544 140.7 529.516 144.086 532.259 146.743C535.002 149.4 538.644 150.729 543.187 150.729C548.93 150.729 553.516 148.243 556.944 143.271V106.886ZM615.699 157.414C613.299 157.414 610.813 157.371 608.242 157.286C605.67 157.2 602.885 157.157 599.885 157.157C597.142 157.157 594.356 157.2 591.527 157.286C588.785 157.371 586.127 157.414 583.556 157.414C583.299 156.043 583.299 154.714 583.556 153.429C586.47 153.257 588.613 153 589.985 152.657C591.356 152.229 592.256 151.371 592.685 150.086C593.113 148.8 593.327 146.743 593.327 143.914V115.114C593.327 111.771 593.199 109.286 592.942 107.657C592.685 106.029 591.87 104.914 590.499 104.314C589.213 103.629 586.942 103.071 583.685 102.643C583.427 101.443 583.427 100.329 583.685 99.3C587.456 98.6143 591.056 97.7572 594.485 96.7286C597.913 95.7 601.213 94.5857 604.385 93.3857L606.57 94.1572C606.485 96.8143 606.399 99.3 606.313 101.614C606.313 103.929 606.313 106.114 606.313 108.171V142.629C606.313 145.971 606.485 148.371 606.827 149.829C607.256 151.286 608.113 152.229 609.399 152.657C610.77 153 612.87 153.257 615.699 153.429C615.956 154.714 615.956 156.043 615.699 157.414ZM589.985 71.5286C589.985 69.0429 590.842 66.9429 592.556 65.2286C594.356 63.5143 596.499 62.6572 598.985 62.6572C601.385 62.6572 603.442 63.5143 605.156 65.2286C606.956 66.9429 607.856 69 607.856 71.4C607.856 73.6286 606.999 75.6857 605.285 77.5715C603.57 79.3714 601.385 80.2714 598.727 80.2714C596.327 80.2714 594.27 79.4143 592.556 77.7C590.842 75.9857 589.985 73.9286 589.985 71.5286ZM665.837 158.571C660.18 158.571 656.623 155.743 655.165 150.086C649.08 155.914 642.865 158.829 636.523 158.829C632.151 158.829 628.423 157.543 625.337 154.971C622.337 152.314 620.837 148.671 620.837 144.043C620.837 132.729 632.365 125.614 655.423 122.7C655.423 120.643 655.423 118.543 655.423 116.4C655.508 114.257 655.551 111.986 655.551 109.586C655.551 106.586 654.437 104.271 652.208 102.643C650.065 100.929 647.451 100.071 644.365 100.071C642.137 100.071 640.251 100.414 638.708 101.1C638.708 103.071 638.28 105.086 637.423 107.143C636.565 109.2 635.365 110.957 633.823 112.414C632.365 113.786 630.565 114.471 628.423 114.471C626.537 114.471 625.037 113.957 623.923 112.929C622.894 111.814 622.38 110.486 622.38 108.943C622.38 106.886 623.323 104.957 625.208 103.157C627.18 101.271 629.665 99.6857 632.665 98.4C635.665 97.0286 638.794 95.9572 642.051 95.1857C645.308 94.4143 648.223 94.0286 650.794 94.0286C653.965 94.0286 656.88 94.6286 659.537 95.8286C662.28 96.9429 664.465 98.6572 666.094 100.971C667.808 103.2 668.665 105.986 668.665 109.329C668.665 111.386 668.623 114.086 668.537 117.429C668.451 120.686 668.365 124.2 668.28 127.971C668.28 131.657 668.237 135.171 668.151 138.514C668.065 141.857 668.023 144.557 668.023 146.614C668.023 149.357 669.223 150.729 671.623 150.729C673.165 150.729 675.523 150.214 678.694 149.186C679.037 149.614 679.251 150.086 679.337 150.6C679.508 151.114 679.637 151.586 679.723 152.014C677.58 154.329 675.308 156 672.908 157.029C670.594 158.057 668.237 158.571 665.837 158.571ZM655.165 146.614L655.423 127.329C647.537 128.357 642.094 130.029 639.094 132.343C636.18 134.657 634.723 137.614 634.723 141.214C634.723 144.214 635.494 146.529 637.037 148.157C638.665 149.7 640.68 150.471 643.08 150.471C644.623 150.471 646.337 150.129 648.223 149.443C650.194 148.757 652.508 147.814 655.165 146.614Z" fill="currentColor"></path><rect x="715" y="65" width="195" height="105" rx="52.5" fill="currentColor" fill-opacity="0.05"></rect><path d="M767.529 142.875L754.049 107.938H762.552L769.309 127.582C769.705 128.812 770.078 130.032 770.43 131.24C770.781 132.449 771.078 133.559 771.32 134.569H771.616C771.858 133.559 772.144 132.449 772.473 131.24C772.825 130.032 773.198 128.812 773.594 127.582L780.186 107.938H788.689L775.472 142.875H767.529ZM810.856 143.633C806.901 143.633 803.528 142.71 800.737 140.865C797.969 138.997 795.871 136.305 794.442 132.79C793.014 129.252 792.3 124.989 792.3 120.001V118.255C792.3 113.245 793.014 108.982 794.442 105.467C795.871 101.929 797.969 99.2373 800.737 97.3916C803.528 95.5239 806.901 94.5901 810.856 94.5901C814.789 94.5901 818.129 95.5129 820.875 97.3586C823.644 99.2043 825.731 101.907 827.138 105.467C828.566 109.004 829.28 113.267 829.28 118.255V120.001C829.28 124.989 828.577 129.252 827.171 132.79C825.764 136.327 823.677 139.019 820.908 140.865C818.162 142.71 814.811 143.633 810.856 143.633ZM810.889 136.382C813.064 136.382 814.877 135.789 816.327 134.602C817.799 133.416 818.898 131.658 819.623 129.329C820.348 126.978 820.711 124.066 820.711 120.595V117.694C820.711 114.223 820.337 111.311 819.59 108.96C818.865 106.609 817.777 104.84 816.327 103.654C814.877 102.445 813.064 101.841 810.889 101.841C808.714 101.841 806.879 102.434 805.385 103.621C803.912 104.785 802.792 106.554 802.023 108.927C801.276 111.278 800.902 114.201 800.902 117.694V120.595C800.902 124.044 801.287 126.945 802.056 129.296C802.825 131.647 803.945 133.416 805.418 134.602C806.89 135.789 808.714 136.382 810.889 136.382ZM838.988 143.205C838 143.205 837.099 142.985 836.286 142.545C835.495 142.106 834.879 141.491 834.44 140.7C834.001 139.909 833.781 139.019 833.781 138.03C833.781 137.019 834.001 136.118 834.44 135.327C834.879 134.536 835.495 133.921 836.286 133.482C837.099 133.042 838 132.823 838.988 132.823C839.977 132.823 840.867 133.042 841.658 133.482C842.449 133.921 843.064 134.536 843.504 135.327C843.943 136.118 844.163 137.019 844.163 138.03C844.163 139.019 843.943 139.909 843.504 140.7C843.064 141.491 842.449 142.106 841.658 142.545C840.867 142.985 839.977 143.205 838.988 143.205ZM857.365 142.875V104.511L846.39 111.663V103.357L858.453 95.3481H865.802V142.875H857.365Z" fill="currentColor"></path></svg></a></div><div class="mx-auto flex w-full"><button class="focus-visible:ring-ring inline-flex items-center justify-center gap-x-2 whitespace-nowrap text-sm font-medium transition-colors focus-visible:outline-none focus-visible:ring-1 disabled:pointer-events-none disabled:cursor-not-allowed disabled:opacity-50 [&amp;&gt;[data-slot=icon]]:-mx-0.5 [&amp;&gt;[data-slot=icon]]:my-0.5 [&amp;&gt;[data-slot=icon]]:size-5 [&amp;&gt;[data-slot=icon]]:shrink-0 [&amp;&gt;[data-slot=icon]]:text-[--btn-icon] [&amp;&gt;[data-slot=icon]]:sm:my-1 [&amp;&gt;[data-slot=icon]]:sm:size-4 border-input text-primary hover:border-primary/15 border hover:bg-overlay-hover py-2 max-w-full px-3 shadow-none sm:w-80 focus-visible:z-1 mx-auto h-full w-full rounded-full bg-surface-l1" type="button"><div class="flex items-center justify-between sm:w-full gap-4"><div class="flex items-center justify-start gap-2"><span class="inline-flex items-center justify-center p-0 m-0 w-4 h-4 text-muted" data-namespace="@xai/icons" data-slot="icon"><svg xmlns="http://www.w3.org/2000/svg" fill="currentColor" viewBox="0 0 24 24" aria-hidden="true" class="w-4 h-4" focusable="false" style="fill:currentColor"><path d="m18.031 16.617 4.283 4.282-1.415 1.415-4.282-4.283A8.96 8.96 0 0 1 11 20c-4.968 0-9-4.032-9-9s4.032-9 9-9 9 4.032 9 9a8.96 8.96 0 0 1-1.969 5.617m-2.006-.742A6.98 6.98 0 0 0 18 11c0-3.867-3.133-7-7-7s-7 3.133-7 7 3.133 7 7 7a6.98 6.98 0 0 0 4.875-1.975z"></path></svg></span><p class="text-sm text-muted hidden sm:block">Search</p></div><span class="hidden sm:block"><div class="bg-foreground/10 text-muted inline-flex items-center rounded-md px-1 py-0.5 text-center font-sans text-xs font-normal tracking-widest rtl:space-x-reverse"><span>âŒ˜</span><span class="text-xs">K</span></div></span></div></button></div><div class="flex items-center gap-2 justify-self-end"><button class="focus-visible:ring-ring inline-flex items-center justify-center gap-x-2 whitespace-nowrap rounded-full text-sm font-medium transition-colors focus-visible:outline-none focus-visible:ring-1 disabled:pointer-events-none disabled:cursor-not-allowed disabled:opacity-50 [&amp;&gt;[data-slot=icon]]:-mx-0.5 [&amp;&gt;[data-slot=icon]]:my-0.5 [&amp;&gt;[data-slot=icon]]:size-5 [&amp;&gt;[data-slot=icon]]:shrink-0 [&amp;&gt;[data-slot=icon]]:text-[--btn-icon] [&amp;&gt;[data-slot=icon]]:sm:my-1 [&amp;&gt;[data-slot=icon]]:sm:size-4 text-primary hover:bg-overlay-hover px-4 py-2 w-9 h-9 flex-shrink-0" type="button" id="radix-_R_7apfiumdb_" aria-haspopup="menu" aria-expanded="false" data-state="closed"><span class="inline-flex items-center justify-center p-0 m-0 w-6 h-6 rotate-0 scale-100 transition-all dark:-rotate-90 dark:scale-0" data-namespace="@xai/icons" data-slot="icon"><svg xmlns="http://www.w3.org/2000/svg" fill="currentColor" viewBox="0 0 24 24" aria-hidden="true" class="w-6 h-6" focusable="false" style="fill:currentColor"><path d="M12 18a6 6 0 1 1 0-12 6 6 0 0 1 0 12m0-2a4 4 0 1 0 0-8 4 4 0 0 0 0 8M11 1h2v3h-2zm0 19h2v3h-2zM3.515 4.929l1.414-1.414L7.05 5.636 5.636 7.05zM16.95 18.364l1.414-1.414 2.121 2.121-1.414 1.414zm2.121-14.85 1.414 1.415-2.121 2.121-1.414-1.414zM5.636 16.95l1.414 1.414-2.121 2.121-1.414-1.414zM23 11v2h-3v-2zM4 11v2H1v-2z"></path></svg></span><span class="inline-flex items-center justify-center p-0 m-0 w-6 h-6 absolute rotate-90 scale-0 transition-all dark:rotate-0 dark:scale-100" data-namespace="@xai/icons" data-slot="icon"><svg xmlns="http://www.w3.org/2000/svg" fill="currentColor" viewBox="0 0 24 24" aria-hidden="true" class="w-6 h-6" focusable="false" style="fill:currentColor"><path d="M10 7a7 7 0 0 0 12 4.9v.1c0 5.523-4.477 10-10 10S2 17.523 2 12 6.477 2 12 2h.1A6.98 6.98 0 0 0 10 7m-6 5a8 8 0 0 0 15.062 3.762A9 9 0 0 1 8.238 4.938 8 8 0 0 0 4 12"></path></svg></span><span class="sr-only">Toggle theme</span></button></div></div><div class="flex h-full items-center md:hidden justify-between max-w-full py-6 px-4 w-full mx-auto pt-8"><div class="flex items-center"><div class="-ml-2"><button class="focus-visible:ring-ring inline-flex items-center justify-center gap-x-2 whitespace-nowrap rounded-full text-sm font-medium transition-colors focus-visible:outline-none focus-visible:ring-1 disabled:pointer-events-none disabled:cursor-not-allowed disabled:opacity-50 [&amp;&gt;[data-slot=icon]]:-mx-0.5 [&amp;&gt;[data-slot=icon]]:my-0.5 [&amp;&gt;[data-slot=icon]]:size-5 [&amp;&gt;[data-slot=icon]]:shrink-0 [&amp;&gt;[data-slot=icon]]:text-[--btn-icon] [&amp;&gt;[data-slot=icon]]:sm:my-1 [&amp;&gt;[data-slot=icon]]:sm:size-4 text-primary hover:bg-overlay-hover h-9 w-9" type="button" aria-label="Toggle table of contents"><svg xmlns="http://www.w3.org/2000/svg" width="24" height="24" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round" class="lucide lucide-list h-6 w-6"><path d="M3 12h.01"></path><path d="M3 18h.01"></path><path d="M3 6h.01"></path><path d="M8 12h13"></path><path d="M8 18h13"></path><path d="M8 6h13"></path></svg></button></div><a class="cursor-pointer" href="/"><svg width="160" height="auto" viewBox="0 0 955 225" fill="none" xmlns="http://www.w3.org/2000/svg"><path d="M99.6937 159.214C90.008 159.214 81.5652 157.414 74.3652 153.814C67.1652 150.214 61.5509 144.986 57.5223 138.129C53.5794 131.271 51.608 123.043 51.608 113.443C51.608 103.843 53.5794 95.4857 57.5223 88.3714C61.5509 81.2572 67.1652 75.7286 74.3652 71.7857C81.6509 67.8429 90.1794 65.8714 99.9509 65.8714C103.208 65.8714 106.679 66.1286 110.365 66.6429C114.051 67.0714 117.222 67.6714 119.879 68.4429C121.508 68.8714 123.008 69.2572 124.379 69.6C125.751 69.9429 127.122 70.1143 128.494 70.1143C129.522 70.1143 130.551 69.9857 131.579 69.7286C131.751 73.5 131.922 77.4 132.094 81.4286C132.265 85.4572 132.522 89.6572 132.865 94.0286C131.065 94.2857 129.565 94.3714 128.365 94.2857C126.651 86.4 123.522 80.5714 118.979 76.8C114.437 72.9429 108.394 71.0143 100.851 71.0143C94.8509 71.0143 89.708 72.1286 85.4223 74.3572C81.2223 76.5 77.7937 79.4572 75.1366 83.2286C72.5652 87 70.6794 91.3714 69.4794 96.3429C68.2794 101.229 67.6794 106.457 67.6794 112.029C67.6794 120.171 68.9223 127.371 71.408 133.629C73.8937 139.886 77.6652 144.814 82.7223 148.414C87.8652 151.929 94.2937 153.686 102.008 153.686C104.408 153.686 107.065 153.471 109.979 153.043C112.894 152.529 115.679 151.757 118.337 150.729V134.529C118.337 131.871 118.208 129.814 117.951 128.357C117.779 126.814 117.222 125.7 116.279 125.014C115.422 124.329 114.008 123.857 112.037 123.6C110.151 123.257 107.537 122.957 104.194 122.7C103.937 121.329 103.937 119.957 104.194 118.586C105.994 118.586 108.179 118.629 110.751 118.714C113.322 118.714 115.894 118.757 118.465 118.843C121.122 118.843 123.308 118.843 125.022 118.843C127.679 118.843 130.722 118.8 134.151 118.714C137.665 118.629 140.665 118.586 143.151 118.586C143.322 119.871 143.322 121.2 143.151 122.571C139.637 123 137.108 123.429 135.565 123.857C134.022 124.286 133.079 125.143 132.737 126.429C132.394 127.714 132.222 129.9 132.222 132.986V137.1C132.222 141.129 132.308 144.514 132.479 147.257C132.737 150 132.951 151.971 133.122 153.171C121.208 157.2 110.065 159.214 99.6937 159.214ZM148.19 157.414C147.933 156.043 147.933 154.714 148.19 153.429C151.105 153.257 153.248 153 154.619 152.657C155.99 152.229 156.89 151.371 157.319 150.086C157.748 148.8 157.962 146.743 157.962 143.914V115.114C157.962 111.771 157.79 109.286 157.448 107.657C157.19 106.029 156.376 104.914 155.005 104.314C153.719 103.629 151.49 103.071 148.319 102.643C148.062 101.443 148.062 100.329 148.319 99.3C151.748 98.6143 155.09 97.8429 158.348 96.9857C161.605 96.0429 165.033 94.8429 168.633 93.3857L170.819 94.1572V105.471C176.819 97.8429 182.948 94.0286 189.205 94.0286C192.205 94.0286 194.433 94.8429 195.89 96.4714C197.348 98.0143 198.076 99.7714 198.076 101.743C198.076 104.057 197.305 105.857 195.762 107.143C194.219 108.343 192.462 108.943 190.49 108.943C188.862 108.943 187.233 108.514 185.605 107.657C184.062 106.8 182.905 105.471 182.133 103.671C179.219 103.671 176.605 104.829 174.29 107.143C172.062 109.371 170.948 111.986 170.948 114.986V142.629C170.948 145.971 171.119 148.371 171.462 149.829C171.89 151.286 172.919 152.229 174.548 152.657C176.262 153 179.005 153.257 182.776 153.429C182.948 154.629 182.948 155.957 182.776 157.414C179.862 157.414 176.862 157.371 173.776 157.286C170.69 157.2 167.519 157.157 164.262 157.157C161.09 157.157 158.262 157.2 155.776 157.286C153.376 157.371 150.848 157.414 148.19 157.414ZM229.285 158.829C223.028 158.829 217.542 157.5 212.828 154.843C208.199 152.1 204.599 148.371 202.028 143.657C199.457 138.857 198.171 133.371 198.171 127.2C198.171 120.514 199.499 114.686 202.157 109.714C204.899 104.743 208.714 100.886 213.599 98.1429C218.485 95.4 224.099 94.0286 230.442 94.0286C236.699 94.0286 242.142 95.4 246.771 98.1429C251.399 100.886 254.999 104.657 257.571 109.457C260.142 114.257 261.428 119.7 261.428 125.786C261.428 132.043 260.057 137.7 257.314 142.757C254.657 147.729 250.928 151.671 246.128 154.586C241.328 157.414 235.714 158.829 229.285 158.829ZM212.699 125.657C212.699 134.4 214.114 141.343 216.942 146.486C219.857 151.543 224.185 154.071 229.928 154.071C235.414 154.071 239.614 151.671 242.528 146.871C245.442 141.986 246.899 135.471 246.899 127.329C246.899 118.671 245.442 111.771 242.528 106.629C239.614 101.486 235.371 98.9143 229.799 98.9143C224.314 98.9143 220.071 101.271 217.071 105.986C214.157 110.7 212.699 117.257 212.699 125.657ZM267.394 157.414C267.308 157.071 267.265 156.729 267.265 156.386C267.265 156.043 267.265 155.7 267.265 155.357C267.265 155.014 267.265 154.714 267.265 154.457C267.265 154.114 267.308 153.771 267.394 153.429C270.308 153.257 272.451 153 273.822 152.657C275.194 152.229 276.094 151.371 276.522 150.086C276.951 148.8 277.165 146.743 277.165 143.914V79.5C277.165 76.8429 276.908 74.8714 276.394 73.5857C275.965 72.2143 274.979 71.2714 273.437 70.7572C271.979 70.1572 269.751 69.7286 266.751 69.4714C266.665 69.1286 266.622 68.8286 266.622 68.5714C266.622 68.3143 266.622 68.0572 266.622 67.8C266.622 67.4572 266.622 67.1572 266.622 66.9C266.622 66.6429 266.665 66.3429 266.751 66C270.179 65.5714 273.694 64.9286 277.294 64.0714C280.894 63.1286 284.579 61.8429 288.351 60.2143L290.537 60.9857C290.451 62.8714 290.365 65.0143 290.279 67.4143C290.279 69.8143 290.279 72.4286 290.279 75.2572V122.957C291.308 122.957 292.165 122.786 292.851 122.443C293.537 122.1 294.094 121.757 294.522 121.414C294.694 121.243 295.037 120.943 295.551 120.514C296.065 120 296.965 119.1 298.251 117.814C299.537 116.529 301.379 114.6 303.779 112.029C306.008 109.543 307.765 107.614 309.051 106.243C310.422 104.786 311.108 103.586 311.108 102.643C311.108 101.957 310.508 101.4 309.308 100.971C308.194 100.457 306.651 100.157 304.679 100.071C304.594 99.7286 304.551 99.3857 304.551 99.0429C304.551 98.7 304.551 98.3572 304.551 98.0143C304.551 97.6714 304.551 97.3286 304.551 96.9857C304.551 96.6429 304.594 96.3 304.679 95.9572C306.394 95.9572 308.537 96 311.108 96.0857C313.765 96.1714 316.122 96.2143 318.179 96.2143C319.208 96.2143 320.665 96.2143 322.551 96.2143C324.522 96.1286 326.494 96.0857 328.465 96.0857C330.437 96.0857 331.894 96.0857 332.837 96.0857C332.922 96.4286 332.965 96.7714 332.965 97.1143C333.051 97.4572 333.094 97.8 333.094 98.1429C333.094 98.4857 333.051 98.8286 332.965 99.1714C332.965 99.4286 332.922 99.7286 332.837 100.071C328.379 100.157 324.608 101.271 321.522 103.414C318.437 105.471 315.479 107.914 312.651 110.743L303.394 120L321.137 143.4C323.022 145.886 324.565 147.857 325.765 149.314C327.051 150.686 328.422 151.671 329.879 152.271C331.337 152.871 333.351 153.257 335.922 153.429C336.094 154.629 336.094 155.957 335.922 157.414C334.808 157.414 333.137 157.371 330.908 157.286C328.765 157.2 325.379 157.157 320.751 157.157C320.065 157.157 319.037 157.157 317.665 157.157C316.294 157.157 315.008 157.243 313.808 157.414C313.808 156.471 313.294 155.186 312.265 153.557C311.237 151.843 310.422 150.6 309.822 149.829C309.565 149.4 308.922 148.5 307.894 147.129C306.865 145.671 305.622 144 304.165 142.114C302.794 140.143 301.379 138.171 299.922 136.2C298.465 134.143 297.137 132.343 295.937 130.8C294.994 129.514 294.094 128.529 293.237 127.843C292.465 127.071 291.479 126.686 290.279 126.686V142.629C290.279 145.971 290.408 148.371 290.665 149.829C291.008 151.286 291.737 152.229 292.851 152.657C294.051 153 295.851 153.257 298.251 153.429C298.422 154.714 298.422 156.043 298.251 157.414C296.022 157.414 293.665 157.371 291.179 157.286C288.779 157.2 286.165 157.157 283.337 157.157C280.594 157.157 277.894 157.2 275.237 157.286C272.579 157.371 269.965 157.414 267.394 157.414ZM369.34 157.414C366.94 157.414 364.454 157.371 361.883 157.286C359.311 157.2 356.526 157.157 353.526 157.157C350.783 157.157 347.997 157.2 345.169 157.286C342.426 157.371 339.769 157.414 337.197 157.414C336.94 156.043 336.94 154.714 337.197 153.429C340.111 153.257 342.254 153 343.626 152.657C344.997 152.229 345.897 151.371 346.326 150.086C346.754 148.8 346.969 146.743 346.969 143.914V115.114C346.969 111.771 346.84 109.286 346.583 107.657C346.326 106.029 345.511 104.914 344.14 104.314C342.854 103.629 340.583 103.071 337.326 102.643C337.069 101.443 337.069 100.329 337.326 99.3C341.097 98.6143 344.697 97.7572 348.126 96.7286C351.554 95.7 354.854 94.5857 358.026 93.3857L360.211 94.1572C360.126 96.8143 360.04 99.3 359.954 101.614C359.954 103.929 359.954 106.114 359.954 108.171V142.629C359.954 145.971 360.126 148.371 360.469 149.829C360.897 151.286 361.754 152.229 363.04 152.657C364.411 153 366.511 153.257 369.34 153.429C369.597 154.714 369.597 156.043 369.34 157.414ZM343.626 71.5286C343.626 69.0429 344.483 66.9429 346.197 65.2286C347.997 63.5143 350.14 62.6572 352.626 62.6572C355.026 62.6572 357.083 63.5143 358.797 65.2286C360.597 66.9429 361.497 69 361.497 71.4C361.497 73.6286 360.64 75.6857 358.926 77.5715C357.211 79.3714 355.026 80.2714 352.369 80.2714C349.969 80.2714 347.911 79.4143 346.197 77.7C344.483 75.9857 343.626 73.9286 343.626 71.5286ZM372.678 188.914C372.592 187.543 372.592 186.214 372.678 184.929C375.678 184.757 377.864 184.457 379.235 184.029C380.607 183.6 381.464 182.743 381.807 181.457C382.235 180.257 382.45 178.286 382.45 175.543V115.114C382.45 111.771 382.278 109.286 381.935 107.657C381.678 106.029 380.864 104.914 379.492 104.314C378.207 103.629 375.978 103.071 372.807 102.643C372.635 101.443 372.635 100.329 372.807 99.3C376.321 98.6143 379.75 97.8 383.092 96.8572C386.435 95.9143 389.907 94.7572 393.507 93.3857L395.307 94.2857C395.221 96.4286 395.178 98.2714 395.178 99.8143C395.178 101.271 395.178 102.686 395.178 104.057C398.521 100.543 401.821 98.0143 405.078 96.4714C408.335 94.8429 411.807 94.0286 415.492 94.0286C420.892 94.0286 425.435 95.4429 429.121 98.2714C432.892 101.1 435.764 104.786 437.735 109.329C439.707 113.871 440.692 118.8 440.692 124.114C440.692 130.371 439.321 136.157 436.578 141.471C433.921 146.7 430.192 150.9 425.392 154.071C420.592 157.243 415.021 158.829 408.678 158.829C406.192 158.829 403.835 158.614 401.607 158.186C399.378 157.843 397.278 157.329 395.307 156.643V174C395.307 177.343 395.564 179.743 396.078 181.2C396.592 182.657 397.707 183.557 399.421 183.9C401.135 184.329 403.835 184.629 407.521 184.8C407.607 186.171 407.607 187.543 407.521 188.914C404.607 188.914 401.65 188.871 398.65 188.786C395.735 188.7 392.521 188.657 389.007 188.657C385.664 188.657 382.792 188.7 380.392 188.786C377.992 188.871 375.421 188.914 372.678 188.914ZM395.178 146.1C398.864 151.414 403.75 154.071 409.835 154.071C414.121 154.071 417.507 152.871 419.992 150.471C422.564 148.071 424.407 144.943 425.521 141.086C426.721 137.229 427.321 133.157 427.321 128.871C427.321 124.586 426.764 120.386 425.65 116.271C424.535 112.157 422.692 108.771 420.121 106.114C417.635 103.371 414.207 102 409.835 102C404.607 102 399.721 104.529 395.178 109.586V146.1ZM477.335 158.829C471.25 158.829 466.107 157.414 461.907 154.586C457.707 151.757 454.493 147.986 452.264 143.271C450.121 138.471 449.05 133.2 449.05 127.457C449.05 121.543 450.164 116.057 452.393 111C454.707 105.943 458.05 101.871 462.421 98.7857C466.793 95.6143 472.107 94.0286 478.364 94.0286C485.907 94.0286 491.778 96.3 495.978 100.843C500.264 105.3 502.407 111.086 502.407 118.2C502.407 119.057 502.364 119.829 502.278 120.514C502.278 121.114 502.235 121.629 502.15 122.057L461.65 121.671C461.65 122.014 461.65 122.314 461.65 122.571C461.65 130.971 463.578 137.571 467.435 142.371C471.293 147.171 476.693 149.571 483.635 149.571C489.464 149.571 495.207 147.686 500.864 143.914C501.721 144.943 502.364 145.929 502.793 146.871C495.507 154.843 487.021 158.829 477.335 158.829ZM462.035 116.914L488.65 116.4C488.735 116.229 488.778 116.014 488.778 115.757C488.778 115.414 488.778 115.2 488.778 115.114C488.778 110.486 487.75 106.629 485.693 103.543C483.721 100.457 480.764 98.9143 476.821 98.9143C473.135 98.9143 469.921 100.414 467.178 103.414C464.435 106.414 462.721 110.914 462.035 116.914ZM559.644 158.957L557.587 158.057L557.073 149.186C554.073 152.443 550.987 154.886 547.816 156.514C544.73 158.057 541.302 158.829 537.53 158.829C532.216 158.829 527.544 157.414 523.516 154.586C519.573 151.671 516.53 147.9 514.387 143.271C512.244 138.643 511.173 133.629 511.173 128.229C511.173 121.971 512.502 116.271 515.159 111.129C517.902 105.986 521.716 101.871 526.602 98.7857C531.573 95.6143 537.359 94.0286 543.959 94.0286C545.93 94.0286 547.987 94.2 550.13 94.5429C552.273 94.8 554.502 95.2714 556.816 95.9572V79.5C556.816 76.8429 556.559 74.8714 556.044 73.5857C555.53 72.2143 554.502 71.2714 552.959 70.7572C551.502 70.1572 549.273 69.7286 546.273 69.4714C546.016 68.3572 546.016 67.2 546.273 66C549.702 65.5714 553.216 64.9286 556.816 64.0714C560.416 63.1286 564.102 61.8429 567.873 60.2143L570.059 60.9857C569.973 62.8714 569.887 65.0143 569.802 67.4143C569.802 69.8143 569.802 72.4286 569.802 75.2572V139.029C569.802 142.286 569.93 144.729 570.187 146.357C570.445 147.986 571.216 149.143 572.502 149.829C573.787 150.429 575.973 150.986 579.059 151.5C579.316 152.614 579.316 153.771 579.059 154.971C575.63 155.486 572.287 156.043 569.03 156.643C565.773 157.243 562.644 158.014 559.644 158.957ZM556.944 106.886C553.259 101.829 548.416 99.3 542.416 99.3C536.502 99.3 532.044 101.486 529.044 105.857C526.044 110.143 524.544 116.1 524.544 123.729C524.544 128.186 525.144 132.471 526.344 136.586C527.544 140.7 529.516 144.086 532.259 146.743C535.002 149.4 538.644 150.729 543.187 150.729C548.93 150.729 553.516 148.243 556.944 143.271V106.886ZM615.699 157.414C613.299 157.414 610.813 157.371 608.242 157.286C605.67 157.2 602.885 157.157 599.885 157.157C597.142 157.157 594.356 157.2 591.527 157.286C588.785 157.371 586.127 157.414 583.556 157.414C583.299 156.043 583.299 154.714 583.556 153.429C586.47 153.257 588.613 153 589.985 152.657C591.356 152.229 592.256 151.371 592.685 150.086C593.113 148.8 593.327 146.743 593.327 143.914V115.114C593.327 111.771 593.199 109.286 592.942 107.657C592.685 106.029 591.87 104.914 590.499 104.314C589.213 103.629 586.942 103.071 583.685 102.643C583.427 101.443 583.427 100.329 583.685 99.3C587.456 98.6143 591.056 97.7572 594.485 96.7286C597.913 95.7 601.213 94.5857 604.385 93.3857L606.57 94.1572C606.485 96.8143 606.399 99.3 606.313 101.614C606.313 103.929 606.313 106.114 606.313 108.171V142.629C606.313 145.971 606.485 148.371 606.827 149.829C607.256 151.286 608.113 152.229 609.399 152.657C610.77 153 612.87 153.257 615.699 153.429C615.956 154.714 615.956 156.043 615.699 157.414ZM589.985 71.5286C589.985 69.0429 590.842 66.9429 592.556 65.2286C594.356 63.5143 596.499 62.6572 598.985 62.6572C601.385 62.6572 603.442 63.5143 605.156 65.2286C606.956 66.9429 607.856 69 607.856 71.4C607.856 73.6286 606.999 75.6857 605.285 77.5715C603.57 79.3714 601.385 80.2714 598.727 80.2714C596.327 80.2714 594.27 79.4143 592.556 77.7C590.842 75.9857 589.985 73.9286 589.985 71.5286ZM665.837 158.571C660.18 158.571 656.623 155.743 655.165 150.086C649.08 155.914 642.865 158.829 636.523 158.829C632.151 158.829 628.423 157.543 625.337 154.971C622.337 152.314 620.837 148.671 620.837 144.043C620.837 132.729 632.365 125.614 655.423 122.7C655.423 120.643 655.423 118.543 655.423 116.4C655.508 114.257 655.551 111.986 655.551 109.586C655.551 106.586 654.437 104.271 652.208 102.643C650.065 100.929 647.451 100.071 644.365 100.071C642.137 100.071 640.251 100.414 638.708 101.1C638.708 103.071 638.28 105.086 637.423 107.143C636.565 109.2 635.365 110.957 633.823 112.414C632.365 113.786 630.565 114.471 628.423 114.471C626.537 114.471 625.037 113.957 623.923 112.929C622.894 111.814 622.38 110.486 622.38 108.943C622.38 106.886 623.323 104.957 625.208 103.157C627.18 101.271 629.665 99.6857 632.665 98.4C635.665 97.0286 638.794 95.9572 642.051 95.1857C645.308 94.4143 648.223 94.0286 650.794 94.0286C653.965 94.0286 656.88 94.6286 659.537 95.8286C662.28 96.9429 664.465 98.6572 666.094 100.971C667.808 103.2 668.665 105.986 668.665 109.329C668.665 111.386 668.623 114.086 668.537 117.429C668.451 120.686 668.365 124.2 668.28 127.971C668.28 131.657 668.237 135.171 668.151 138.514C668.065 141.857 668.023 144.557 668.023 146.614C668.023 149.357 669.223 150.729 671.623 150.729C673.165 150.729 675.523 150.214 678.694 149.186C679.037 149.614 679.251 150.086 679.337 150.6C679.508 151.114 679.637 151.586 679.723 152.014C677.58 154.329 675.308 156 672.908 157.029C670.594 158.057 668.237 158.571 665.837 158.571ZM655.165 146.614L655.423 127.329C647.537 128.357 642.094 130.029 639.094 132.343C636.18 134.657 634.723 137.614 634.723 141.214C634.723 144.214 635.494 146.529 637.037 148.157C638.665 149.7 640.68 150.471 643.08 150.471C644.623 150.471 646.337 150.129 648.223 149.443C650.194 148.757 652.508 147.814 655.165 146.614Z" fill="currentColor"></path><rect x="715" y="65" width="195" height="105" rx="52.5" fill="currentColor" fill-opacity="0.05"></rect><path d="M767.529 142.875L754.049 107.938H762.552L769.309 127.582C769.705 128.812 770.078 130.032 770.43 131.24C770.781 132.449 771.078 133.559 771.32 134.569H771.616C771.858 133.559 772.144 132.449 772.473 131.24C772.825 130.032 773.198 128.812 773.594 127.582L780.186 107.938H788.689L775.472 142.875H767.529ZM810.856 143.633C806.901 143.633 803.528 142.71 800.737 140.865C797.969 138.997 795.871 136.305 794.442 132.79C793.014 129.252 792.3 124.989 792.3 120.001V118.255C792.3 113.245 793.014 108.982 794.442 105.467C795.871 101.929 797.969 99.2373 800.737 97.3916C803.528 95.5239 806.901 94.5901 810.856 94.5901C814.789 94.5901 818.129 95.5129 820.875 97.3586C823.644 99.2043 825.731 101.907 827.138 105.467C828.566 109.004 829.28 113.267 829.28 118.255V120.001C829.28 124.989 828.577 129.252 827.171 132.79C825.764 136.327 823.677 139.019 820.908 140.865C818.162 142.71 814.811 143.633 810.856 143.633ZM810.889 136.382C813.064 136.382 814.877 135.789 816.327 134.602C817.799 133.416 818.898 131.658 819.623 129.329C820.348 126.978 820.711 124.066 820.711 120.595V117.694C820.711 114.223 820.337 111.311 819.59 108.96C818.865 106.609 817.777 104.84 816.327 103.654C814.877 102.445 813.064 101.841 810.889 101.841C808.714 101.841 806.879 102.434 805.385 103.621C803.912 104.785 802.792 106.554 802.023 108.927C801.276 111.278 800.902 114.201 800.902 117.694V120.595C800.902 124.044 801.287 126.945 802.056 129.296C802.825 131.647 803.945 133.416 805.418 134.602C806.89 135.789 808.714 136.382 810.889 136.382ZM838.988 143.205C838 143.205 837.099 142.985 836.286 142.545C835.495 142.106 834.879 141.491 834.44 140.7C834.001 139.909 833.781 139.019 833.781 138.03C833.781 137.019 834.001 136.118 834.44 135.327C834.879 134.536 835.495 133.921 836.286 133.482C837.099 133.042 838 132.823 838.988 132.823C839.977 132.823 840.867 133.042 841.658 133.482C842.449 133.921 843.064 134.536 843.504 135.327C843.943 136.118 844.163 137.019 844.163 138.03C844.163 139.019 843.943 139.909 843.504 140.7C843.064 141.491 842.449 142.106 841.658 142.545C840.867 142.985 839.977 143.205 838.988 143.205ZM857.365 142.875V104.511L846.39 111.663V103.357L858.453 95.3481H865.802V142.875H857.365Z" fill="currentColor"></path></svg></a></div><div class="flex items-center gap-1"><button class="focus-visible:ring-ring inline-flex items-center justify-center gap-x-2 whitespace-nowrap rounded-full text-sm font-medium transition-colors focus-visible:outline-none focus-visible:ring-1 disabled:pointer-events-none disabled:cursor-not-allowed disabled:opacity-50 [&amp;&gt;[data-slot=icon]]:-mx-0.5 [&amp;&gt;[data-slot=icon]]:my-0.5 [&amp;&gt;[data-slot=icon]]:size-5 [&amp;&gt;[data-slot=icon]]:shrink-0 [&amp;&gt;[data-slot=icon]]:text-[--btn-icon] [&amp;&gt;[data-slot=icon]]:sm:my-1 [&amp;&gt;[data-slot=icon]]:sm:size-4 text-primary hover:bg-overlay-hover px-4 py-2 w-9 h-9 flex-shrink-0 [&amp;_svg]:!w-5" type="button" id="radix-_R_aipfiumdb_" aria-haspopup="menu" aria-expanded="false" data-state="closed"><span class="inline-flex items-center justify-center p-0 m-0 w-6 h-6 rotate-0 scale-100 transition-all dark:-rotate-90 dark:scale-0" data-namespace="@xai/icons" data-slot="icon"><svg xmlns="http://www.w3.org/2000/svg" fill="currentColor" viewBox="0 0 24 24" aria-hidden="true" class="w-6 h-6" focusable="false" style="fill:currentColor"><path d="M12 18a6 6 0 1 1 0-12 6 6 0 0 1 0 12m0-2a4 4 0 1 0 0-8 4 4 0 0 0 0 8M11 1h2v3h-2zm0 19h2v3h-2zM3.515 4.929l1.414-1.414L7.05 5.636 5.636 7.05zM16.95 18.364l1.414-1.414 2.121 2.121-1.414 1.414zm2.121-14.85 1.414 1.415-2.121 2.121-1.414-1.414zM5.636 16.95l1.414 1.414-2.121 2.121-1.414-1.414zM23 11v2h-3v-2zM4 11v2H1v-2z"></path></svg></span><span class="inline-flex items-center justify-center p-0 m-0 w-6 h-6 absolute rotate-90 scale-0 transition-all dark:rotate-0 dark:scale-100" data-namespace="@xai/icons" data-slot="icon"><svg xmlns="http://www.w3.org/2000/svg" fill="currentColor" viewBox="0 0 24 24" aria-hidden="true" class="w-6 h-6" focusable="false" style="fill:currentColor"><path d="M10 7a7 7 0 0 0 12 4.9v.1c0 5.523-4.477 10-10 10S2 17.523 2 12 6.477 2 12 2h.1A6.98 6.98 0 0 0 10 7m-6 5a8 8 0 0 0 15.062 3.762A9 9 0 0 1 8.238 4.938 8 8 0 0 0 4 12"></path></svg></span><span class="sr-only">Toggle theme</span></button><button class="focus-visible:ring-ring inline-flex items-center justify-center gap-x-2 whitespace-nowrap rounded-full text-sm font-medium transition-colors focus-visible:outline-none focus-visible:ring-1 disabled:pointer-events-none disabled:cursor-not-allowed disabled:opacity-50 [&amp;&gt;[data-slot=icon]]:-mx-0.5 [&amp;&gt;[data-slot=icon]]:my-0.5 [&amp;&gt;[data-slot=icon]]:size-5 [&amp;&gt;[data-slot=icon]]:shrink-0 [&amp;&gt;[data-slot=icon]]:text-[--btn-icon] [&amp;&gt;[data-slot=icon]]:sm:my-1 [&amp;&gt;[data-slot=icon]]:sm:size-4 text-primary hover:bg-overlay-hover h-9 w-9" type="button"><svg xmlns="http://www.w3.org/2000/svg" width="24" height="24" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round" class="lucide lucide-search h-5 w-5"><circle cx="11" cy="11" r="8"></circle><path d="m21 21-4.3-4.3"></path></svg></button></div></div></header><div class="bg-surface-base fixed right-0 top-16 z-50 h-[calc(100vh-4rem)] w-full transform border-l transition-transform duration-300 ease-in-out sm:w-1/2 md:hidden translate-x-full"><div class="flex flex-col gap-4 p-4"><div class="flex flex-row gap-2"><button class="focus-visible:ring-ring inline-flex items-center gap-x-2 whitespace-nowrap text-sm font-medium transition-colors focus-visible:outline-none focus-visible:ring-1 disabled:pointer-events-none disabled:cursor-not-allowed disabled:opacity-50 [&amp;&gt;[data-slot=icon]]:-mx-0.5 [&amp;&gt;[data-slot=icon]]:my-0.5 [&amp;&gt;[data-slot=icon]]:size-5 [&amp;&gt;[data-slot=icon]]:shrink-0 [&amp;&gt;[data-slot=icon]]:text-[--btn-icon] [&amp;&gt;[data-slot=icon]]:sm:my-1 [&amp;&gt;[data-slot=icon]]:sm:size-4 border-input text-primary hover:border-primary/15 border hover:bg-overlay-hover py-2 max-w-full shadow-none sm:w-80 h-10 w-full justify-start rounded-full bg-surface-l1 px-4" type="button"><div class="flex items-center justify-between sm:w-full gap-4"><div class="flex items-center justify-start gap-2"><span class="inline-flex items-center justify-center p-0 m-0 w-4 h-4 text-muted" data-namespace="@xai/icons" data-slot="icon"><svg xmlns="http://www.w3.org/2000/svg" fill="currentColor" viewBox="0 0 24 24" aria-hidden="true" class="w-4 h-4" focusable="false" style="fill:currentColor"><path d="m18.031 16.617 4.283 4.282-1.415 1.415-4.282-4.283A8.96 8.96 0 0 1 11 20c-4.968 0-9-4.032-9-9s4.032-9 9-9 9 4.032 9 9a8.96 8.96 0 0 1-1.969 5.617m-2.006-.742A6.98 6.98 0 0 0 18 11c0-3.867-3.133-7-7-7s-7 3.133-7 7 3.133 7 7 7a6.98 6.98 0 0 0 4.875-1.975z"></path></svg></span><p class="text-sm text-muted hidden sm:block">Search</p></div><span class="hidden sm:block"><div class="bg-foreground/10 text-muted inline-flex items-center rounded-md px-1 py-0.5 text-center font-sans text-xs font-normal tracking-widest rtl:space-x-reverse"><span>âŒ˜</span><span class="text-xs">K</span></div></span></div></button></div></div></div><div><div class="min-[1350px]:grid min-[1350px]:grid-cols-[1fr_3fr_1fr]"><nav class="bg-surface-base hidden h-[calc(100vh-4rem)] overflow-y-auto px-6 pb-32 min-[1350px]:sticky min-[1350px]:top-16 min-[1350px]:block scrollbar-none [-ms-overflow-style:none] [scrollbar-width:none] [&amp;::-webkit-scrollbar]:hidden [overscroll-behavior:contain] pt-8"><ul class="space-y-2 text-sm"><li style="padding-left:0rem" class="flex items-start gap-2"><div class="bg-foreground mt-[0.5rem] h-1 w-1 flex-shrink-0 transition-opacity opacity-0"></div><a href="#cytokine-release-syndrome" class="transition-opacity hover:opacity-100 opacity-50">Cytokine release syndrome</a></li><li style="padding-left:0.75rem" class="flex items-start gap-2"><div class="bg-foreground mt-[0.5rem] h-1 w-1 flex-shrink-0 transition-opacity opacity-0"></div><a href="#signs-and-symptoms" class="transition-opacity hover:opacity-100 opacity-50">Signs and symptoms</a></li><li style="padding-left:0.75rem" class="flex items-start gap-2"><div class="bg-foreground mt-[0.5rem] h-1 w-1 flex-shrink-0 transition-opacity opacity-0"></div><a href="#cause" class="transition-opacity hover:opacity-100 opacity-50">Cause</a></li><li style="padding-left:1.5rem" class="flex items-start gap-2"><div class="bg-foreground mt-[0.5rem] h-1 w-1 flex-shrink-0 transition-opacity opacity-0"></div><a href="#medications" class="transition-opacity hover:opacity-100 opacity-50">Medications</a></li><li style="padding-left:0.75rem" class="flex items-start gap-2"><div class="bg-foreground mt-[0.5rem] h-1 w-1 flex-shrink-0 transition-opacity opacity-0"></div><a href="#diagnosis" class="transition-opacity hover:opacity-100 opacity-50">Diagnosis</a></li><li style="padding-left:1.5rem" class="flex items-start gap-2"><div class="bg-foreground mt-[0.5rem] h-1 w-1 flex-shrink-0 transition-opacity opacity-0"></div><a href="#classification" class="transition-opacity hover:opacity-100 opacity-50">Classification</a></li><li style="padding-left:0.75rem" class="flex items-start gap-2"><div class="bg-foreground mt-[0.5rem] h-1 w-1 flex-shrink-0 transition-opacity opacity-0"></div><a href="#prevention" class="transition-opacity hover:opacity-100 opacity-50">Prevention</a></li><li style="padding-left:0.75rem" class="flex items-start gap-2"><div class="bg-foreground mt-[0.5rem] h-1 w-1 flex-shrink-0 transition-opacity opacity-0"></div><a href="#management" class="transition-opacity hover:opacity-100 opacity-50">Management</a></li><li style="padding-left:0.75rem" class="flex items-start gap-2"><div class="bg-foreground mt-[0.5rem] h-1 w-1 flex-shrink-0 transition-opacity opacity-0"></div><a href="#epidemiology" class="transition-opacity hover:opacity-100 opacity-50">Epidemiology</a></li><li style="padding-left:0rem" class="flex items-start gap-2"><div class="bg-foreground mt-[0.5rem] h-1 w-1 flex-shrink-0 transition-opacity opacity-0"></div><a href="#therapeutic-targets-for-cytokine-release-syndrome-in-car-t-therapy" class="transition-opacity hover:opacity-100 opacity-50">Therapeutic Targets for Cytokine Release Syndrome in CAR-T Therapy</a></li><li style="padding-left:0.75rem" class="flex items-start gap-2"><div class="bg-foreground mt-[0.5rem] h-1 w-1 flex-shrink-0 transition-opacity opacity-0"></div><a href="#research" class="transition-opacity hover:opacity-100 opacity-50">Research</a></li><li style="padding-left:0.75rem" class="flex items-start gap-2"><div class="bg-foreground mt-[0.5rem] h-1 w-1 flex-shrink-0 transition-opacity opacity-0"></div><a href="#references" class="transition-opacity hover:opacity-100 opacity-50">References</a></li></ul></nav><div class="relative top-16 pb-32 pt-8 px-4 md:px-8"><div class="mx-auto max-w-[850px]"><button data-state="closed" type="button" class="flex items-center"><div class="text-fg-tertiary mb-2 flex cursor-help items-center gap-2 text-sm"><span class="inline-flex items-center justify-center p-0 m-0" data-namespace="@xai/icons" data-slot="icon" style="height:16px;width:16px"><svg xmlns="http://www.w3.org/2000/svg" fill="none" viewBox="0 0 33 33" aria-hidden="true" class="" focusable="false" style="fill:currentColor;height:16px;width:16px"><path fill="currentColor" d="m13.237 21.04 11.082-8.19c.543-.4 1.32-.244 1.578.38 1.363 3.288.754 7.241-1.957 9.955-2.71 2.714-6.482 3.31-9.93 1.954l-3.765 1.745c5.401 3.697 11.96 2.782 16.059-1.324 3.251-3.255 4.258-7.692 3.317-11.693l.008.009c-1.365-5.878.336-8.227 3.82-13.031q.123-.17.247-.345l-4.585 4.59v-.014L13.234 21.044M10.95 23.031c-3.877-3.707-3.208-9.446.1-12.755 2.446-2.449 6.454-3.448 9.952-1.979L24.76 6.56c-.677-.49-1.545-1.017-2.54-1.387A12.465 12.465 0 0 0 8.675 7.901c-3.519 3.523-4.625 8.94-2.725 13.561 1.42 3.454-.907 5.898-3.251 8.364-.83.874-1.664 1.749-2.335 2.674l10.583-9.466"></path></svg></span><span>Fact-checked by Grok<!-- --> <!-- -->4 days ago</span></div></button><article class="text-[16px]"><h1 id="cytokine-release-syndrome" class="group relative mb-2 scroll-mt-24 font-serif text-[2.125em] font-semibold tracking-[-1px] [&amp;:not(:first-child)]:mt-14" node="[object Object]">Cytokine release syndrome<button class="focus-visible:ring-ring gap-x-2 whitespace-nowrap rounded-full font-medium focus-visible:outline-none focus-visible:ring-1 disabled:pointer-events-none disabled:cursor-not-allowed disabled:opacity-50 [&amp;&gt;[data-slot=icon]]:-mx-0.5 [&amp;&gt;[data-slot=icon]]:my-0.5 [&amp;&gt;[data-slot=icon]]:size-5 [&amp;&gt;[data-slot=icon]]:shrink-0 [&amp;&gt;[data-slot=icon]]:text-[--btn-icon] [&amp;&gt;[data-slot=icon]]:sm:my-1 [&amp;&gt;[data-slot=icon]]:sm:size-4 text-primary text-xs ml-2 inline-flex h-6 w-6 items-center justify-center p-0 align-middle opacity-0 transition-opacity hover:bg-gray-100 dark:hover:bg-gray-800" type="button" aria-label="Copy link to heading" data-state="closed"><svg xmlns="http://www.w3.org/2000/svg" width="24" height="24" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round" class="lucide lucide-link h-4 w-4"><path d="M10 13a5 5 0 0 0 7.54.54l3-3a5 5 0 0 0-7.07-7.07l-1.72 1.71"></path><path d="M14 11a5 5 0 0 0-7.54-.54l-3 3a5 5 0 0 0 7.07 7.07l1.71-1.71"></path></svg></button></h1>

















<!-- -->
<span class="mb-4 block break-words text-[1em] leading-7">In <span class="inline text-[1em] leading-7">immunology</span>, <strong>cytokine release syndrome</strong> (<strong>CRS</strong>) is a form of <span class="inline text-[1em] leading-7">systemic inflammatory response syndrome</span> (SIRS) that can be triggered by a variety of factors such as infections and certain drugs.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_a1abav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[3]</sup> CRS is a type of cytokine storm syndrome (CSS)<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_c1abav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[4]</sup> and occurs when large numbers of <span class="inline text-[1em] leading-7">white blood cells</span> are activated and release <span class="inline text-[1em] leading-7">inflammatory cytokines</span>, which in turn activate yet more white blood cells. CRS is also an <span class="inline text-[1em] leading-7">adverse effect</span> of some <span class="inline text-[1em] leading-7">monoclonal antibody</span> medications, as well as <span class="inline text-[1em] leading-7">adoptive T-cell therapies</span>.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_o1abav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[5]</sup><sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_p1abav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[6]</sup> When occurring as a result of a medication, it is also known as an <strong>infusion reaction</strong>.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_t1abav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[1]</sup> CRS gained widespread attention during the COVID-19 pandemic due to its role in severe cases.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_v1abav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[7]</sup><sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_101abav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[8]</sup></span>
<span class="mb-4 block break-words text-[1em] leading-7">The term <strong>cytokine storm</strong> is often used interchangeably with CRS but, despite the fact that they have similar <span class="inline text-[1em] leading-7">clinical phenotype</span>, their characteristics are different. When occurring as a result of a therapy, CRS symptoms may be delayed until days or weeks after treatment. Immediate-onset reactions associated with some therapies are termed cytokine storms,<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_61qbav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[9]</sup> although severe cases of CRS have also been called cytokine storms.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_81qbav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[2]</sup></span>
<h2 id="signs-and-symptoms" class="group relative mb-2 mt-7 scroll-mt-24 font-serif text-[1.714286em] font-semibold border-border-l1 pb-1 border-b overflow-hidden" node="[object Object]">Signs and symptoms<button class="focus-visible:ring-ring gap-x-2 whitespace-nowrap rounded-full font-medium focus-visible:outline-none focus-visible:ring-1 disabled:pointer-events-none disabled:cursor-not-allowed disabled:opacity-50 [&amp;&gt;[data-slot=icon]]:-mx-0.5 [&amp;&gt;[data-slot=icon]]:my-0.5 [&amp;&gt;[data-slot=icon]]:size-5 [&amp;&gt;[data-slot=icon]]:shrink-0 [&amp;&gt;[data-slot=icon]]:text-[--btn-icon] [&amp;&gt;[data-slot=icon]]:sm:my-1 [&amp;&gt;[data-slot=icon]]:sm:size-4 text-primary text-xs ml-2 inline-flex h-6 w-6 items-center justify-center p-0 align-middle opacity-0 transition-opacity hover:bg-gray-100 dark:hover:bg-gray-800" type="button" aria-label="Copy link to heading" data-state="closed"><svg xmlns="http://www.w3.org/2000/svg" width="24" height="24" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round" class="lucide lucide-link h-4 w-4"><path d="M10 13a5 5 0 0 0 7.54.54l3-3a5 5 0 0 0-7.07-7.07l-1.72 1.71"></path><path d="M14 11a5 5 0 0 0-7.54-.54l-3 3a5 5 0 0 0 7.07 7.07l1.71-1.71"></path></svg></button></h2>
<span class="mb-4 block break-words text-[1em] leading-7">Symptoms include fever that tends to fluctuate, fatigue, loss of appetite, muscle and joint pain, nausea, vomiting, diarrhea, rashes, fast breathing, rapid heartbeat, low blood pressure, seizures, headache, confusion, delirium, hallucinations, tremor, and loss of coordination.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_22qbav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[5]</sup></span>
<span class="mb-4 block break-words text-[1em] leading-7">Lab tests and clinical monitoring show low blood oxygen, widened pulse pressure, increased cardiac output (early), potentially diminished cardiac output (late), high levels of nitrogen compounds in the blood, elevated D-dimer, elevated transaminases, hypofibrinogenemia and excessive bleeding, higher-than-normal level of bilirubin, elevated C-reactive protein (CRP) and ferritin.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_23abav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[5]</sup><sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_33abav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[10]</sup></span>
<h2 id="cause" class="group relative mb-2 mt-7 scroll-mt-24 font-serif text-[1.714286em] font-semibold border-border-l1 pb-1 border-b overflow-hidden" node="[object Object]">Cause<button class="focus-visible:ring-ring gap-x-2 whitespace-nowrap rounded-full font-medium focus-visible:outline-none focus-visible:ring-1 disabled:pointer-events-none disabled:cursor-not-allowed disabled:opacity-50 [&amp;&gt;[data-slot=icon]]:-mx-0.5 [&amp;&gt;[data-slot=icon]]:my-0.5 [&amp;&gt;[data-slot=icon]]:size-5 [&amp;&gt;[data-slot=icon]]:shrink-0 [&amp;&gt;[data-slot=icon]]:text-[--btn-icon] [&amp;&gt;[data-slot=icon]]:sm:my-1 [&amp;&gt;[data-slot=icon]]:sm:size-4 text-primary text-xs ml-2 inline-flex h-6 w-6 items-center justify-center p-0 align-middle opacity-0 transition-opacity hover:bg-gray-100 dark:hover:bg-gray-800" type="button" aria-label="Copy link to heading" data-state="closed"><svg xmlns="http://www.w3.org/2000/svg" width="24" height="24" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round" class="lucide lucide-link h-4 w-4"><path d="M10 13a5 5 0 0 0 7.54.54l3-3a5 5 0 0 0-7.07-7.07l-1.72 1.71"></path><path d="M14 11a5 5 0 0 0-7.54-.54l-3 3a5 5 0 0 0 7.07 7.07l1.71-1.71"></path></svg></button></h2>
<span class="mb-4 block break-words text-[1em] leading-7">CRS occurs when large numbers of <span class="inline text-[1em] leading-7">white blood cells</span>, including <span class="inline text-[1em] leading-7">B cells</span>, <span class="inline text-[1em] leading-7">T cells</span>, <span class="inline text-[1em] leading-7">natural killer cells</span>, <span class="inline text-[1em] leading-7">macrophages</span>, <span class="inline text-[1em] leading-7">dendritic cells</span>, and <span class="inline text-[1em] leading-7">monocytes</span> are activated and release <span class="inline text-[1em] leading-7">inflammatory cytokines</span>, which activate more white blood cells in a positive feedback loop of pathogenic inflammation.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_i4abav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[5]</sup> Immune cells are activated by stressed or infected cells through receptor-ligand interactions.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_k4abav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[11]</sup></span>
<span class="mb-4 block break-words text-[1em] leading-7">This can occur when the <span class="inline text-[1em] leading-7">immune system</span> is fighting <span class="inline text-[1em] leading-7">pathogens</span>, as cytokines produced by immune cells recruit more effector immune cells such as <span class="inline text-[1em] leading-7">T-cells</span> and inflammatory monocytes (which differentiate into <span class="inline text-[1em] leading-7">macrophages</span>) to the site of inflammation or infection. In addition, pro-inflammatory cytokines binding their cognate receptor on immune cells results in activation and stimulation of further cytokine production.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_a4qbav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[12]</sup></span>
<span class="mb-4 block break-words text-[1em] leading-7"><span class="inline text-[1em] leading-7">Adoptive cell transfer</span> of autologous T-cells modified with <span class="inline text-[1em] leading-7">chimeric antigen receptors</span> (CAR-T cell therapy) also causes CRS.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_55abav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[5]</sup> Serum samples of patients with CAR-T associated CRS have elevated levels of <span class="inline text-[1em] leading-7">IL-6</span>, <span class="inline text-[1em] leading-7">IFN-Î³</span>, <span class="inline text-[1em] leading-7">IL-8</span> (CXCL8), <span class="inline text-[1em] leading-7">IL-10</span>, <span class="inline text-[1em] leading-7">GM-CSF</span>, <span class="inline text-[1em] leading-7">MIP-1Î±</span>/<span class="inline text-[1em] leading-7">Î²</span>, <span class="inline text-[1em] leading-7">MCP-1</span> (CCL2), <span class="inline text-[1em] leading-7">CXCL9</span>, and <span class="inline text-[1em] leading-7">CXCL10</span> (IP-10).<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_r5abav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[13]</sup> The most predictive biomarkers 36h after CAR-T infusion of CRS are a fever â‰¥38.9 Â°C (102 Â°F) and elevated levels of MCP-1 in serum.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_t5abav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[14]</sup> Many of the cytokines elevated in CRS are not produced by CAR-T cells, but by myeloid cells that are pathogenically licensed through T-cell-mediated activating mechanisms. For example, <span class="inline text-[1em] leading-7">in vitro</span> co-culture experiments have demonstrated IL-6, MCP-1, and MIP-1 are not produced by CAR-T cells, but rather by inflammatory myeloid lineage cells.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_115abav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[15]</sup> <span class="inline text-[1em] leading-7">In vivo</span> models have demonstrated NSG (NOD/SCID/Î³-chain deficient mice) with defects of both lymphocyte and myeloid lineage compartments do not develop CRS after CAR-T cell infusion.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_155abav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[16]</sup></span>
<span class="mb-4 block break-words text-[1em] leading-7">In addition to adoptive T-cell therapies, severe CRS or cytokine reactions can occur in a number of infectious and non-infectious conditions including <span class="inline text-[1em] leading-7">graft-versus-host disease</span> (GVHD), <span class="inline text-[1em] leading-7">acute respiratory distress syndrome</span> (ARDS), <span class="inline text-[1em] leading-7">sepsis</span>, <span class="inline text-[1em] leading-7">Ebola</span>, <span class="inline text-[1em] leading-7">avian influenza</span>, <span class="inline text-[1em] leading-7">smallpox</span>, and cytokine storms in infections such as <span class="inline text-[1em] leading-7">monkeypox</span>.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_g5qbav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[17]</sup><sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_h5qbav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[11]</sup> In infections, these reactions are often termed cytokine storms, distinct in timing and context from therapy-induced CRS, though sharing similar mechanisms.</span>
<span class="mb-4 block break-words text-[1em] leading-7">Although <span class="inline text-[1em] leading-7">severe acute respiratory syndrome coronavirus 2</span> (SARS-CoV-2) is sufficiently cleared by the early acute phase anti-viral response in most individuals, some progress to a hyperinflammatory condition, often with life-threatening pulmonary involvement. This systemic hyperinflammation results in inflammatory lymphocytic and monocytic infiltration of the lung and the heart, causing ARDS and cardiac failure.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_46abav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[7]</sup> Patients with fulminant COVID-19 and ARDS have classical serum biomarkers of CRS including elevated CRP, LDH, IL-6, and <span class="inline text-[1em] leading-7">ferritin</span>.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_86abav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[8]</sup></span>
<span class="mb-4 block break-words text-[1em] leading-7"><span class="inline text-[1em] leading-7">Hemophagocytic lymphohistiocytosis</span> and <span class="inline text-[1em] leading-7">Epstein-Barr virus-related hemophagocytic lymphohistiocytosis</span> are caused by extreme elevations in cytokines and can be regarded as one form of severe cytokine release syndrome.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_56qbav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[18]</sup></span>
<h3 id="medications" class="group relative mb-2 mt-7 scroll-mt-24 font-serif text-[1.428571em] font-semibold" node="[object Object]">Medications<button class="focus-visible:ring-ring gap-x-2 whitespace-nowrap rounded-full font-medium focus-visible:outline-none focus-visible:ring-1 disabled:pointer-events-none disabled:cursor-not-allowed disabled:opacity-50 [&amp;&gt;[data-slot=icon]]:-mx-0.5 [&amp;&gt;[data-slot=icon]]:my-0.5 [&amp;&gt;[data-slot=icon]]:size-5 [&amp;&gt;[data-slot=icon]]:shrink-0 [&amp;&gt;[data-slot=icon]]:text-[--btn-icon] [&amp;&gt;[data-slot=icon]]:sm:my-1 [&amp;&gt;[data-slot=icon]]:sm:size-4 text-primary text-xs ml-2 inline-flex h-6 w-6 items-center justify-center p-0 align-middle opacity-0 transition-opacity hover:bg-gray-100 dark:hover:bg-gray-800" type="button" aria-label="Copy link to heading" data-state="closed"><svg xmlns="http://www.w3.org/2000/svg" width="24" height="24" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round" class="lucide lucide-link h-4 w-4"><path d="M10 13a5 5 0 0 0 7.54.54l3-3a5 5 0 0 0-7.07-7.07l-1.72 1.71"></path><path d="M14 11a5 5 0 0 0-7.54-.54l-3 3a5 5 0 0 0 7.07 7.07l1.71-1.71"></path></svg></button></h3>
<span class="mb-4 block break-words text-[1em] leading-7">Cytokine reaction syndrome may also be induced by certain medications, such as the <span class="inline text-[1em] leading-7">CD20</span> antibody <span class="inline text-[1em] leading-7">rituximab</span> and the <span class="inline text-[1em] leading-7">CD19</span> CAR T cell <span class="inline text-[1em] leading-7">tisagenlecleucel</span>. The experimental drug <span class="inline text-[1em] leading-7">TGN1412</span>â€”also known as Theralizumabâ€”caused extremely serious symptoms when given to six participants in a <span class="inline text-[1em] leading-7">Phase I trial</span>.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_e7qbav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[2]</sup> A controlled and limited CRS is triggered by active fever therapy with mixed bacterial vaccines (MBV) according to <span class="inline text-[1em] leading-7">Coley</span>; it is used for oncological and certain chronic diseases.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_i7qbav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[19]</sup> CRS has also arisen with <span class="inline text-[1em] leading-7">biotherapeutics</span> such as monoclonal antibodies intended to suppress or activate the immune system through receptors on white blood cells. <span class="inline text-[1em] leading-7">Muromonab-CD3</span>, an anti-<span class="inline text-[1em] leading-7">CD3</span> monoclonal antibody intended to suppress the immune system to prevent rejection of <span class="inline text-[1em] leading-7">organ transplants</span>; <span class="inline text-[1em] leading-7">alemtuzumab</span>, which is anti-<span class="inline text-[1em] leading-7">CD52</span> and used to treat blood cancers as well as <span class="inline text-[1em] leading-7">multiple sclerosis</span> and in organ transplants; and <span class="inline text-[1em] leading-7">rituximab</span>, which is anti-<span class="inline text-[1em] leading-7">CD20</span> and used to treat blood cancers and auto-immune disorders, all cause CRS.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_167qbav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[5]</sup> Rare cases of cytokine storm have been reported following COVID-19 vaccination, though causality is not established.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_187qbav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[20]</sup></span>
<h2 id="diagnosis" class="group relative mb-2 mt-7 scroll-mt-24 font-serif text-[1.714286em] font-semibold border-border-l1 pb-1 border-b overflow-hidden" node="[object Object]">Diagnosis<button class="focus-visible:ring-ring gap-x-2 whitespace-nowrap rounded-full font-medium focus-visible:outline-none focus-visible:ring-1 disabled:pointer-events-none disabled:cursor-not-allowed disabled:opacity-50 [&amp;&gt;[data-slot=icon]]:-mx-0.5 [&amp;&gt;[data-slot=icon]]:my-0.5 [&amp;&gt;[data-slot=icon]]:size-5 [&amp;&gt;[data-slot=icon]]:shrink-0 [&amp;&gt;[data-slot=icon]]:text-[--btn-icon] [&amp;&gt;[data-slot=icon]]:sm:my-1 [&amp;&gt;[data-slot=icon]]:sm:size-4 text-primary text-xs ml-2 inline-flex h-6 w-6 items-center justify-center p-0 align-middle opacity-0 transition-opacity hover:bg-gray-100 dark:hover:bg-gray-800" type="button" aria-label="Copy link to heading" data-state="closed"><svg xmlns="http://www.w3.org/2000/svg" width="24" height="24" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round" class="lucide lucide-link h-4 w-4"><path d="M10 13a5 5 0 0 0 7.54.54l3-3a5 5 0 0 0-7.07-7.07l-1.72 1.71"></path><path d="M14 11a5 5 0 0 0-7.54-.54l-3 3a5 5 0 0 0 7.07 7.07l1.71-1.71"></path></svg></button></h2>
<span class="mb-4 block break-words text-[1em] leading-7">CRS needs to be distinguished from symptoms of the disease itself and, in the case of drugs, from other adverse effects; for example, tumor lysis syndrome requires different interventions. Differential diagnosis involves clinical judgment supported by objective biomarkers, including elevated levels of cytokines such as IL-6, IFN-Î³, IL-2, and IL-10, as well as CRP and ferritin, which aid in confirming CRS and assessing severity as of 2024.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_28qbav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[21]</sup><sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_38qbav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[22]</sup></span>
<h3 id="classification" class="group relative mb-2 mt-7 scroll-mt-24 font-serif text-[1.428571em] font-semibold" node="[object Object]">Classification<button class="focus-visible:ring-ring gap-x-2 whitespace-nowrap rounded-full font-medium focus-visible:outline-none focus-visible:ring-1 disabled:pointer-events-none disabled:cursor-not-allowed disabled:opacity-50 [&amp;&gt;[data-slot=icon]]:-mx-0.5 [&amp;&gt;[data-slot=icon]]:my-0.5 [&amp;&gt;[data-slot=icon]]:size-5 [&amp;&gt;[data-slot=icon]]:shrink-0 [&amp;&gt;[data-slot=icon]]:text-[--btn-icon] [&amp;&gt;[data-slot=icon]]:sm:my-1 [&amp;&gt;[data-slot=icon]]:sm:size-4 text-primary text-xs ml-2 inline-flex h-6 w-6 items-center justify-center p-0 align-middle opacity-0 transition-opacity hover:bg-gray-100 dark:hover:bg-gray-800" type="button" aria-label="Copy link to heading" data-state="closed"><svg xmlns="http://www.w3.org/2000/svg" width="24" height="24" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round" class="lucide lucide-link h-4 w-4"><path d="M10 13a5 5 0 0 0 7.54.54l3-3a5 5 0 0 0-7.07-7.07l-1.72 1.71"></path><path d="M14 11a5 5 0 0 0-7.54-.54l-3 3a5 5 0 0 0 7.07 7.07l1.71-1.71"></path></svg></button></h3>
<span class="mb-4 block break-words text-[1em] leading-7">CRS is a form of systemic inflammatory response syndrome and is an adverse effect of some drugs, particularly monoclonal antibodies and adoptive T-cell therapies.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_29qbav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[5]</sup></span>
<span class="mb-4 block break-words text-[1em] leading-7">The current standard for grading CRS, especially in the context of immune effector cell therapies, is the American Society for Transplantation and Cellular Therapy (ASTCT) consensus grading system established in 2019. This system classifies CRS based on fever (â‰¥38Â°C not attributable to other causes), hypotension, and hypoxia, with organ toxicities graded separately using CTCAE v5.0 (2017). The grades are as follows:<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_2aabav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[23]</sup></span>

































<div class="border-border-l1 overflow-x-auto rounded-lg border my-6 w-full"><table node="[object Object]" class="w-full border-collapse text-sm"><thead node="[object Object]" class="border-border-l1 border-b bg-surface-l1"><tr node="[object Object]" class="divide-border-l1 divide-x bg-surface-l1"><th node="[object Object]" class="dark:text-fg-primary bg-gray-100 px-2 py-1 text-left align-top font-bold dark:bg-black"><span class="text-[1em] leading-7">CRS Parameter</span></th><th node="[object Object]" class="dark:text-fg-primary bg-gray-100 px-2 py-1 text-left align-top font-bold dark:bg-black"><span class="text-[1em] leading-7">Grade 1</span></th><th node="[object Object]" class="dark:text-fg-primary bg-gray-100 px-2 py-1 text-left align-top font-bold dark:bg-black"><span class="text-[1em] leading-7">Grade 2</span></th><th node="[object Object]" class="dark:text-fg-primary bg-gray-100 px-2 py-1 text-left align-top font-bold dark:bg-black"><span class="text-[1em] leading-7">Grade 3</span></th><th node="[object Object]" class="dark:text-fg-primary bg-gray-100 px-2 py-1 text-left align-top font-bold dark:bg-black"><span class="text-[1em] leading-7">Grade 4</span></th></tr></thead><tbody node="[object Object]" class="divide-border-l1 divide-y"><tr node="[object Object]" class="divide-border-l1 divide-x bg-surface-l1"><td node="[object Object]" class="text-fg-primary px-2 py-1 align-top"><span class="text-[1em] leading-7">Fever</span></td><td node="[object Object]" class="text-fg-primary px-2 py-1 align-top"><span class="text-[1em] leading-7">â‰¥38Â°C</span></td><td node="[object Object]" class="text-fg-primary px-2 py-1 align-top"><span class="text-[1em] leading-7">â‰¥38Â°C</span></td><td node="[object Object]" class="text-fg-primary px-2 py-1 align-top"><span class="text-[1em] leading-7">â‰¥38Â°C</span></td><td node="[object Object]" class="text-fg-primary px-2 py-1 align-top"><span class="text-[1em] leading-7">â‰¥38Â°C</span></td></tr><tr node="[object Object]" class="divide-border-l1 divide-x bg-surface-l1"><td node="[object Object]" class="text-fg-primary px-2 py-1 align-top"><span class="text-[1em] leading-7">Hypotension</span></td><td node="[object Object]" class="text-fg-primary px-2 py-1 align-top"><span class="text-[1em] leading-7">None</span></td><td node="[object Object]" class="text-fg-primary px-2 py-1 align-top"><span class="text-[1em] leading-7">Not requiring vasopressors</span></td><td node="[object Object]" class="text-fg-primary px-2 py-1 align-top"><span class="text-[1em] leading-7">Requiring 1 vasopressor (with or without vasopressin)</span></td><td node="[object Object]" class="text-fg-primary px-2 py-1 align-top"><span class="text-[1em] leading-7">Requiring multiple vasopressors (excluding vasopressin)</span></td></tr><tr node="[object Object]" class="divide-border-l1 divide-x bg-surface-l1"><td node="[object Object]" class="text-fg-primary px-2 py-1 align-top"><span class="text-[1em] leading-7">Hypoxia</span></td><td node="[object Object]" class="text-fg-primary px-2 py-1 align-top"><span class="text-[1em] leading-7">None</span></td><td node="[object Object]" class="text-fg-primary px-2 py-1 align-top"><span class="text-[1em] leading-7">Requiring low-flow nasal cannula (â‰¤6 L/min) or blow-by</span></td><td node="[object Object]" class="text-fg-primary px-2 py-1 align-top"><span class="text-[1em] leading-7">Requiring high-flow nasal cannula (&gt;6 L/min), facemask, nonrebreather mask, or Venturi mask</span></td><td node="[object Object]" class="text-fg-primary px-2 py-1 align-top"><span class="text-[1em] leading-7">Requiring positive pressure (e.g., CPAP, BiPAP, intubation, mechanical ventilation)</span></td></tr></tbody></table></div>
<span class="mb-4 block break-words text-[1em] leading-7">CRS grade is determined by the more severe event among hypotension or hypoxia not attributable to any other cause. There is no grade 5 in the ASTCT system; death would be attributed to complications.</span>
<h2 id="prevention" class="group relative mb-2 mt-7 scroll-mt-24 font-serif text-[1.714286em] font-semibold border-border-l1 pb-1 border-b overflow-hidden" node="[object Object]">Prevention<button class="focus-visible:ring-ring gap-x-2 whitespace-nowrap rounded-full font-medium focus-visible:outline-none focus-visible:ring-1 disabled:pointer-events-none disabled:cursor-not-allowed disabled:opacity-50 [&amp;&gt;[data-slot=icon]]:-mx-0.5 [&amp;&gt;[data-slot=icon]]:my-0.5 [&amp;&gt;[data-slot=icon]]:size-5 [&amp;&gt;[data-slot=icon]]:shrink-0 [&amp;&gt;[data-slot=icon]]:text-[--btn-icon] [&amp;&gt;[data-slot=icon]]:sm:my-1 [&amp;&gt;[data-slot=icon]]:sm:size-4 text-primary text-xs ml-2 inline-flex h-6 w-6 items-center justify-center p-0 align-middle opacity-0 transition-opacity hover:bg-gray-100 dark:hover:bg-gray-800" type="button" aria-label="Copy link to heading" data-state="closed"><svg xmlns="http://www.w3.org/2000/svg" width="24" height="24" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round" class="lucide lucide-link h-4 w-4"><path d="M10 13a5 5 0 0 0 7.54.54l3-3a5 5 0 0 0-7.07-7.07l-1.72 1.71"></path><path d="M14 11a5 5 0 0 0-7.54-.54l-3 3a5 5 0 0 0 7.07 7.07l1.71-1.71"></path></svg></button></h2>
<span class="mb-4 block break-words text-[1em] leading-7">Severe CRS caused by some drugs, such as monoclonal antibodies, can be prevented by using lower doses, infusing slowly, and administering anti-histamines or corticosteroids before and during administration of the drug.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_2cabav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[1]</sup></span>
<span class="mb-4 block break-words text-[1em] leading-7">In vitro assays have been developed to understand the risk that pre-clinical drug candidates might cause CRS and guide dosing for Phase I trials, and regulatory agencies expect to see results of such tests in investigational new drug applications.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_2cqbav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[2]</sup><sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_3cqbav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[24]</sup></span>
<span class="mb-4 block break-words text-[1em] leading-7">A modified Chandler loop model can be used as a preclinical tool to assess infusion reactions.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_2dabav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[25]</sup></span>
<span class="mb-4 block break-words text-[1em] leading-7">For CAR T-cell therapies, prophylactic corticosteroids are generally avoided to preserve therapeutic efficacy, with prevention relying instead on dose fractionation and close monitoring.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_2dqbav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[3]</sup></span>
<h2 id="management" class="group relative mb-2 mt-7 scroll-mt-24 font-serif text-[1.714286em] font-semibold border-border-l1 pb-1 border-b overflow-hidden" node="[object Object]">Management<button class="focus-visible:ring-ring gap-x-2 whitespace-nowrap rounded-full font-medium focus-visible:outline-none focus-visible:ring-1 disabled:pointer-events-none disabled:cursor-not-allowed disabled:opacity-50 [&amp;&gt;[data-slot=icon]]:-mx-0.5 [&amp;&gt;[data-slot=icon]]:my-0.5 [&amp;&gt;[data-slot=icon]]:size-5 [&amp;&gt;[data-slot=icon]]:shrink-0 [&amp;&gt;[data-slot=icon]]:text-[--btn-icon] [&amp;&gt;[data-slot=icon]]:sm:my-1 [&amp;&gt;[data-slot=icon]]:sm:size-4 text-primary text-xs ml-2 inline-flex h-6 w-6 items-center justify-center p-0 align-middle opacity-0 transition-opacity hover:bg-gray-100 dark:hover:bg-gray-800" type="button" aria-label="Copy link to heading" data-state="closed"><svg xmlns="http://www.w3.org/2000/svg" width="24" height="24" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round" class="lucide lucide-link h-4 w-4"><path d="M10 13a5 5 0 0 0 7.54.54l3-3a5 5 0 0 0-7.07-7.07l-1.72 1.71"></path><path d="M14 11a5 5 0 0 0-7.54-.54l-3 3a5 5 0 0 0 7.07 7.07l1.71-1.71"></path></svg></button></h2>
<span class="mb-4 block break-words text-[1em] leading-7">Treatment for less severe CRS is supportive, addressing the symptoms like fever, muscle pain, or fatigue. Moderate CRS requires oxygen therapy and giving fluids and antihypotensive agents to raise blood pressure. For moderate to severe CRS, the use of immunosuppressive agents like corticosteroids may be necessary, but judgment must be used to avoid negating the effect of drugs intended to activate the immune system.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_2eqbav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[5]</sup></span>
<span class="mb-4 block break-words text-[1em] leading-7">Tocilizumab, an anti-IL-6 monoclonal antibody, was FDA approved for steroid-refractory CRS based on retrospective case study data.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_2fabav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[5]</sup><sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_3fabav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[6]</sup> Siltuximab is an alternative anti-IL-6 agent for cases refractory to tocilizumab. As of 2025, tocilizumab biosimilars (e.g., tocilizumab-anoh) are also approved for CRS management.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_5fabav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[26]</sup><sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_6fabav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[27]</sup></span>
<span class="mb-4 block break-words text-[1em] leading-7">Lenzilumab, an investigational anti-GM-CSF monoclonal antibody, showed efficacy in reducing cytokine release in a phase 3 trial for COVID-19-associated CRS-like symptoms by reducing activation of myeloid cells and decreasing the production of IL-1, IL-6, MCP-1, MIP-1, and IP-10.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_2fqbav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[28]</sup><sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_3fqbav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[29]</sup></span>
<span class="mb-4 block break-words text-[1em] leading-7">Although frequently used to treat severe CRS in people with ARDS, corticosteroids are recommended in current guidelines for moderate-to-severe ARDS (conditional, moderate certainty), with evidence of reduced 28-day mortality; NSAIDs have been evaluated in clinical trials and have shown no effect on lung mechanics, gas exchange, or beneficial outcome in early established ARDS.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_2gabav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[30]</sup><sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_3gabav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[31]</sup></span>
<h2 id="epidemiology" class="group relative mb-2 mt-7 scroll-mt-24 font-serif text-[1.714286em] font-semibold border-border-l1 pb-1 border-b overflow-hidden" node="[object Object]">Epidemiology<button class="focus-visible:ring-ring gap-x-2 whitespace-nowrap rounded-full font-medium focus-visible:outline-none focus-visible:ring-1 disabled:pointer-events-none disabled:cursor-not-allowed disabled:opacity-50 [&amp;&gt;[data-slot=icon]]:-mx-0.5 [&amp;&gt;[data-slot=icon]]:my-0.5 [&amp;&gt;[data-slot=icon]]:size-5 [&amp;&gt;[data-slot=icon]]:shrink-0 [&amp;&gt;[data-slot=icon]]:text-[--btn-icon] [&amp;&gt;[data-slot=icon]]:sm:my-1 [&amp;&gt;[data-slot=icon]]:sm:size-4 text-primary text-xs ml-2 inline-flex h-6 w-6 items-center justify-center p-0 align-middle opacity-0 transition-opacity hover:bg-gray-100 dark:hover:bg-gray-800" type="button" aria-label="Copy link to heading" data-state="closed"><svg xmlns="http://www.w3.org/2000/svg" width="24" height="24" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round" class="lucide lucide-link h-4 w-4"><path d="M10 13a5 5 0 0 0 7.54.54l3-3a5 5 0 0 0-7.07-7.07l-1.72 1.71"></path><path d="M14 11a5 5 0 0 0-7.54-.54l-3 3a5 5 0 0 0 7.07 7.07l1.71-1.71"></path></svg></button></h2>
<span class="mb-4 block break-words text-[1em] leading-7">The incidence of cytokine release syndrome (CRS) varies by trigger. In immune-modulating antibody therapies, such as rituximab, minor and moderate CRS are common, occurring in up to 80% of infusions, while severe CRS (grade â‰¥3) is rare, with rates below 5%.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_2habav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[6]</sup> In chimeric antigen receptor T-cell (CAR-T) therapies, any-grade CRS affects 50-100% of patients, with severe cases in 5-15% depending on the product and malignancy treated, though rates have decreased with prophylactic measures like tocilizumab as of 2023.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_4habav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[6]</sup><sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_5habav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[24]</sup> CRS also occurs in infections, contributing to systemic inflammatory response in approximately 20-30% of severe sepsis cases, particularly highlighted during the COVID-19 pandemic where it was implicated in many intensive care admissions.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_7habav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[7]</sup><sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_8habav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[8]</sup></span>
<h1 id="therapeutic-targets-for-cytokine-release-syndrome-in-car-t-therapy" class="group relative mb-2 scroll-mt-24 font-serif text-[2.125em] font-semibold tracking-[-1px] [&amp;:not(:first-child)]:mt-14" node="[object Object]">Therapeutic Targets for Cytokine Release Syndrome in CAR-T Therapy<button class="focus-visible:ring-ring gap-x-2 whitespace-nowrap rounded-full font-medium focus-visible:outline-none focus-visible:ring-1 disabled:pointer-events-none disabled:cursor-not-allowed disabled:opacity-50 [&amp;&gt;[data-slot=icon]]:-mx-0.5 [&amp;&gt;[data-slot=icon]]:my-0.5 [&amp;&gt;[data-slot=icon]]:size-5 [&amp;&gt;[data-slot=icon]]:shrink-0 [&amp;&gt;[data-slot=icon]]:text-[--btn-icon] [&amp;&gt;[data-slot=icon]]:sm:my-1 [&amp;&gt;[data-slot=icon]]:sm:size-4 text-primary text-xs ml-2 inline-flex h-6 w-6 items-center justify-center p-0 align-middle opacity-0 transition-opacity hover:bg-gray-100 dark:hover:bg-gray-800" type="button" aria-label="Copy link to heading" data-state="closed"><svg xmlns="http://www.w3.org/2000/svg" width="24" height="24" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round" class="lucide lucide-link h-4 w-4"><path d="M10 13a5 5 0 0 0 7.54.54l3-3a5 5 0 0 0-7.07-7.07l-1.72 1.71"></path><path d="M14 11a5 5 0 0 0-7.54-.54l-3 3a5 5 0 0 0 7.07 7.07l1.71-1.71"></path></svg></button></h1>
<h2 id="research" class="group relative mb-2 mt-7 scroll-mt-24 font-serif text-[1.714286em] font-semibold border-border-l1 pb-1 border-b overflow-hidden" node="[object Object]">Research<button class="focus-visible:ring-ring gap-x-2 whitespace-nowrap rounded-full font-medium focus-visible:outline-none focus-visible:ring-1 disabled:pointer-events-none disabled:cursor-not-allowed disabled:opacity-50 [&amp;&gt;[data-slot=icon]]:-mx-0.5 [&amp;&gt;[data-slot=icon]]:my-0.5 [&amp;&gt;[data-slot=icon]]:size-5 [&amp;&gt;[data-slot=icon]]:shrink-0 [&amp;&gt;[data-slot=icon]]:text-[--btn-icon] [&amp;&gt;[data-slot=icon]]:sm:my-1 [&amp;&gt;[data-slot=icon]]:sm:size-4 text-primary text-xs ml-2 inline-flex h-6 w-6 items-center justify-center p-0 align-middle opacity-0 transition-opacity hover:bg-gray-100 dark:hover:bg-gray-800" type="button" aria-label="Copy link to heading" data-state="closed"><svg xmlns="http://www.w3.org/2000/svg" width="24" height="24" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round" class="lucide lucide-link h-4 w-4"><path d="M10 13a5 5 0 0 0 7.54.54l3-3a5 5 0 0 0-7.07-7.07l-1.72 1.71"></path><path d="M14 11a5 5 0 0 0-7.54-.54l-3 3a5 5 0 0 0 7.07 7.07l1.71-1.71"></path></svg></button></h2>
<span class="mb-4 block break-words text-[1em] leading-7">Key therapeutic targets to abrogate hyper-inflammation in CRS are IL-1, IL-6, and GM-CSF. An in vivo model found that GM-CSF knockout CAR-T cells do not induce CRS in mice. However, IL-1R knockout and IL-6 knockout hosts were susceptible to CRS after the administration of wild-type CAR-T cells.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_2iqbav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[16]</sup> It is thought this may be because IL-1 and IL-6, which are myeloid-derived cytokines, are thus too far downstream of the inflammatory cascade. Moreover, while tocilizumab (anti-IL-6R monoclonal antibody) may have an anti-inflammatory and antipyretic effect, it has been shown to increase serum levels of IL-6 by saturating the receptor.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_4iqbav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[32]</sup> However, tocilizumab may not fully ameliorate neurotoxicity and has been associated in some studies with paradoxical worsening due to increased IL-6 signaling in the central nervous system.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_6iqbav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[33]</sup> Monoclonal antibody blockade of GM-CSF with lenzilumab has been demonstrated to protect mice from CAR-T associated CRS and neurotoxicity while maintaining anti-leukemic efficacy.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_8iqbav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[34]</sup> More recent research (as of 2023) has identified IL-6 translation as a therapeutic target, with metoprolol demonstrating potential to reduce CRS in human models without impairing CAR-T function.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_aiqbav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[35]</sup> Lenzilumab remains under investigation in ongoing clinical trials (Phase 2/3) for preventing CRS and neurotoxicity in CAR-T therapy.</span></article><div id="references" class="min-w-0 scroll-mt-8 overflow-hidden"><div class="text-[16px]"><h2 id="references" node="[object Object]" class="mb-2 mt-7 scroll-mt-24 font-serif text-[1.714286em] font-semibold border-border-l1 pb-1 border-b overflow-hidden">References</h2></div><ol class="columns-1 gap-x-12 [counter-reset:item] md:columns-2"><li id="1" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7">Vogel WH (April 2010). <a href="https://doi.org/10.1188%2F10.CJON.E10-E21" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">&quot;Infusion reactions: diagnosis, assessment, and management&quot;</a>. <em>Clinical Journal of Oncology Nursing</em>. <strong>14</strong> (2): E10-21. <span class="inline text-[1em] leading-7">doi</span>:<a href="https://doi.org/10.1188%2F10.CJON.E10-E21" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">10.1188/10.CJON.E10-E21</a>. <span class="inline text-[1em] leading-7">PMID</span> <a href="https://pubmed.ncbi.nlm.nih.gov/20350882" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">20350882</a>.</span></div></li><li id="2" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7">Vidal JM, Kawabata TT, Thorpe R, Silva-Lima B, Cederbrant K, Poole S, et al. (August 2010). &quot;In vitro cytokine release assays for predicting cytokine release syndrome: the current state-of-the-science. Report of a European Medicines Agency Workshop&quot;. <em>Cytokine</em>. <strong>51</strong> (2): 213â€“5. <span class="inline text-[1em] leading-7">doi</span>:<a href="https://doi.org/10.1016%2Fj.cyto.2010.04.008" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">10.1016/j.cyto.2010.04.008</a>. <span class="inline text-[1em] leading-7">PMID</span> <a href="https://pubmed.ncbi.nlm.nih.gov/20471854" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">20471854</a>.</span></div></li><li id="3" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7">Shimabukuro-Vornhagen A, GÃ¶del P, Subklewe M, Stemmler HJ, SchlÃ¶ÃŸer HA, Schlaak M, et al. (June 2018). <a href="https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6003181" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">&quot;Cytokine release syndrome&quot;</a>. <em>Journal for Immunotherapy of Cancer</em>. <strong>6</strong> (1): 56. <span class="inline text-[1em] leading-7">doi</span>:<a href="https://doi.org/10.1186%2Fs40425-018-0343-9" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">10.1186/s40425-018-0343-9</a>. <span class="inline text-[1em] leading-7">PMC</span> <a href="https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6003181" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">6003181</a>. <span class="inline text-[1em] leading-7">PMID</span> <a href="https://pubmed.ncbi.nlm.nih.gov/29907163" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">29907163</a>.</span></div></li><li id="4" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7">Behrens EM, Koretzky GA (June 2017). <a href="https://doi.org/10.1002%2Fart.40071" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">&quot;Review: Cytokine Storm Syndrome: Looking Toward the Precision Medicine Era&quot;</a>. <em>Arthritis &amp; Rheumatology</em>. <strong>69</strong> (6): 1135â€“1143. <span class="inline text-[1em] leading-7">doi</span>:<a href="https://doi.org/10.1002%2Fart.40071" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">10.1002/art.40071</a>. <span class="inline text-[1em] leading-7">PMID</span> <a href="https://pubmed.ncbi.nlm.nih.gov/28217930" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">28217930</a>. <span class="inline text-[1em] leading-7">S2CID</span> <a href="https://api.semanticscholar.org/CorpusID:21925082" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">21925082</a>.</span></div></li><li id="5" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7">Lee DW, Gardner R, Porter DL, Louis CU, Ahmed N, Jensen M, et al. (July 2014). <a href="https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4093680" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">&quot;Current concepts in the diagnosis and management of cytokine release syndrome&quot;</a>. <em>Blood</em>. <strong>124</strong> (2): 188â€“95. <span class="inline text-[1em] leading-7">doi</span>:<a href="https://doi.org/10.1182%2Fblood-2014-05-552729" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">10.1182/blood-2014-05-552729</a>. <span class="inline text-[1em] leading-7">PMC</span> <a href="https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4093680" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">4093680</a>. <span class="inline text-[1em] leading-7">PMID</span> <a href="https://pubmed.ncbi.nlm.nih.gov/24876563" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">24876563</a>.</span></div></li><li id="6" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7">Kroschinsky F, StÃ¶lzel F, von Bonin S, Beutel G, Kochanek M, Kiehl M, Schellongowski P (April 2017). <a href="https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5391608" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">&quot;New drugs, new toxicities: severe side effects of modern targeted and immunotherapy of cancer and their management&quot;</a>. <em>Critical Care</em>. <strong>21</strong> (1): 89. <span class="inline text-[1em] leading-7">doi</span>:<a href="https://doi.org/10.1186%2Fs13054-017-1678-1" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">10.1186/s13054-017-1678-1</a>. <span class="inline text-[1em] leading-7">PMC</span> <a href="https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5391608" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">5391608</a>. <span class="inline text-[1em] leading-7">PMID</span> <a href="https://pubmed.ncbi.nlm.nih.gov/28407743" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">28407743</a>.</span></div></li><li id="16" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7">Wadman M, Couzin-Frankel J, Kaiser J, Matacic C (April 2020). <a href="https://doi.org/10.1126%2Fscience.368.6489.356" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">&quot;A rampage through the body&quot;</a>. <em>Science</em>. <strong>368</strong> (6489): 356â€“360. <span class="inline text-[1em] leading-7">Bibcode</span>:<a href="https://ui.adsabs.harvard.edu/abs/2020Sci...368..356W" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">2020Sci...368..356W</a>. <span class="inline text-[1em] leading-7">doi</span>:<a href="https://doi.org/10.1126%2Fscience.368.6489.356" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">10.1126/science.368.6489.356</a>. <span class="inline text-[1em] leading-7">PMID</span> <a href="https://pubmed.ncbi.nlm.nih.gov/32327580" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">32327580</a>. <span class="inline text-[1em] leading-7">S2CID</span> <a href="https://api.semanticscholar.org/CorpusID:216110951" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">216110951</a>.</span></div></li><li id="17" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7">Zhang C, Wu Z, Li JW, Zhao H, Wang GQ (March 2020). <a href="https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7118634" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">&quot;The cytokine release syndrome (CRS) of severe COVID-19 and Interleukin-6 receptor (IL-6R) antagonist Tocilizumab may be the key to reduce the mortality&quot;</a>. <em>International Journal of Antimicrobial Agents</em>. <strong>55</strong> (5): 105954. <span class="inline text-[1em] leading-7">doi</span>:<a href="https://doi.org/10.1016%2Fj.ijantimicag.2020.105954" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">10.1016/j.ijantimicag.2020.105954</a>. <span class="inline text-[1em] leading-7">PMC</span> <a href="https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7118634" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">7118634</a>. <span class="inline text-[1em] leading-7">PMID</span> <a href="https://pubmed.ncbi.nlm.nih.gov/32234467" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">32234467</a>.</span></div></li><li id="7" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7">Porter D, Frey N, Wood PA, Weng Y, Grupp SA (March 2018). <a href="https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5833070" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">&quot;Grading of cytokine release syndrome associated with the CAR T cell therapy tisagenlecleucel&quot;</a>. <em>Journal of Hematology &amp; Oncology</em>. <strong>11</strong> (1): 35. <span class="inline text-[1em] leading-7">doi</span>:<a href="https://doi.org/10.1186%2Fs13045-018-0571-y" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">10.1186/s13045-018-0571-y</a>. <span class="inline text-[1em] leading-7">PMC</span> <a href="https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5833070" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">5833070</a>. <span class="inline text-[1em] leading-7">PMID</span> <a href="https://pubmed.ncbi.nlm.nih.gov/29499750" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">29499750</a>.</span></div></li><li id="8" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7">Bonifant CL, Jackson HJ, Brentjens RJ, Curran KJ (2016). <a href="https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5008265" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">&quot;Toxicity and management in CAR T-cell therapy&quot;</a>. <em>Molecular Therapy: Oncolytics</em>. <strong>3</strong> : 16011. <span class="inline text-[1em] leading-7">doi</span>:<a href="https://doi.org/10.1038%2Fmto.2016.11" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">10.1038/mto.2016.11</a>. <span class="inline text-[1em] leading-7">PMC</span> <a href="https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5008265" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">5008265</a>. <span class="inline text-[1em] leading-7">PMID</span> <a href="https://pubmed.ncbi.nlm.nih.gov/27626062" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">27626062</a>.</span></div></li><li id="9" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7">Liu Q, Zhou YH, Yang ZQ (January 2016). <a href="https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4711683" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">&quot;The cytokine storm of severe influenza and development of immunomodulatory therapy&quot;</a>. <em>Cellular &amp; Molecular Immunology</em>. <strong>13</strong> (1): 3â€“10. <span class="inline text-[1em] leading-7">doi</span>:<a href="https://doi.org/10.1038%2Fcmi.2015.74" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">10.1038/cmi.2015.74</a>. <span class="inline text-[1em] leading-7">PMC</span> <a href="https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4711683" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">4711683</a>. <span class="inline text-[1em] leading-7">PMID</span> <a href="https://pubmed.ncbi.nlm.nih.gov/26189369" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">26189369</a>.</span></div></li><li id="10" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7">Murphy K, Travers P, Walport M (2007). <a href="https://archive.org/details/janewaysimmunobi00murp" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">&quot;Signaling Through Immune System Receptors&quot;</a>. <em>Janeway&#x27;s Immunobiology</em> (7th ed.). London: Garland. <span class="inline text-[1em] leading-7">ISBN</span> 978-0-8153-4123-9.</span></div></li><li id="11" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7">Teachey DT, Lacey SF, Shaw PA, Melenhorst JJ, Maude SL, Frey N, et al. (June 2016). <a href="https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5448406" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">&quot;Identification of Predictive Biomarkers for Cytokine Release Syndrome after Chimeric Antigen Receptor T-cell Therapy for Acute Lymphoblastic Leukemia&quot;</a>. <em>Cancer Discovery</em>. <strong>6</strong> (6): 664â€“79. <span class="inline text-[1em] leading-7">doi</span>:<a href="https://doi.org/10.1158%2F2159-8290.CD-16-0040" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">10.1158/2159-8290.CD-16-0040</a>. <span class="inline text-[1em] leading-7">PMC</span> <a href="https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5448406" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">5448406</a>. <span class="inline text-[1em] leading-7">PMID</span> <a href="https://pubmed.ncbi.nlm.nih.gov/27076371" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">27076371</a>.</span></div></li><li id="12" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7">Hay KA, Hanafi LA, Li D, Gust J, Liles WC, Wurfel MM, et al. (November 2017). <a href="https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5701525" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">&quot;Kinetics and biomarkers of severe cytokine release syndrome after CD19 chimeric antigen receptor-modified T-cell therapy&quot;</a>. <em>Blood</em>. <strong>130</strong> (21): 2295â€“2306. <span class="inline text-[1em] leading-7">doi</span>:<a href="https://doi.org/10.1182%2Fblood-2017-06-793141" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">10.1182/blood-2017-06-793141</a>. <span class="inline text-[1em] leading-7">PMC</span> <a href="https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5701525" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">5701525</a>. <span class="inline text-[1em] leading-7">PMID</span> <a href="https://pubmed.ncbi.nlm.nih.gov/28924019" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">28924019</a>.</span></div></li><li id="13" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7">Barrett DM, et al. (2016). <a href="https://ashpublications.org/blood/article/128/22/654/99086/Interleukin-6-Is-Not-Made-By-Chimeric-Antigen" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">&quot;Interleukin 6 Is Not Made By Chimeric Antigen Receptor T Cells and Does Not Impact Their Function&quot;</a>. <em>Blood</em>. <strong>128</strong> (22): 654. <span class="inline text-[1em] leading-7">doi</span>:<a href="https://doi.org/10.1182%2Fblood.V128.22.654.654" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">10.1182/blood.V128.22.654.654</a>.</span></div></li><li id="14" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7">Sentman ML, Murad JM, Cook WJ, Wu MR, Reder J, Baumeister SH, et al. (December 2016). <a href="https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5136298" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">&quot;Mechanisms of Acute Toxicity in NKG2D Chimeric Antigen Receptor T Cell-Treated Mice&quot;</a>. <em>Journal of Immunology</em>. <strong>197</strong> (12): 4674â€“4685. <span class="inline text-[1em] leading-7">doi</span>:<a href="https://doi.org/10.4049%2Fjimmunol.1600769" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">10.4049/jimmunol.1600769</a>. <span class="inline text-[1em] leading-7">PMC</span> <a href="https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5136298" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">5136298</a>. <span class="inline text-[1em] leading-7">PMID</span> <a href="https://pubmed.ncbi.nlm.nih.gov/27849169" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">27849169</a>.</span></div></li><li id="15" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7">Drazen JM, Cecil RL, Goldman L, Bennett JC (2000). <a href="https://archive.org/details/ceciltextbookofm00ceci" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300"><em>Cecil Textbook of Medicine</em></a> (21st ed.). Philadelphia: W.B. Saunders. <span class="inline text-[1em] leading-7">ISBN</span> 978-0-7216-7996-9.</span></div></li><li id="18" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7">Rezk SA, Zhao X, Weiss LM (September 2018). &quot;Epstein-Barr virus (EBV)-associated lymphoid proliferations, a 2018 update&quot;. <em>Human Pathology</em>. <strong>79</strong> : 18â€“41. <span class="inline text-[1em] leading-7">doi</span>:<a href="https://doi.org/10.1016%2Fj.humpath.2018.05.020" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">10.1016/j.humpath.2018.05.020</a>. <span class="inline text-[1em] leading-7">PMID</span> <a href="https://pubmed.ncbi.nlm.nih.gov/29885408" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">29885408</a>. <span class="inline text-[1em] leading-7">S2CID</span> <a href="https://api.semanticscholar.org/CorpusID:47010934" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">47010934</a>.</span></div></li><li id="19" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7">E. GÃ¶hring: <em>Active Fever Therapy with MBV â€“ Coley&#x27;s Toxins: The Perfect Storm of Cytokines</em> , Epubli, Berlin 2019, <span class="inline text-[1em] leading-7">ISBN</span> 978-3748530596.</span></div></li><li id="https://doi.org/10.3389/fimmu.2022.967226" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7"><a href="https://doi.org/10.3389/fimmu.2022.967226" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">https://doi.org/10.3389/fimmu.2022.967226</a></span></div></li><li id="https://www.frontiersin.org/journals/immunology/articles/10.3389/fimmu.2024.1450173/full" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7"><a href="https://www.frontiersin.org/journals/immunology/articles/10.3389/fimmu.2024.1450173/full" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">https://www.frontiersin.org/journals/immunology/articles/10.3389/fimmu.2024.1450173/full</a></span></div></li><li id="https://link.springer.com/article/10.1007/s44272-025-00044-0" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7"><a href="https://link.springer.com/article/10.1007/s44272-025-00044-0" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">https://link.springer.com/article/10.1007/s44272-025-00044-0</a></span></div></li><li id="https://doi.org/10.1016/j.bbmt.2018.12.758" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7"><a href="https://doi.org/10.1016/j.bbmt.2018.12.758" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">https://doi.org/10.1016/j.bbmt.2018.12.758</a></span></div></li><li id="21" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7"><a href="https://web.archive.org/web/20191213233706/https://www.fda.gov/media/85017/download" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">&quot;Guidance for Industry: Immunogenicity Assessment for Therapeutic Protein Products&quot;</a> (PDF). FDA. August 2014. Archived from <a href="https://www.fda.gov/media/85017/download" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">the original</a> on December 13, 2019.</span></div></li><li id="22" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7">Fletcher EA, Eltahir M, Lindqvist F, Rieth J, TÃ¶rnqvist G, Leja-Jarblad J, Mangsbo SM (January 2018). <a href="https://doi.org/10.1016%2Fj.intimp.2017.10.021" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">&quot;Extracorporeal human whole blood in motion, as a tool to predict first-infusion reactions and mechanism-of-action of immunotherapeutics&quot;</a>. <em>International Immunopharmacology</em>. <strong>54</strong> : 1â€“11. <span class="inline text-[1em] leading-7">doi</span>:<a href="https://doi.org/10.1016%2Fj.intimp.2017.10.021" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">10.1016/j.intimp.2017.10.021</a>. <span class="inline text-[1em] leading-7">PMID</span> <a href="https://pubmed.ncbi.nlm.nih.gov/29100032" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">29100032</a>.</span></div></li><li id="https://www.astctjournal.org/article/S1083-8791(18)31292-0/fulltext" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7"><a href="https://www.astctjournal.org/article/S1083-8791(18)31292-0/fulltext" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">https://www.astctjournal.org/article/S1083-8791(18)31292-0/fulltext</a></span></div></li><li id="https://www.targetedonc.com/view/fda-expands-approval-for-tocilizumab-biosimilar-to-treat-crs" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7"><a href="https://www.targetedonc.com/view/fda-expands-approval-for-tocilizumab-biosimilar-to-treat-crs" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">https://www.targetedonc.com/view/fda-expands-approval-for-tocilizumab-biosimilar-to-treat-crs</a></span></div></li><li id="23" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7">Zelalem T, Charles B, Jason B, Christopher P, Claudia L, Colleen K, Vincent M, Robert O, Victoria C, William A, Cameron D, Dale C, Omar A, Gabrielle C, Andrew B (December 2021). <a href="https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8109186" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">&quot;Lenzilumab in hospitalised patients with COVID-19 pneumonia (LIVE-AIR): a phase 3, randomised, placebo controlled trial&quot;</a>. <em>Lancet Respiratory Medicine</em>. <strong>9</strong> (12): 237â€“246. <span class="inline text-[1em] leading-7">doi</span>:<a href="https://doi.org/10.1016%2FS2213-2600%2821%2900494-X" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">10.1016/S2213-2600(21)00494-X</a>. <span class="inline text-[1em] leading-7">PMC</span> <a href="https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8109186" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">8109186</a>. <span class="inline text-[1em] leading-7">PMID</span> <a href="https://pubmed.ncbi.nlm.nih.gov/33972949" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">33972949</a>.</span></div></li><li id="24" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7">Temesgen, Zelalem; Burger, Charles; Baker, Jason; Polk, Christopher; Libertin, Claudia; Kelley, Colleen; Marconi, Vincent; Orenstein, Robert; Catterson, Victoria; Aronstein, William; Durrant, Cameron; Chappell, Dale; Chappell, Gabrielle; Ahmed, Omar; Badley, Andrew (2021). <a href="https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8503207" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">&quot;C-Reactive Protein as a Biomarker for Improved Efficacy of Lenzilumab in Patients with Covid-19: Results from the Live-Air Trial&quot;</a>. <em>Chest</em>. <strong>160</strong> (4): A2522 â€“ A2524. <span class="inline text-[1em] leading-7">doi</span>:<a href="https://doi.org/10.1016%2Fj.chest.2021.08.029" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">10.1016/j.chest.2021.08.029</a>. <span class="inline text-[1em] leading-7">PMC</span> <a href="https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8503207" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">8503207</a>. <span class="inline text-[1em] leading-7">S2CID</span> <a href="https://api.semanticscholar.org/CorpusID:238585501" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">238585501</a>.</span></div></li><li id="https://www.atsjournals.org/doi/10.1164/rccm.202311-2011ST" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7"><a href="https://www.atsjournals.org/doi/10.1164/rccm.202311-2011ST" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">https://www.atsjournals.org/doi/10.1164/rccm.202311-2011ST</a></span></div></li><li id="https://www.sccm.org/clinical-resources/guidelines/guidelines/use-of-corticosteroids-in-sepsis-ards-cap" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7"><a href="https://www.sccm.org/clinical-resources/guidelines/guidelines/use-of-corticosteroids-in-sepsis-ards-cap" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">https://www.sccm.org/clinical-resources/guidelines/guidelines/use-of-corticosteroids-in-sepsis-ards-cap</a></span></div></li><li id="26" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7">Santomasso BD, Park JH, Salloum D, Riviere I, Flynn J, Mead E, et al. (August 2018). <a href="https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6385599" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">&quot;Clinical and Biological Correlates of Neurotoxicity Associated with CAR T-cell Therapy in Patients with B-cell Acute Lymphoblastic Leukemia&quot;</a>. <em>Cancer Discovery</em>. <strong>8</strong> (8): 958â€“971. <span class="inline text-[1em] leading-7">doi</span>:<a href="https://doi.org/10.1158%2F2159-8290.CD-17-1319" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">10.1158/2159-8290.CD-17-1319</a>. <span class="inline text-[1em] leading-7">PMC</span> <a href="https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6385599" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">6385599</a>. <span class="inline text-[1em] leading-7">PMID</span> <a href="https://pubmed.ncbi.nlm.nih.gov/29880584" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">29880584</a>.</span></div></li><li id="https://www.sciencedirect.com/science/article/pii/S2473952924003604" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7"><a href="https://www.sciencedirect.com/science/article/pii/S2473952924003604" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">https://www.sciencedirect.com/science/article/pii/S2473952924003604</a></span></div></li><li id="27" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7">Sterner RM, Sakemura R, Cox MJ, Yang N, Khadka RH, Forsman CL, et al. (February 2019). <a href="https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6376281" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">&quot;GM-CSF inhibition reduces cytokine release syndrome and neuroinflammation but enhances CAR-T cell function in xenografts&quot;</a>. <em>Blood</em>. <strong>133</strong> (7): 697â€“709. <span class="inline text-[1em] leading-7">doi</span>:<a href="https://doi.org/10.1182%2Fblood-2018-10-881722" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">10.1182/blood-2018-10-881722</a>. <span class="inline text-[1em] leading-7">PMC</span> <a href="https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6376281" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">6376281</a>. <span class="inline text-[1em] leading-7">PMID</span> <a href="https://pubmed.ncbi.nlm.nih.gov/30463995" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">30463995</a>.</span></div></li><li id="https://pmc.ncbi.nlm.nih.gov/articles/PMC10432851/" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7"><a href="https://pmc.ncbi.nlm.nih.gov/articles/PMC10432851/" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">https://pmc.ncbi.nlm.nih.gov/articles/PMC10432851/</a></span></div></li></ol></div><div class="text-fg-secondary text-xs [&amp;_*]:mb-2"><hr class="border-border-l1 my-8 rounded-sm border-t"/>
<span class="mb-4 block break-words text-[1em] leading-7">The content is adapted from <a href="https://en.wikipedia.org/wiki/Cytokine_release_syndrome" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">Wikipedia</a>, licensed under Creative Commons Attribution-ShareAlike 4.0 License.</span></div></div></div><div class="hidden min-[1400px]:block"></div></div></div><!--$--><!--/$--><div role="region" aria-label="Notifications (F8)" tabindex="-1" style="pointer-events:none"><ol tabindex="-1" class="pointer-events-none fixed top-0 z-[100] flex max-h-screen w-full flex-col-reverse p-4 max-sm:left-0 sm:bottom-0 sm:right-0 sm:top-auto sm:max-w-[420px] sm:flex-col pl-16 pr-2 pt-16 sm:px-4"></ol></div><script type="application/json" id="server-client-data-experimentation">{"status":"uninitialized"}</script><script src="/_next/static/chunks/webpack-e121ed42680f327e.js" nonce="ZTYwMmJhNmYtNzA2Mi00ODJjLTkyZWMtZTEyMjYyYjIxODZj" id="_R_" async=""></script><script nonce="ZTYwMmJhNmYtNzA2Mi00ODJjLTkyZWMtZTEyMjYyYjIxODZj">(self.__next_f=self.__next_f||[]).push([0])</script><script nonce="ZTYwMmJhNmYtNzA2Mi00ODJjLTkyZWMtZTEyMjYyYjIxODZj">self.__next_f.push([1,"1:\"$Sreact.fragment\"\n3:I[91363,[],\"\"]\n4:I[23775,[],\"\"]\n5:I[57654,[\"8739\",\"static/chunks/63f0ec43-8ee6a76d70472249.js\",\"7670\",\"static/chunks/7670-7326298c9856172b.js\",\"282\",\"static/chunks/282-691fffb366e24ca5.js\",\"7515\",\"static/chunks/7515-336759ef5dad2b52.js\",\"927\",\"static/chunks/927-34e2a6da3e15e26b.js\",\"5855\",\"static/chunks/5855-243eeca8f0e4cabd.js\",\"4393\",\"static/chunks/4393-1c8dff25ec904469.js\",\"2225\",\"static/chunks/2225-454cf9f44775e7ce.js\",\"7618\",\"static/chunks/7618-43536a8fb0dd3bfe.js\",\"3699\",\"static/chunks/app/page/%5Bslug%5D/layout-55a344716dd57c44.js\"],\"PageHeaderProvider\"]\n6:I[17618,[\"8739\",\"static/chunks/63f0ec43-8ee6a76d70472249.js\",\"7670\",\"static/chunks/7670-7326298c9856172b.js\",\"282\",\"static/chunks/282-691fffb366e24ca5.js\",\"7515\",\"static/chunks/7515-336759ef5dad2b52.js\",\"927\",\"static/chunks/927-34e2a6da3e15e26b.js\",\"5855\",\"static/chunks/5855-243eeca8f0e4cabd.js\",\"4393\",\"static/chunks/4393-1c8dff25ec904469.js\",\"2225\",\"static/chunks/2225-454cf9f44775e7ce.js\",\"7618\",\"static/chunks/7618-43536a8fb0dd3bfe.js\",\"3699\",\"static/chunks/app/page/%5Bslug%5D/layout-55a344716dd57c44.js\"],\"HeaderContent\"]\n7:I[25529,[\"8739\",\"static/chunks/63f0ec43-8ee6a76d70472249.js\",\"7670\",\"static/chunks/7670-7326298c9856172b.js\",\"282\",\"static/chunks/282-691fffb366e24ca5.js\",\"7515\",\"static/chunks/7515-336759ef5dad2b52.js\",\"927\",\"static/chunks/927-34e2a6da3e15e26b.js\",\"7720\",\"static/chunks/7720-3a1e7e411adba2d3.js\",\"7086\",\"static/chunks/7086-1f1c4891d766e04f.js\",\"5855\",\"static/chunks/5855-243eeca8f0e4cabd.js\",\"4393\",\"static/chunks/4393-1c8dff25ec904469.js\",\"2225\",\"static/chunks/2225-454cf9f44775e7ce.js\",\"7618\",\"static/chunks/7618-43536a8fb0dd3bfe.js\",\"6751\",\"static/chunks/app/page/%5Bslug%5D/not-found-69a3edc7db5749d6.js\"],\"default\"]\n9:I[6666,[],\"OutletBoundary\"]\nb:I[80415,[],\"AsyncMetadataOutlet\"]\nd:I[6666,[],\"ViewportBoundary\"]\nf:I[6666,[],\"MetadataBoundary\"]\n10:\"$Sreact.suspense\"\n12:I[95909,[\"4219\",\"static/chunks/app/global-error-4d07d20223cd4b4c.js\"],\"default\"]\n"])</script><script nonce="ZTYwMmJhNmYtNzA2Mi00ODJjLTkyZWMtZTEyMjYyYjIxODZj">self.__next_f.push([1,"13:I[51498,[\"8739\",\"static/chunks/63f0ec43-8ee6a76d70472249.js\",\"2254\",\"static/chunks/8208b75a-a48e5a4507a0de91.js\",\"7670\",\"static/chunks/7670-7326298c9856172b.js\",\"282\",\"static/chunks/282-691fffb366e24ca5.js\",\"7515\",\"static/chunks/7515-336759ef5dad2b52.js\",\"5497\",\"static/chunks/5497-ab85ef3ea59dd353.js\",\"927\",\"static/chunks/927-34e2a6da3e15e26b.js\",\"6281\",\"static/chunks/6281-c6e84786dade3614.js\",\"7086\",\"static/chunks/7086-1f1c4891d766e04f.js\",\"2660\",\"static/chunks/2660-d983a7f287e89f18.js\",\"5002\",\"static/chunks/5002-9735c25beda556ba.js\",\"3655\",\"static/chunks/3655-6717081f7512305a.js\",\"8945\",\"static/chunks/8945-e4e3cf487f5e27c7.js\",\"5855\",\"static/chunks/5855-243eeca8f0e4cabd.js\",\"9214\",\"static/chunks/9214-a10614844a67ba31.js\",\"2225\",\"static/chunks/2225-454cf9f44775e7ce.js\",\"4789\",\"static/chunks/4789-2080f6497f78b5b6.js\",\"7177\",\"static/chunks/app/layout-226f2bd71acf9f9e.js\"],\"ConstantsProvider\"]\n"])</script><script nonce="ZTYwMmJhNmYtNzA2Mi00ODJjLTkyZWMtZTEyMjYyYjIxODZj">self.__next_f.push([1,"14:I[91073,[\"8739\",\"static/chunks/63f0ec43-8ee6a76d70472249.js\",\"2254\",\"static/chunks/8208b75a-a48e5a4507a0de91.js\",\"7670\",\"static/chunks/7670-7326298c9856172b.js\",\"282\",\"static/chunks/282-691fffb366e24ca5.js\",\"7515\",\"static/chunks/7515-336759ef5dad2b52.js\",\"5497\",\"static/chunks/5497-ab85ef3ea59dd353.js\",\"927\",\"static/chunks/927-34e2a6da3e15e26b.js\",\"6281\",\"static/chunks/6281-c6e84786dade3614.js\",\"7086\",\"static/chunks/7086-1f1c4891d766e04f.js\",\"2660\",\"static/chunks/2660-d983a7f287e89f18.js\",\"5002\",\"static/chunks/5002-9735c25beda556ba.js\",\"3655\",\"static/chunks/3655-6717081f7512305a.js\",\"8945\",\"static/chunks/8945-e4e3cf487f5e27c7.js\",\"5855\",\"static/chunks/5855-243eeca8f0e4cabd.js\",\"9214\",\"static/chunks/9214-a10614844a67ba31.js\",\"2225\",\"static/chunks/2225-454cf9f44775e7ce.js\",\"4789\",\"static/chunks/4789-2080f6497f78b5b6.js\",\"7177\",\"static/chunks/app/layout-226f2bd71acf9f9e.js\"],\"default\"]\n"])</script><script nonce="ZTYwMmJhNmYtNzA2Mi00ODJjLTkyZWMtZTEyMjYyYjIxODZj">self.__next_f.push([1,"15:I[38642,[\"8739\",\"static/chunks/63f0ec43-8ee6a76d70472249.js\",\"2254\",\"static/chunks/8208b75a-a48e5a4507a0de91.js\",\"7670\",\"static/chunks/7670-7326298c9856172b.js\",\"282\",\"static/chunks/282-691fffb366e24ca5.js\",\"7515\",\"static/chunks/7515-336759ef5dad2b52.js\",\"5497\",\"static/chunks/5497-ab85ef3ea59dd353.js\",\"927\",\"static/chunks/927-34e2a6da3e15e26b.js\",\"6281\",\"static/chunks/6281-c6e84786dade3614.js\",\"7086\",\"static/chunks/7086-1f1c4891d766e04f.js\",\"2660\",\"static/chunks/2660-d983a7f287e89f18.js\",\"5002\",\"static/chunks/5002-9735c25beda556ba.js\",\"3655\",\"static/chunks/3655-6717081f7512305a.js\",\"8945\",\"static/chunks/8945-e4e3cf487f5e27c7.js\",\"5855\",\"static/chunks/5855-243eeca8f0e4cabd.js\",\"9214\",\"static/chunks/9214-a10614844a67ba31.js\",\"2225\",\"static/chunks/2225-454cf9f44775e7ce.js\",\"4789\",\"static/chunks/4789-2080f6497f78b5b6.js\",\"7177\",\"static/chunks/app/layout-226f2bd71acf9f9e.js\"],\"default\"]\n"])</script><script nonce="ZTYwMmJhNmYtNzA2Mi00ODJjLTkyZWMtZTEyMjYyYjIxODZj">self.__next_f.push([1,"16:I[99648,[\"8739\",\"static/chunks/63f0ec43-8ee6a76d70472249.js\",\"2254\",\"static/chunks/8208b75a-a48e5a4507a0de91.js\",\"4684\",\"static/chunks/24cf1b50-159cca90b09285e0.js\",\"1829\",\"static/chunks/9ffa21ba-c069766d809bd4c7.js\",\"7670\",\"static/chunks/7670-7326298c9856172b.js\",\"282\",\"static/chunks/282-691fffb366e24ca5.js\",\"7515\",\"static/chunks/7515-336759ef5dad2b52.js\",\"5497\",\"static/chunks/5497-ab85ef3ea59dd353.js\",\"7720\",\"static/chunks/7720-3a1e7e411adba2d3.js\",\"6281\",\"static/chunks/6281-c6e84786dade3614.js\",\"7086\",\"static/chunks/7086-1f1c4891d766e04f.js\",\"600\",\"static/chunks/600-9a9fcafaaa6c1c4c.js\",\"5002\",\"static/chunks/5002-9735c25beda556ba.js\",\"5448\",\"static/chunks/5448-2a3cfd853d899c9a.js\",\"5855\",\"static/chunks/5855-243eeca8f0e4cabd.js\",\"4393\",\"static/chunks/4393-1c8dff25ec904469.js\",\"9214\",\"static/chunks/9214-a10614844a67ba31.js\",\"8\",\"static/chunks/8-8ca70ca619d8e099.js\",\"4789\",\"static/chunks/4789-2080f6497f78b5b6.js\",\"6304\",\"static/chunks/app/page/%5Bslug%5D/page-540a27b6839afde5.js\"],\"default\"]\n"])</script><script nonce="ZTYwMmJhNmYtNzA2Mi00ODJjLTkyZWMtZTEyMjYyYjIxODZj">self.__next_f.push([1,"17:I[78825,[\"8739\",\"static/chunks/63f0ec43-8ee6a76d70472249.js\",\"2254\",\"static/chunks/8208b75a-a48e5a4507a0de91.js\",\"7670\",\"static/chunks/7670-7326298c9856172b.js\",\"282\",\"static/chunks/282-691fffb366e24ca5.js\",\"7515\",\"static/chunks/7515-336759ef5dad2b52.js\",\"5497\",\"static/chunks/5497-ab85ef3ea59dd353.js\",\"927\",\"static/chunks/927-34e2a6da3e15e26b.js\",\"6281\",\"static/chunks/6281-c6e84786dade3614.js\",\"7086\",\"static/chunks/7086-1f1c4891d766e04f.js\",\"2660\",\"static/chunks/2660-d983a7f287e89f18.js\",\"5002\",\"static/chunks/5002-9735c25beda556ba.js\",\"3655\",\"static/chunks/3655-6717081f7512305a.js\",\"8945\",\"static/chunks/8945-e4e3cf487f5e27c7.js\",\"5855\",\"static/chunks/5855-243eeca8f0e4cabd.js\",\"9214\",\"static/chunks/9214-a10614844a67ba31.js\",\"2225\",\"static/chunks/2225-454cf9f44775e7ce.js\",\"4789\",\"static/chunks/4789-2080f6497f78b5b6.js\",\"7177\",\"static/chunks/app/layout-226f2bd71acf9f9e.js\"],\"default\"]\n"])</script><script nonce="ZTYwMmJhNmYtNzA2Mi00ODJjLTkyZWMtZTEyMjYyYjIxODZj">self.__next_f.push([1,"18:I[8550,[\"8739\",\"static/chunks/63f0ec43-8ee6a76d70472249.js\",\"2254\",\"static/chunks/8208b75a-a48e5a4507a0de91.js\",\"7670\",\"static/chunks/7670-7326298c9856172b.js\",\"282\",\"static/chunks/282-691fffb366e24ca5.js\",\"7515\",\"static/chunks/7515-336759ef5dad2b52.js\",\"5497\",\"static/chunks/5497-ab85ef3ea59dd353.js\",\"927\",\"static/chunks/927-34e2a6da3e15e26b.js\",\"6281\",\"static/chunks/6281-c6e84786dade3614.js\",\"7086\",\"static/chunks/7086-1f1c4891d766e04f.js\",\"2660\",\"static/chunks/2660-d983a7f287e89f18.js\",\"5002\",\"static/chunks/5002-9735c25beda556ba.js\",\"3655\",\"static/chunks/3655-6717081f7512305a.js\",\"8945\",\"static/chunks/8945-e4e3cf487f5e27c7.js\",\"5855\",\"static/chunks/5855-243eeca8f0e4cabd.js\",\"9214\",\"static/chunks/9214-a10614844a67ba31.js\",\"2225\",\"static/chunks/2225-454cf9f44775e7ce.js\",\"4789\",\"static/chunks/4789-2080f6497f78b5b6.js\",\"7177\",\"static/chunks/app/layout-226f2bd71acf9f9e.js\"],\"MixpanelProvider\"]\n"])</script><script nonce="ZTYwMmJhNmYtNzA2Mi00ODJjLTkyZWMtZTEyMjYyYjIxODZj">self.__next_f.push([1,"19:I[12290,[\"8739\",\"static/chunks/63f0ec43-8ee6a76d70472249.js\",\"2254\",\"static/chunks/8208b75a-a48e5a4507a0de91.js\",\"7670\",\"static/chunks/7670-7326298c9856172b.js\",\"282\",\"static/chunks/282-691fffb366e24ca5.js\",\"7515\",\"static/chunks/7515-336759ef5dad2b52.js\",\"5497\",\"static/chunks/5497-ab85ef3ea59dd353.js\",\"927\",\"static/chunks/927-34e2a6da3e15e26b.js\",\"6281\",\"static/chunks/6281-c6e84786dade3614.js\",\"7086\",\"static/chunks/7086-1f1c4891d766e04f.js\",\"2660\",\"static/chunks/2660-d983a7f287e89f18.js\",\"5002\",\"static/chunks/5002-9735c25beda556ba.js\",\"3655\",\"static/chunks/3655-6717081f7512305a.js\",\"8945\",\"static/chunks/8945-e4e3cf487f5e27c7.js\",\"5855\",\"static/chunks/5855-243eeca8f0e4cabd.js\",\"9214\",\"static/chunks/9214-a10614844a67ba31.js\",\"2225\",\"static/chunks/2225-454cf9f44775e7ce.js\",\"4789\",\"static/chunks/4789-2080f6497f78b5b6.js\",\"7177\",\"static/chunks/app/layout-226f2bd71acf9f9e.js\"],\"MobileTocProvider\"]\n"])</script><script nonce="ZTYwMmJhNmYtNzA2Mi00ODJjLTkyZWMtZTEyMjYyYjIxODZj">self.__next_f.push([1,"1a:I[53947,[\"8739\",\"static/chunks/63f0ec43-8ee6a76d70472249.js\",\"2254\",\"static/chunks/8208b75a-a48e5a4507a0de91.js\",\"7670\",\"static/chunks/7670-7326298c9856172b.js\",\"282\",\"static/chunks/282-691fffb366e24ca5.js\",\"7515\",\"static/chunks/7515-336759ef5dad2b52.js\",\"5497\",\"static/chunks/5497-ab85ef3ea59dd353.js\",\"927\",\"static/chunks/927-34e2a6da3e15e26b.js\",\"6281\",\"static/chunks/6281-c6e84786dade3614.js\",\"7086\",\"static/chunks/7086-1f1c4891d766e04f.js\",\"2660\",\"static/chunks/2660-d983a7f287e89f18.js\",\"5002\",\"static/chunks/5002-9735c25beda556ba.js\",\"3655\",\"static/chunks/3655-6717081f7512305a.js\",\"8945\",\"static/chunks/8945-e4e3cf487f5e27c7.js\",\"5855\",\"static/chunks/5855-243eeca8f0e4cabd.js\",\"9214\",\"static/chunks/9214-a10614844a67ba31.js\",\"2225\",\"static/chunks/2225-454cf9f44775e7ce.js\",\"4789\",\"static/chunks/4789-2080f6497f78b5b6.js\",\"7177\",\"static/chunks/app/layout-226f2bd71acf9f9e.js\"],\"NuqsAdapter\"]\n"])</script><script nonce="ZTYwMmJhNmYtNzA2Mi00ODJjLTkyZWMtZTEyMjYyYjIxODZj">self.__next_f.push([1,"1b:I[91873,[\"2254\",\"static/chunks/8208b75a-a48e5a4507a0de91.js\",\"7670\",\"static/chunks/7670-7326298c9856172b.js\",\"282\",\"static/chunks/282-691fffb366e24ca5.js\",\"5497\",\"static/chunks/5497-ab85ef3ea59dd353.js\",\"6281\",\"static/chunks/6281-c6e84786dade3614.js\",\"9214\",\"static/chunks/9214-a10614844a67ba31.js\",\"8039\",\"static/chunks/app/error-4a29e9399afba038.js\"],\"default\"]\n1c:I[5091,[\"8739\",\"static/chunks/63f0ec43-8ee6a76d70472249.js\",\"7670\",\"static/chunks/7670-7326298c9856172b.js\",\"282\",\"static/chunks/282-691fffb366e24ca5.js\",\"7515\",\"static/chunks/7515-336759ef5dad2b52.js\",\"927\",\"static/chunks/927-34e2a6da3e15e26b.js\",\"7720\",\"static/chunks/7720-3a1e7e411adba2d3.js\",\"7086\",\"static/chunks/7086-1f1c4891d766e04f.js\",\"5855\",\"static/chunks/5855-243eeca8f0e4cabd.js\",\"4393\",\"static/chunks/4393-1c8dff25ec904469.js\",\"2225\",\"static/chunks/2225-454cf9f44775e7ce.js\",\"7618\",\"static/chunks/7618-43536a8fb0dd3bfe.js\",\"4345\",\"static/chunks/app/not-found-dd95690acf732f18.js\"],\"default\"]\n"])</script><script nonce="ZTYwMmJhNmYtNzA2Mi00ODJjLTkyZWMtZTEyMjYyYjIxODZj">self.__next_f.push([1,"1d:I[16091,[\"8739\",\"static/chunks/63f0ec43-8ee6a76d70472249.js\",\"2254\",\"static/chunks/8208b75a-a48e5a4507a0de91.js\",\"7670\",\"static/chunks/7670-7326298c9856172b.js\",\"282\",\"static/chunks/282-691fffb366e24ca5.js\",\"7515\",\"static/chunks/7515-336759ef5dad2b52.js\",\"5497\",\"static/chunks/5497-ab85ef3ea59dd353.js\",\"927\",\"static/chunks/927-34e2a6da3e15e26b.js\",\"6281\",\"static/chunks/6281-c6e84786dade3614.js\",\"7086\",\"static/chunks/7086-1f1c4891d766e04f.js\",\"2660\",\"static/chunks/2660-d983a7f287e89f18.js\",\"5002\",\"static/chunks/5002-9735c25beda556ba.js\",\"3655\",\"static/chunks/3655-6717081f7512305a.js\",\"8945\",\"static/chunks/8945-e4e3cf487f5e27c7.js\",\"5855\",\"static/chunks/5855-243eeca8f0e4cabd.js\",\"9214\",\"static/chunks/9214-a10614844a67ba31.js\",\"2225\",\"static/chunks/2225-454cf9f44775e7ce.js\",\"4789\",\"static/chunks/4789-2080f6497f78b5b6.js\",\"7177\",\"static/chunks/app/layout-226f2bd71acf9f9e.js\"],\"default\"]\n"])</script><script nonce="ZTYwMmJhNmYtNzA2Mi00ODJjLTkyZWMtZTEyMjYyYjIxODZj">self.__next_f.push([1,":HL[\"/_next/static/media/1f2316909698f815.p.woff2\",\"font\",{\"crossOrigin\":\"\",\"nonce\":\"ZTYwMmJhNmYtNzA2Mi00ODJjLTkyZWMtZTEyMjYyYjIxODZj\",\"type\":\"font/woff2\"}]\n:HL[\"/_next/static/media/3d4419af2cf8609b.p.woff2\",\"font\",{\"crossOrigin\":\"\",\"nonce\":\"ZTYwMmJhNmYtNzA2Mi00ODJjLTkyZWMtZTEyMjYyYjIxODZj\",\"type\":\"font/woff2\"}]\n:HL[\"/_next/static/media/4dec29efcaeb336c.p.woff2\",\"font\",{\"crossOrigin\":\"\",\"nonce\":\"ZTYwMmJhNmYtNzA2Mi00ODJjLTkyZWMtZTEyMjYyYjIxODZj\",\"type\":\"font/woff2\"}]\n:HL[\"/_next/static/media/74452ea3ef0f9101.p.woff2\",\"font\",{\"crossOrigin\":\"\",\"nonce\":\"ZTYwMmJhNmYtNzA2Mi00ODJjLTkyZWMtZTEyMjYyYjIxODZj\",\"type\":\"font/woff2\"}]\n:HL[\"/_next/static/media/904ef0a86fe32a00.p.woff2\",\"font\",{\"crossOrigin\":\"\",\"nonce\":\"ZTYwMmJhNmYtNzA2Mi00ODJjLTkyZWMtZTEyMjYyYjIxODZj\",\"type\":\"font/woff2\"}]\n:HL[\"/_next/static/media/d886a03bcda7ad8f.p.woff2\",\"font\",{\"crossOrigin\":\"\",\"nonce\":\"ZTYwMmJhNmYtNzA2Mi00ODJjLTkyZWMtZTEyMjYyYjIxODZj\",\"type\":\"font/woff2\"}]\n:HL[\"/_next/static/media/e1447589d6f59c4b.p.woff2\",\"font\",{\"crossOrigin\":\"\",\"nonce\":\"ZTYwMmJhNmYtNzA2Mi00ODJjLTkyZWMtZTEyMjYyYjIxODZj\",\"type\":\"font/woff2\"}]\n:HL[\"/_next/static/media/f5a90156f8995c8c.p.woff2\",\"font\",{\"crossOrigin\":\"\",\"nonce\":\"ZTYwMmJhNmYtNzA2Mi00ODJjLTkyZWMtZTEyMjYyYjIxODZj\",\"type\":\"font/woff2\"}]\n:HL[\"/_next/static/css/62c4caba71dfda84.css\",\"style\",{\"nonce\":\"ZTYwMmJhNmYtNzA2Mi00ODJjLTkyZWMtZTEyMjYyYjIxODZj\"}]\n:HL[\"/_next/static/css/eb3d87f98fe1565f.css\",\"style\",{\"nonce\":\"ZTYwMmJhNmYtNzA2Mi00ODJjLTkyZWMtZTEyMjYyYjIxODZj\"}]\n:HL[\"/_next/static/css/1b5e561215938d4d.css\",\"style\",{\"nonce\":\"ZTYwMmJhNmYtNzA2Mi00ODJjLTkyZWMtZTEyMjYyYjIxODZj\"}]\n:HL[\"/_next/static/css/0227d069a630d414.css\",\"style\",{\"nonce\":\"ZTYwMmJhNmYtNzA2Mi00ODJjLTkyZWMtZTEyMjYyYjIxODZj\"}]\n:HL[\"/_next/static/css/f87fff2ab93d05a7.css\",\"style\",{\"nonce\":\"ZTYwMmJhNmYtNzA2Mi00ODJjLTkyZWMtZTEyMjYyYjIxODZj\"}]\n"])</script><script nonce="ZTYwMmJhNmYtNzA2Mi00ODJjLTkyZWMtZTEyMjYyYjIxODZj">self.__next_f.push([1,"0:{\"P\":null,\"b\":\"BpM29AX4fmgcUxZ_6t0le\",\"p\":\"\",\"c\":[\"\",\"page\",\"Cytokine_release_syndrome\"],\"i\":false,\"f\":[[[\"\",{\"children\":[\"page\",{\"children\":[[\"slug\",\"Cytokine_release_syndrome\",\"d\"],{\"children\":[\"__PAGE__\",{}]}]}]},\"$undefined\",\"$undefined\",true],[\"\",[\"$\",\"$1\",\"c\",{\"children\":[[[\"$\",\"link\",\"0\",{\"rel\":\"stylesheet\",\"href\":\"/_next/static/css/62c4caba71dfda84.css\",\"precedence\":\"next\",\"crossOrigin\":\"$undefined\",\"nonce\":\"ZTYwMmJhNmYtNzA2Mi00ODJjLTkyZWMtZTEyMjYyYjIxODZj\"}],[\"$\",\"link\",\"1\",{\"rel\":\"stylesheet\",\"href\":\"/_next/static/css/eb3d87f98fe1565f.css\",\"precedence\":\"next\",\"crossOrigin\":\"$undefined\",\"nonce\":\"ZTYwMmJhNmYtNzA2Mi00ODJjLTkyZWMtZTEyMjYyYjIxODZj\"}],[\"$\",\"link\",\"2\",{\"rel\":\"stylesheet\",\"href\":\"/_next/static/css/1b5e561215938d4d.css\",\"precedence\":\"next\",\"crossOrigin\":\"$undefined\",\"nonce\":\"ZTYwMmJhNmYtNzA2Mi00ODJjLTkyZWMtZTEyMjYyYjIxODZj\"}],[\"$\",\"link\",\"3\",{\"rel\":\"stylesheet\",\"href\":\"/_next/static/css/0227d069a630d414.css\",\"precedence\":\"next\",\"crossOrigin\":\"$undefined\",\"nonce\":\"ZTYwMmJhNmYtNzA2Mi00ODJjLTkyZWMtZTEyMjYyYjIxODZj\"}]],\"$L2\"]}],{\"children\":[\"page\",[\"$\",\"$1\",\"c\",{\"children\":[null,[\"$\",\"$L3\",null,{\"parallelRouterKey\":\"children\",\"error\":\"$undefined\",\"errorStyles\":\"$undefined\",\"errorScripts\":\"$undefined\",\"template\":[\"$\",\"$L4\",null,{}],\"templateStyles\":\"$undefined\",\"templateScripts\":\"$undefined\",\"notFound\":\"$undefined\",\"forbidden\":\"$undefined\",\"unauthorized\":\"$undefined\"}]]}],{\"children\":[[\"slug\",\"Cytokine_release_syndrome\",\"d\"],[\"$\",\"$1\",\"c\",{\"children\":[null,[\"$\",\"$L5\",null,{\"children\":[[\"$\",\"$L6\",null,{\"maxWidth\":\"full\",\"mobileOptions\":{\"right\":{\"showFixedIssues\":true,\"showThemeSwitcher\":true,\"showSearch\":true,\"showTableOfContents\":true}}}],[\"$\",\"$L3\",null,{\"parallelRouterKey\":\"children\",\"error\":\"$undefined\",\"errorStyles\":\"$undefined\",\"errorScripts\":\"$undefined\",\"template\":[\"$\",\"$L4\",null,{}],\"templateStyles\":\"$undefined\",\"templateScripts\":\"$undefined\",\"notFound\":[[\"$\",\"$L7\",null,{}],[]],\"forbidden\":\"$undefined\",\"unauthorized\":\"$undefined\"}]]}]]}],{\"children\":[\"__PAGE__\",[\"$\",\"$1\",\"c\",{\"children\":[\"$L8\",[[\"$\",\"link\",\"0\",{\"rel\":\"stylesheet\",\"href\":\"/_next/static/css/f87fff2ab93d05a7.css\",\"precedence\":\"next\",\"crossOrigin\":\"$undefined\",\"nonce\":\"ZTYwMmJhNmYtNzA2Mi00ODJjLTkyZWMtZTEyMjYyYjIxODZj\"}]],[\"$\",\"$L9\",null,{\"children\":[\"$La\",[\"$\",\"$Lb\",null,{\"promise\":\"$@c\"}]]}]]}],{},null,false]},null,false]},null,false]},null,false],[\"$\",\"$1\",\"h\",{\"children\":[null,[[\"$\",\"$Ld\",null,{\"children\":\"$Le\"}],[\"$\",\"meta\",null,{\"name\":\"next-size-adjust\",\"content\":\"\"}]],[\"$\",\"$Lf\",null,{\"children\":[\"$\",\"div\",null,{\"hidden\":true,\"children\":[\"$\",\"$10\",null,{\"fallback\":null,\"children\":\"$L11\"}]}]}]]}],false]],\"m\":\"$undefined\",\"G\":[\"$12\",[]],\"s\":false,\"S\":false}\n"])</script><script nonce="ZTYwMmJhNmYtNzA2Mi00ODJjLTkyZWMtZTEyMjYyYjIxODZj">self.__next_f.push([1,"2:[\"$\",\"html\",null,{\"lang\":\"en\",\"className\":\"bg-surface-base antialiased\",\"suppressHydrationWarning\":true,\"children\":[[\"$\",\"head\",null,{\"children\":[[\"$\",\"title\",null,{\"children\":\"Grokipedia\"}],[\"$\",\"meta\",null,{\"name\":\"description\",\"content\":\"Grokipedia is an open source, comprehensive collection of all knowledge.\"}],[\"$\",\"link\",null,{\"rel\":\"icon\",\"type\":\"image/x-icon\",\"href\":\"/favicon.ico\",\"sizes\":\"48x48\"}],[\"$\",\"link\",null,{\"rel\":\"icon\",\"href\":\"/images/icon-dark.png\",\"media\":\"(prefers-color-scheme: light)\",\"type\":\"image/png\"}],[\"$\",\"link\",null,{\"rel\":\"icon\",\"href\":\"/images/icon-light.png\",\"media\":\"(prefers-color-scheme: dark)\",\"type\":\"image/png\"}],[\"$\",\"link\",null,{\"rel\":\"apple-touch-icon\",\"href\":\"/icon-192x192.png\"}],[\"$\",\"link\",null,{\"rel\":\"manifest\",\"href\":\"/manifest.webmanifest\"}],[\"$\",\"meta\",null,{\"name\":\"robots\",\"content\":\"index, follow\"}],[\"$\",\"meta\",null,{\"name\":\"googlebot\",\"content\":\"index, follow, max-snippet:-1\"}],[\"$\",\"meta\",null,{\"property\":\"og:title\",\"content\":\"Grokipedia\"}],[\"$\",\"meta\",null,{\"property\":\"og:description\",\"content\":\"Grokipedia is an open source, comprehensive collection of all knowledge.\"}],[\"$\",\"meta\",null,{\"property\":\"og:url\",\"content\":\"https://grokipedia.com\"}],[\"$\",\"meta\",null,{\"property\":\"og:site_name\",\"content\":\"Grokipedia\"}],[\"$\",\"meta\",null,{\"property\":\"og:locale\",\"content\":\"en_US\"}],[\"$\",\"meta\",null,{\"property\":\"og:type\",\"content\":\"website\"}],[\"$\",\"meta\",null,{\"property\":\"og:image\",\"content\":\"https://grokipedia.com/icon-512x512.png\"}],[\"$\",\"meta\",null,{\"property\":\"og:image:width\",\"content\":\"512\"}],[\"$\",\"meta\",null,{\"property\":\"og:image:height\",\"content\":\"512\"}],[\"$\",\"meta\",null,{\"property\":\"og:image:alt\",\"content\":\"Grokipedia\"}],[\"$\",\"meta\",null,{\"name\":\"twitter:card\",\"content\":\"summary\"}],[\"$\",\"meta\",null,{\"name\":\"twitter:creator\",\"content\":\"@Grokipedia\"}],[\"$\",\"meta\",null,{\"name\":\"twitter:title\",\"content\":\"Grokipedia\"}],[\"$\",\"meta\",null,{\"name\":\"twitter:description\",\"content\":\"Grokipedia is an open source, comprehensive collection of all knowledge.\"}],[\"$\",\"meta\",null,{\"name\":\"twitter:image\",\"content\":\"https://grokipedia.com/icon-512x512.png\"}]]}],[\"$\",\"body\",null,{\"className\":\"flex h-[100svh] w-full flex-col __variable_13c637 __variable_8a0ba0 __variable_779740 __variable_2484fd __variable_525cc3 __variable_13486b\",\"children\":[[\"$\",\"$L13\",null,{\"children\":[\"$\",\"$L14\",null,{\"children\":[\"$\",\"$L15\",null,{\"defaultTheme\":\"dark\",\"nonce\":\"ZTYwMmJhNmYtNzA2Mi00ODJjLTkyZWMtZTEyMjYyYjIxODZj\",\"children\":[\"$\",\"$L16\",null,{\"children\":[\"$\",\"$L17\",null,{\"children\":[\"$\",\"$L18\",null,{\"children\":[\"$\",\"$L19\",null,{\"children\":[\"$\",\"$L1a\",null,{\"children\":[[\"$\",\"$L3\",null,{\"parallelRouterKey\":\"children\",\"error\":\"$1b\",\"errorStyles\":[],\"errorScripts\":[],\"template\":[\"$\",\"$L4\",null,{}],\"templateStyles\":\"$undefined\",\"templateScripts\":\"$undefined\",\"notFound\":[[\"$\",\"$L1c\",null,{}],[]],\"forbidden\":\"$undefined\",\"unauthorized\":\"$undefined\"}],[\"$\",\"$L1d\",null,{}]]}]}]}]}]}]}]}]}],[\"$\",\"script\",null,{\"type\":\"application/json\",\"id\":\"server-client-data-experimentation\",\"children\":\"{\\\"status\\\":\\\"uninitialized\\\"}\"}]]}]]}]\n"])</script><script nonce="ZTYwMmJhNmYtNzA2Mi00ODJjLTkyZWMtZTEyMjYyYjIxODZj">self.__next_f.push([1,"e:[[\"$\",\"meta\",\"0\",{\"charSet\":\"utf-8\"}],[\"$\",\"meta\",\"1\",{\"name\":\"viewport\",\"content\":\"width=device-width, initial-scale=1, interactive-widget=resizes-content\"}]]\na:null\n"])</script><script nonce="ZTYwMmJhNmYtNzA2Mi00ODJjLTkyZWMtZTEyMjYyYjIxODZj">self.__next_f.push([1,"1e:I[42712,[\"8739\",\"static/chunks/63f0ec43-8ee6a76d70472249.js\",\"2254\",\"static/chunks/8208b75a-a48e5a4507a0de91.js\",\"4684\",\"static/chunks/24cf1b50-159cca90b09285e0.js\",\"1829\",\"static/chunks/9ffa21ba-c069766d809bd4c7.js\",\"7670\",\"static/chunks/7670-7326298c9856172b.js\",\"282\",\"static/chunks/282-691fffb366e24ca5.js\",\"7515\",\"static/chunks/7515-336759ef5dad2b52.js\",\"5497\",\"static/chunks/5497-ab85ef3ea59dd353.js\",\"7720\",\"static/chunks/7720-3a1e7e411adba2d3.js\",\"6281\",\"static/chunks/6281-c6e84786dade3614.js\",\"7086\",\"static/chunks/7086-1f1c4891d766e04f.js\",\"600\",\"static/chunks/600-9a9fcafaaa6c1c4c.js\",\"5002\",\"static/chunks/5002-9735c25beda556ba.js\",\"5448\",\"static/chunks/5448-2a3cfd853d899c9a.js\",\"5855\",\"static/chunks/5855-243eeca8f0e4cabd.js\",\"4393\",\"static/chunks/4393-1c8dff25ec904469.js\",\"9214\",\"static/chunks/9214-a10614844a67ba31.js\",\"8\",\"static/chunks/8-8ca70ca619d8e099.js\",\"4789\",\"static/chunks/4789-2080f6497f78b5b6.js\",\"6304\",\"static/chunks/app/page/%5Bslug%5D/page-540a27b6839afde5.js\"],\"HydrationBoundary\"]\n"])</script><script nonce="ZTYwMmJhNmYtNzA2Mi00ODJjLTkyZWMtZTEyMjYyYjIxODZj">self.__next_f.push([1,"21:I[6367,[],\"IconMark\"]\n1f:T3d52,"])</script><script nonce="ZTYwMmJhNmYtNzA2Mi00ODJjLTkyZWMtZTEyMjYyYjIxODZj">self.__next_f.push([1,"# Cytokine release syndrome\n\n| Attribute          | Details                                                                 |\n|--------------------|-------------------------------------------------------------------------|\n| Other names        | Infusion-related reaction (IRR), infusion reaction,[1] cytokine storm[2] |\n| Specialty          | [Immunology](Immunology \"Immunology\")                                   |\n\nIn [immunology](Immunology \"Immunology\"), **cytokine release syndrome** (**CRS**) is a form of [systemic inflammatory response syndrome](Systemic_inflammatory_response_syndrome \"Systemic inflammatory response syndrome\") (SIRS) that can be triggered by a variety of factors such as infections and certain drugs.[3] CRS is a type of cytokine storm syndrome (CSS)[4] and occurs when large numbers of [white blood cells](White_blood_cell \"White blood cell\") are activated and release [inflammatory cytokines](Inflammatory_cytokine \"Inflammatory cytokine\"), which in turn activate yet more white blood cells. CRS is also an [adverse effect](Adverse_effect \"Adverse effect\") of some [monoclonal antibody](Monoclonal_antibody \"Monoclonal antibody\") medications, as well as [adoptive T-cell therapies](Cancer_immunotherapy#Adoptive_T-cell_therapy \"Cancer immunotherapy\").[5][6] When occurring as a result of a medication, it is also known as an **infusion reaction**.[1] CRS gained widespread attention during the COVID-19 pandemic due to its role in severe cases.[16][17]\n\nThe term **cytokine storm** is often used interchangeably with CRS but, despite the fact that they have similar [clinical phenotype](Clinical_phenotype \"Clinical phenotype\"), their characteristics are different. When occurring as a result of a therapy, CRS symptoms may be delayed until days or weeks after treatment. Immediate-onset reactions associated with some therapies are termed cytokine storms,[7] although severe cases of CRS have also been called cytokine storms.[2]\n## Signs and symptoms\n\nSymptoms include fever that tends to fluctuate, fatigue, loss of appetite, muscle and joint pain, nausea, vomiting, diarrhea, rashes, fast breathing, rapid heartbeat, low blood pressure, seizures, headache, confusion, delirium, hallucinations, tremor, and loss of coordination.[5]\n\nLab tests and clinical monitoring show low blood oxygen, widened pulse pressure, increased cardiac output (early), potentially diminished cardiac output (late), high levels of nitrogen compounds in the blood, elevated D-dimer, elevated transaminases, hypofibrinogenemia and excessive bleeding, higher-than-normal level of bilirubin, elevated C-reactive protein (CRP) and ferritin.[5][8]\n## Cause\n\nCRS occurs when large numbers of [white blood cells](White_blood_cell \"White blood cell\"), including [B cells](B_cells \"B cells\"), [T cells](T_cells \"T cells\"), [natural killer cells](Natural_killer_cells \"Natural killer cells\"), [macrophages](Macrophages \"Macrophages\"), [dendritic cells](Dendritic_cells \"Dendritic cells\"), and [monocytes](Monocytes \"Monocytes\") are activated and release [inflammatory cytokines](Inflammatory_cytokine \"Inflammatory cytokine\"), which activate more white blood cells in a positive feedback loop of pathogenic inflammation.[5] Immune cells are activated by stressed or infected cells through receptor-ligand interactions.[9]\n\nThis can occur when the [immune system](Immune_system \"Immune system\") is fighting [pathogens](Pathogen \"Pathogen\"), as cytokines produced by immune cells recruit more effector immune cells such as [T-cells](T-cell \"T-cell\") and inflammatory monocytes (which differentiate into [macrophages](Macrophage \"Macrophage\")) to the site of inflammation or infection. In addition, pro-inflammatory cytokines binding their cognate receptor on immune cells results in activation and stimulation of further cytokine production.[10]\n\n[Adoptive cell transfer](Adoptive_cell_transfer \"Adoptive cell transfer\") of autologous T-cells modified with [chimeric antigen receptors](Chimeric_antigen_receptor \"Chimeric antigen receptor\") (CAR-T cell therapy) also causes CRS.[5] Serum samples of patients with CAR-T associated CRS have elevated levels of [IL-6](Interleukin_6 \"Interleukin 6\"), [IFN-Î³](IFN-%CE%B3 \"IFN-Î³\"), [IL-8](Interleukin_8 \"Interleukin 8\") (CXCL8), [IL-10](Interleukin_10 \"Interleukin 10\"), [GM-CSF](GM-CSF \"GM-CSF\"), [MIP-1Î±](MIP-1%CE%B1 \"MIP-1Î±\")/[Î²](MIP-1%CE%B2 \"MIP-1Î²\"), [MCP-1](MCP-1 \"MCP-1\") (CCL2), [CXCL9](CXCL9 \"CXCL9\"), and [CXCL10](CXCL10 \"CXCL10\") (IP-10).[11] The most predictive biomarkers 36h after CAR-T infusion of CRS are a fever â‰¥38.9 Â°C (102 Â°F) and elevated levels of MCP-1 in serum.[12] Many of the cytokines elevated in CRS are not produced by CAR-T cells, but by myeloid cells that are pathogenically licensed through T-cell-mediated activating mechanisms. For example, [in vitro](In_vitro \"In vitro\") co-culture experiments have demonstrated IL-6, MCP-1, and MIP-1 are not produced by CAR-T cells, but rather by inflammatory myeloid lineage cells.[13] [In vivo](In_vivo \"In vivo\") models have demonstrated NSG (NOD/SCID/Î³-chain deficient mice) with defects of both lymphocyte and myeloid lineage compartments do not develop CRS after CAR-T cell infusion.[14]\n\nIn addition to adoptive T-cell therapies, severe CRS or cytokine reactions can occur in a number of infectious and non-infectious conditions including [graft-versus-host disease](Graft-versus-host_disease \"Graft-versus-host disease\") (GVHD), [acute respiratory distress syndrome](Acute_respiratory_distress_syndrome \"Acute respiratory distress syndrome\") (ARDS), [sepsis](Sepsis \"Sepsis\"), [Ebola](Ebola \"Ebola\"), [avian influenza](Avian_influenza \"Avian influenza\"), [smallpox](Smallpox \"Smallpox\"), and cytokine storms in infections such as [monkeypox](Monkeypox \"Monkeypox\").[15][9] In infections, these reactions are often termed cytokine storms, distinct in timing and context from therapy-induced CRS, though sharing similar mechanisms.\n\nAlthough [severe acute respiratory syndrome coronavirus 2](Severe_acute_respiratory_syndrome_coronavirus_2 \"Severe acute respiratory syndrome coronavirus 2\") (SARS-CoV-2) is sufficiently cleared by the early acute phase anti-viral response in most individuals, some progress to a hyperinflammatory condition, often with life-threatening pulmonary involvement. This systemic hyperinflammation results in inflammatory lymphocytic and monocytic infiltration of the lung and the heart, causing ARDS and cardiac failure.[16] Patients with fulminant COVID-19 and ARDS have classical serum biomarkers of CRS including elevated CRP, LDH, IL-6, and [ferritin](Ferritin \"Ferritin\").[17]\n\n[Hemophagocytic lymphohistiocytosis](Hemophagocytic_lymphohistiocytosis \"Hemophagocytic lymphohistiocytosis\") and [Epstein-Barr virus-related hemophagocytic lymphohistiocytosis](Epstein-Barr_virus-associated_lymphoproliferative_diseases \"Epstein-Barr virus-associated lymphoproliferative diseases\") are caused by extreme elevations in cytokines and can be regarded as one form of severe cytokine release syndrome.[18]\n\n### Medications\n\nCytokine reaction syndrome may also be induced by certain medications, such as the [CD20](CD20 \"CD20\") antibody [rituximab](Rituximab \"Rituximab\") and the [CD19](CD19 \"CD19\") CAR T cell [tisagenlecleucel](Tisagenlecleucel \"Tisagenlecleucel\"). The experimental drug [TGN1412](TGN1412 \"TGN1412\")â€”also known as Theralizumabâ€”caused extremely serious symptoms when given to six participants in a [Phase I trial](Clinical_trial#Phase_I \"Clinical trial\").[2] A controlled and limited CRS is triggered by active fever therapy with mixed bacterial vaccines (MBV) according to [Coley](Coley's_toxins \"Coley's toxins\"); it is used for oncological and certain chronic diseases.[19] CRS has also arisen with [biotherapeutics](Biotherapeutic \"Biotherapeutic\") such as monoclonal antibodies intended to suppress or activate the immune system through receptors on white blood cells. [Muromonab-CD3](Muromonab-CD3 \"Muromonab-CD3\"), an anti-[CD3](CD3_\\(immunology\\) \"CD3 \\(immunology\\)\") monoclonal antibody intended to suppress the immune system to prevent rejection of [organ transplants](Organ_transplant \"Organ transplant\"); [alemtuzumab](Alemtuzumab \"Alemtuzumab\"), which is anti-[CD52](CD52 \"CD52\") and used to treat blood cancers as well as [multiple sclerosis](Multiple_sclerosis \"Multiple sclerosis\") and in organ transplants; and [rituximab](Rituximab \"Rituximab\"), which is anti-[CD20](CD20 \"CD20\") and used to treat blood cancers and auto-immune disorders, all cause CRS.[5] Rare cases of cytokine storm have been reported following COVID-19 vaccination, though causality is not established.[](https://doi.org/10.3389/fimmu.2022.967226)\n## Diagnosis\n\nCRS needs to be distinguished from symptoms of the disease itself and, in the case of drugs, from other adverse effects; for example, tumor lysis syndrome requires different interventions. Differential diagnosis involves clinical judgment supported by objective biomarkers, including elevated levels of cytokines such as IL-6, IFN-Î³, IL-2, and IL-10, as well as CRP and ferritin, which aid in confirming CRS and assessing severity as of 2024.[](https://www.frontiersin.org/journals/immunology/articles/10.3389/fimmu.2024.1450173/full)[](https://link.springer.com/article/10.1007/s44272-025-00044-0)\n\n### Classification\n\nCRS is a form of systemic inflammatory response syndrome and is an adverse effect of some drugs, particularly monoclonal antibodies and adoptive T-cell therapies.[5]\n\nThe current standard for grading CRS, especially in the context of immune effector cell therapies, is the American Society for Transplantation and Cellular Therapy (ASTCT) consensus grading system established in 2019. This system classifies CRS based on fever (â‰¥38Â°C not attributable to other causes), hypotension, and hypoxia, with organ toxicities graded separately using CTCAE v5.0 (2017). The grades are as follows:[](https://doi.org/10.1016/j.bbmt.2018.12.758)\n\n| CRS Parameter | Grade 1 | Grade 2 | Grade 3 | Grade 4 |\n|---------------|---------|---------|---------|---------|\n| Fever         | â‰¥38Â°C   | â‰¥38Â°C   | â‰¥38Â°C   | â‰¥38Â°C   |\n| Hypotension   | None    | Not requiring vasopressors | Requiring 1 vasopressor (with or without vasopressin) | Requiring multiple vasopressors (excluding vasopressin) |\n| Hypoxia       | None    | Requiring low-flow nasal cannula (â‰¤6 L/min) or blow-by | Requiring high-flow nasal cannula (\u003e6 L/min), facemask, nonrebreather mask, or Venturi mask | Requiring positive pressure (e.g., CPAP, BiPAP, intubation, mechanical ventilation) |\n\nCRS grade is determined by the more severe event among hypotension or hypoxia not attributable to any other cause. There is no grade 5 in the ASTCT system; death would be attributed to complications.\n## Prevention\n\nSevere CRS caused by some drugs, such as monoclonal antibodies, can be prevented by using lower doses, infusing slowly, and administering anti-histamines or corticosteroids before and during administration of the drug.[1]\n\nIn vitro assays have been developed to understand the risk that pre-clinical drug candidates might cause CRS and guide dosing for Phase I trials, and regulatory agencies expect to see results of such tests in investigational new drug applications.[2][21]\n\nA modified Chandler loop model can be used as a preclinical tool to assess infusion reactions.[22]\n\nFor CAR T-cell therapies, prophylactic corticosteroids are generally avoided to preserve therapeutic efficacy, with prevention relying instead on dose fractionation and close monitoring.[3]\n## Management\n\nTreatment for less severe CRS is supportive, addressing the symptoms like fever, muscle pain, or fatigue. Moderate CRS requires oxygen therapy and giving fluids and antihypotensive agents to raise blood pressure. For moderate to severe CRS, the use of immunosuppressive agents like corticosteroids may be necessary, but judgment must be used to avoid negating the effect of drugs intended to activate the immune system.[5]\n\nTocilizumab, an anti-IL-6 monoclonal antibody, was FDA approved for steroid-refractory CRS based on retrospective case study data.[5][6] Siltuximab is an alternative anti-IL-6 agent for cases refractory to tocilizumab. As of 2025, tocilizumab biosimilars (e.g., tocilizumab-anoh) are also approved for CRS management.[](https://www.astctjournal.org/article/S1083-8791(18)31292-0/fulltext)[](https://www.targetedonc.com/view/fda-expands-approval-for-tocilizumab-biosimilar-to-treat-crs)\n\nLenzilumab, an investigational anti-GM-CSF monoclonal antibody, showed efficacy in reducing cytokine release in a phase 3 trial for COVID-19-associated CRS-like symptoms by reducing activation of myeloid cells and decreasing the production of IL-1, IL-6, MCP-1, MIP-1, and IP-10.[23][24]\n\nAlthough frequently used to treat severe CRS in people with ARDS, corticosteroids are recommended in current guidelines for moderate-to-severe ARDS (conditional, moderate certainty), with evidence of reduced 28-day mortality; NSAIDs have been evaluated in clinical trials and have shown no effect on lung mechanics, gas exchange, or beneficial outcome in early established ARDS.[](https://www.atsjournals.org/doi/10.1164/rccm.202311-2011ST)[](https://www.sccm.org/clinical-resources/guidelines/guidelines/use-of-corticosteroids-in-sepsis-ards-cap)\n## Epidemiology\n\nThe incidence of cytokine release syndrome (CRS) varies by trigger. In immune-modulating antibody therapies, such as rituximab, minor and moderate CRS are common, occurring in up to 80% of infusions, while severe CRS (grade â‰¥3) is rare, with rates below 5%.[6] In chimeric antigen receptor T-cell (CAR-T) therapies, any-grade CRS affects 50-100% of patients, with severe cases in 5-15% depending on the product and malignancy treated, though rates have decreased with prophylactic measures like tocilizumab as of 2023.[6][21] CRS also occurs in infections, contributing to systemic inflammatory response in approximately 20-30% of severe sepsis cases, particularly highlighted during the COVID-19 pandemic where it was implicated in many intensive care admissions.[16][17]\n# Therapeutic Targets for Cytokine Release Syndrome in CAR-T Therapy\n\n## Research\n\nKey therapeutic targets to abrogate hyper-inflammation in CRS are IL-1, IL-6, and GM-CSF. An in vivo model found that GM-CSF knockout CAR-T cells do not induce CRS in mice. However, IL-1R knockout and IL-6 knockout hosts were susceptible to CRS after the administration of wild-type CAR-T cells.[14] It is thought this may be because IL-1 and IL-6, which are myeloid-derived cytokines, are thus too far downstream of the inflammatory cascade. Moreover, while tocilizumab (anti-IL-6R monoclonal antibody) may have an anti-inflammatory and antipyretic effect, it has been shown to increase serum levels of IL-6 by saturating the receptor.[26] However, tocilizumab may not fully ameliorate neurotoxicity and has been associated in some studies with paradoxical worsening due to increased IL-6 signaling in the central nervous system.[](https://www.sciencedirect.com/science/article/pii/S2473952924003604) Monoclonal antibody blockade of GM-CSF with lenzilumab has been demonstrated to protect mice from CAR-T associated CRS and neurotoxicity while maintaining anti-leukemic efficacy.[27] More recent research (as of 2023) has identified IL-6 translation as a therapeutic target, with metoprolol demonstrating potential to reduce CRS in human models without impairing CAR-T function.[](https://pmc.ncbi.nlm.nih.gov/articles/PMC10432851/) Lenzilumab remains under investigation in ongoing clinical trials (Phase 2/3) for preventing CRS and neurotoxicity in CAR-T therapy."])</script><script nonce="ZTYwMmJhNmYtNzA2Mi00ODJjLTkyZWMtZTEyMjYyYjIxODZj">self.__next_f.push([1,"8:[\"$\",\"$L1e\",null,{\"state\":{\"mutations\":[],\"queries\":[{\"dehydratedAt\":1761886731575,\"state\":{\"data\":{\"page\":{\"citations\":[{\"id\":\"1\",\"title\":\"_**a**_ _**b**_ Vogel WH (April 2010). [\\\"Infusion reactions: diagnosis, assessment, and management\\\"](https://doi.org/10.1188%2F10.CJON.E10-E21). _Clinical Journal of Oncology Nursing_. **14** (2): E10-21. [doi](Doi_\\\\(identifier\\\\) \\\"Doi \\\\(identifier\\\\)\\\"):[10.1188/10.CJON.E10-E21](https://doi.org/10.1188%2F10.CJON.E10-E21). [PMID](PMID_\\\\(identifier\\\\) \\\"PMID \\\\(identifier\\\\)\\\") [20350882](https://pubmed.ncbi.nlm.nih.gov/20350882).\",\"description\":\"1. ^ _**a**_ _**b**_ Vogel WH (April 2010). [\\\"Infusion reactions: diagnosis, assessment, and management\\\"](https://doi.org/10.1188%2F10.CJON.E10-E21). _Clinical Journal of Oncology Nursing_. **14** (2): E10-21. [doi](Doi_\\\\(identifier\\\\) \\\"Doi \\\\(identifier\\\\)\\\"):[10.1188/10.CJON.E10-E21](https://doi.org/10.1188%2F10.CJON.E10-E21). [PMID](PMID_\\\\(identifier\\\\) \\\"PMID \\\\(identifier\\\\)\\\") [20350882](https://pubmed.ncbi.nlm.nih.gov/20350882).\",\"url\":\"https://doi.org/10.1188%2F10.CJON.E10-E21\",\"favicon\":\"\"},{\"id\":\"2\",\"title\":\"_**a**_ _**b**_ _**c**_ _**d**_ Vidal JM, Kawabata TT, Thorpe R, Silva-Lima B, Cederbrant K, Poole S, et al. (August 2010). \\\"In vitro cytokine release assays for predicting cytokine release syndrome: the current state-of-the-science. Report of a European Medicines Agency Workshop\\\". _Cytokine_. **51** (2): 213â€“5\\\\. [doi](Doi_\\\\(identifier\\\\) \\\"Doi \\\\(identifier\\\\)\\\"):[10.1016/j.cyto.2010.04.008](https://doi.org/10.1016%2Fj.cyto.2010.04.008). [PMID](PMID_\\\\(identifier\\\\) \\\"PMID \\\\(identifier\\\\)\\\") [20471854](https://pubmed.ncbi.nlm.nih.gov/20471854).\",\"description\":\"2. ^ _**a**_ _**b**_ _**c**_ _**d**_ Vidal JM, Kawabata TT, Thorpe R, Silva-Lima B, Cederbrant K, Poole S, et al. (August 2010). \\\"In vitro cytokine release assays for predicting cytokine release syndrome: the current state-of-the-science. Report of a European Medicines Agency Workshop\\\". _Cytokine_. **51** (2): 213â€“5\\\\. [doi](Doi_\\\\(identifier\\\\) \\\"Doi \\\\(identifier\\\\)\\\"):[10.1016/j.cyto.2010.04.008](https://doi.org/10.1016%2Fj.cyto.2010.04.008). [PMID](PMID_\\\\(identifier\\\\) \\\"PMID \\\\(identifier\\\\)\\\") [20471854](https://pubmed.ncbi.nlm.nih.gov/20471854).\",\"url\":\"Doi_\\\\(identifier\\\\\",\"favicon\":\"\"},{\"id\":\"3\",\"title\":\"** Shimabukuro-Vornhagen A, GÃ¶del P, Subklewe M, Stemmler HJ, SchlÃ¶ÃŸer HA, Schlaak M, et al. (June 2018). [\\\"Cytokine release syndrome\\\"](https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6003181). _Journal for Immunotherapy of Cancer_. **6** (1): 56. [doi](Doi_\\\\(identifier\\\\) \\\"Doi \\\\(identifier\\\\)\\\"):[10.1186/s40425-018-0343-9](https://doi.org/10.1186%2Fs40425-018-0343-9). [PMC](PMC_\\\\(identifier\\\\) \\\"PMC \\\\(identifier\\\\)\\\") [6003181](https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6003181). [PMID](PMID_\\\\(identifier\\\\) \\\"PMID \\\\(identifier\\\\)\\\") [29907163](https://pubmed.ncbi.nlm.nih.gov/29907163).\",\"description\":\"3. **^** Shimabukuro-Vornhagen A, GÃ¶del P, Subklewe M, Stemmler HJ, SchlÃ¶ÃŸer HA, Schlaak M, et al. (June 2018). [\\\"Cytokine release syndrome\\\"](https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6003181). _Journal for Immunotherapy of Cancer_. **6** (1): 56. [doi](Doi_\\\\(identifier\\\\) \\\"Doi \\\\(identifier\\\\)\\\"):[10.1186/s40425-018-0343-9](https://doi.org/10.1186%2Fs40425-018-0343-9). [PMC](PMC_\\\\(identifier\\\\) \\\"PMC \\\\(identifier\\\\)\\\") [6003181](https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6003181). [PMID](PMID_\\\\(identifier\\\\) \\\"PMID \\\\(identifier\\\\)\\\") [29907163](https://pubmed.ncbi.nlm.nih.gov/29907163).\",\"url\":\"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6003181\",\"favicon\":\"\"},{\"id\":\"4\",\"title\":\"** Behrens EM, Koretzky GA (June 2017). [\\\"Review: Cytokine Storm Syndrome: Looking Toward the Precision Medicine Era\\\"](https://doi.org/10.1002%2Fart.40071). _Arthritis \u0026 Rheumatology_. **69** (6): 1135â€“1143\\\\. [doi](Doi_\\\\(identifier\\\\) \\\"Doi \\\\(identifier\\\\)\\\"):[10.1002/art.40071](https://doi.org/10.1002%2Fart.40071). [PMID](PMID_\\\\(identifier\\\\) \\\"PMID \\\\(identifier\\\\)\\\") [28217930](https://pubmed.ncbi.nlm.nih.gov/28217930). [S2CID](S2CID_\\\\(identifier\\\\) \\\"S2CID \\\\(identifier\\\\)\\\") [21925082](https://api.semanticscholar.org/CorpusID:21925082).\",\"description\":\"4. **^** Behrens EM, Koretzky GA (June 2017). [\\\"Review: Cytokine Storm Syndrome: Looking Toward the Precision Medicine Era\\\"](https://doi.org/10.1002%2Fart.40071). _Arthritis \u0026 Rheumatology_. **69** (6): 1135â€“1143\\\\. [doi](Doi_\\\\(identifier\\\\) \\\"Doi \\\\(identifier\\\\)\\\"):[10.1002/art.40071](https://doi.org/10.1002%2Fart.40071). [PMID](PMID_\\\\(identifier\\\\) \\\"PMID \\\\(identifier\\\\)\\\") [28217930](https://pubmed.ncbi.nlm.nih.gov/28217930). [S2CID](S2CID_\\\\(identifier\\\\) \\\"S2CID \\\\(identifier\\\\)\\\") [21925082](https://api.semanticscholar.org/CorpusID:21925082).\",\"url\":\"https://doi.org/10.1002%2Fart.40071\",\"favicon\":\"\"},{\"id\":\"5\",\"title\":\"_**a**_ _**b**_ _**c**_ _**d**_ _**e**_ _**f**_ _**g**_ _**h**_ _**i**_ _**j**_ _**k**_ _**l**_ Lee DW, Gardner R, Porter DL, Louis CU, Ahmed N, Jensen M, et al. (July 2014). [\\\"Current concepts in the diagnosis and management of cytokine release syndrome\\\"](https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4093680). _Blood_. **124** (2): 188â€“95\\\\. [doi](Doi_\\\\(identifier\\\\) \\\"Doi \\\\(identifier\\\\)\\\"):[10.1182/blood-2014-05-552729](https://doi.org/10.1182%2Fblood-2014-05-552729). [PMC](PMC_\\\\(identifier\\\\) \\\"PMC \\\\(identifier\\\\)\\\") [4093680](https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4093680). [PMID](PMID_\\\\(identifier\\\\) \\\"PMID \\\\(identifier\\\\)\\\") [24876563](https://pubmed.ncbi.nlm.nih.gov/24876563).\",\"description\":\"5. ^ _**a**_ _**b**_ _**c**_ _**d**_ _**e**_ _**f**_ _**g**_ _**h**_ _**i**_ _**j**_ _**k**_ _**l**_ Lee DW, Gardner R, Porter DL, Louis CU, Ahmed N, Jensen M, et al. (July 2014). [\\\"Current concepts in the diagnosis and management of cytokine release syndrome\\\"](https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4093680). _Blood_. **124** (2): 188â€“95\\\\. [doi](Doi_\\\\(identifier\\\\) \\\"Doi \\\\(identifier\\\\)\\\"):[10.1182/blood-2014-05-552729](https://doi.org/10.1182%2Fblood-2014-05-552729). [PMC](PMC_\\\\(identifier\\\\) \\\"PMC \\\\(identifier\\\\)\\\") [4093680](https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4093680). [PMID](PMID_\\\\(identifier\\\\) \\\"PMID \\\\(identifier\\\\)\\\") [24876563](https://pubmed.ncbi.nlm.nih.gov/24876563).\",\"url\":\"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4093680\",\"favicon\":\"\"},{\"id\":\"6\",\"title\":\"_**a**_ _**b**_ _**c**_ Kroschinsky F, StÃ¶lzel F, von Bonin S, Beutel G, Kochanek M, Kiehl M, Schellongowski P (April 2017). [\\\"New drugs, new toxicities: severe side effects of modern targeted and immunotherapy of cancer and their management\\\"](https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5391608). _Critical Care_. **21** (1): 89. [doi](Doi_\\\\(identifier\\\\) \\\"Doi \\\\(identifier\\\\)\\\"):[10.1186/s13054-017-1678-1](https://doi.org/10.1186%2Fs13054-017-1678-1). [PMC](PMC_\\\\(identifier\\\\) \\\"PMC \\\\(identifier\\\\)\\\") [5391608](https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5391608). [PMID](PMID_\\\\(identifier\\\\) \\\"PMID \\\\(identifier\\\\)\\\") [28407743](https://pubmed.ncbi.nlm.nih.gov/28407743).\",\"description\":\"6. ^ _**a**_ _**b**_ _**c**_ Kroschinsky F, StÃ¶lzel F, von Bonin S, Beutel G, Kochanek M, Kiehl M, Schellongowski P (April 2017). [\\\"New drugs, new toxicities: severe side effects of modern targeted and immunotherapy of cancer and their management\\\"](https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5391608). _Critical Care_. **21** (1): 89. [doi](Doi_\\\\(identifier\\\\) \\\"Doi \\\\(identifier\\\\)\\\"):[10.1186/s13054-017-1678-1](https://doi.org/10.1186%2Fs13054-017-1678-1). [PMC](PMC_\\\\(identifier\\\\) \\\"PMC \\\\(identifier\\\\)\\\") [5391608](https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5391608). [PMID](PMID_\\\\(identifier\\\\) \\\"PMID \\\\(identifier\\\\)\\\") [28407743](https://pubmed.ncbi.nlm.nih.gov/28407743).\",\"url\":\"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5391608\",\"favicon\":\"\"},{\"id\":\"7\",\"title\":\"** Porter D, Frey N, Wood PA, Weng Y, Grupp SA (March 2018). [\\\"Grading of cytokine release syndrome associated with the CAR T cell therapy tisagenlecleucel\\\"](https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5833070). _Journal of Hematology \u0026 Oncology_. **11** (1): 35. [doi](Doi_\\\\(identifier\\\\) \\\"Doi \\\\(identifier\\\\)\\\"):[10.1186/s13045-018-0571-y](https://doi.org/10.1186%2Fs13045-018-0571-y). [PMC](PMC_\\\\(identifier\\\\) \\\"PMC \\\\(identifier\\\\)\\\") [5833070](https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5833070). [PMID](PMID_\\\\(identifier\\\\) \\\"PMID \\\\(identifier\\\\)\\\") [29499750](https://pubmed.ncbi.nlm.nih.gov/29499750).\",\"description\":\"7. **^** Porter D, Frey N, Wood PA, Weng Y, Grupp SA (March 2018). [\\\"Grading of cytokine release syndrome associated with the CAR T cell therapy tisagenlecleucel\\\"](https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5833070). _Journal of Hematology \u0026 Oncology_. **11** (1): 35. [doi](Doi_\\\\(identifier\\\\) \\\"Doi \\\\(identifier\\\\)\\\"):[10.1186/s13045-018-0571-y](https://doi.org/10.1186%2Fs13045-018-0571-y). [PMC](PMC_\\\\(identifier\\\\) \\\"PMC \\\\(identifier\\\\)\\\") [5833070](https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5833070). [PMID](PMID_\\\\(identifier\\\\) \\\"PMID \\\\(identifier\\\\)\\\") [29499750](https://pubmed.ncbi.nlm.nih.gov/29499750).\",\"url\":\"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5833070\",\"favicon\":\"\"},{\"id\":\"8\",\"title\":\"** Bonifant CL, Jackson HJ, Brentjens RJ, Curran KJ (2016). [\\\"Toxicity and management in CAR T-cell therapy\\\"](https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5008265). _Molecular Therapy: Oncolytics_. **3** : 16011. [doi](Doi_\\\\(identifier\\\\) \\\"Doi \\\\(identifier\\\\)\\\"):[10.1038/mto.2016.11](https://doi.org/10.1038%2Fmto.2016.11). [PMC](PMC_\\\\(identifier\\\\) \\\"PMC \\\\(identifier\\\\)\\\") [5008265](https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5008265). [PMID](PMID_\\\\(identifier\\\\) \\\"PMID \\\\(identifier\\\\)\\\") [27626062](https://pubmed.ncbi.nlm.nih.gov/27626062).\",\"description\":\"8. **^** Bonifant CL, Jackson HJ, Brentjens RJ, Curran KJ (2016). [\\\"Toxicity and management in CAR T-cell therapy\\\"](https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5008265). _Molecular Therapy: Oncolytics_. **3** : 16011. [doi](Doi_\\\\(identifier\\\\) \\\"Doi \\\\(identifier\\\\)\\\"):[10.1038/mto.2016.11](https://doi.org/10.1038%2Fmto.2016.11). [PMC](PMC_\\\\(identifier\\\\) \\\"PMC \\\\(identifier\\\\)\\\") [5008265](https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5008265). [PMID](PMID_\\\\(identifier\\\\) \\\"PMID \\\\(identifier\\\\)\\\") [27626062](https://pubmed.ncbi.nlm.nih.gov/27626062).\",\"url\":\"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5008265\",\"favicon\":\"\"},{\"id\":\"9\",\"title\":\"** Liu Q, Zhou YH, Yang ZQ (January 2016). [\\\"The cytokine storm of severe influenza and development of immunomodulatory therapy\\\"](https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4711683). _Cellular \u0026 Molecular Immunology_. **13** (1): 3â€“10\\\\. [doi](Doi_\\\\(identifier\\\\) \\\"Doi \\\\(identifier\\\\)\\\"):[10.1038/cmi.2015.74](https://doi.org/10.1038%2Fcmi.2015.74). [PMC](PMC_\\\\(identifier\\\\) \\\"PMC \\\\(identifier\\\\)\\\") [4711683](https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4711683). [PMID](PMID_\\\\(identifier\\\\) \\\"PMID \\\\(identifier\\\\)\\\") [26189369](https://pubmed.ncbi.nlm.nih.gov/26189369).\",\"description\":\"9. **^** Liu Q, Zhou YH, Yang ZQ (January 2016). [\\\"The cytokine storm of severe influenza and development of immunomodulatory therapy\\\"](https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4711683). _Cellular \u0026 Molecular Immunology_. **13** (1): 3â€“10\\\\. [doi](Doi_\\\\(identifier\\\\) \\\"Doi \\\\(identifier\\\\)\\\"):[10.1038/cmi.2015.74](https://doi.org/10.1038%2Fcmi.2015.74). [PMC](PMC_\\\\(identifier\\\\) \\\"PMC \\\\(identifier\\\\)\\\") [4711683](https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4711683). [PMID](PMID_\\\\(identifier\\\\) \\\"PMID \\\\(identifier\\\\)\\\") [26189369](https://pubmed.ncbi.nlm.nih.gov/26189369).\",\"url\":\"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4711683\",\"favicon\":\"\"},{\"id\":\"10\",\"title\":\"** Murphy K, Travers P, Walport M (2007). [\\\"Signaling Through Immune System Receptors\\\"](https://archive.org/details/janewaysimmunobi00murp). _Janeway's Immunobiology_ (7th ed.). London: Garland. [ISBN](ISBN_\\\\(identifier\\\\) \\\"ISBN \\\\(identifier\\\\)\\\") 978-0-8153-4123-9.\",\"description\":\"10. **^** Murphy K, Travers P, Walport M (2007). [\\\"Signaling Through Immune System Receptors\\\"](https://archive.org/details/janewaysimmunobi00murp). _Janeway's Immunobiology_ (7th ed.). London: Garland. [ISBN](ISBN_\\\\(identifier\\\\) \\\"ISBN \\\\(identifier\\\\)\\\") 978-0-8153-4123-9.\",\"url\":\"https://archive.org/details/janewaysimmunobi00murp\",\"favicon\":\"\"},{\"id\":\"11\",\"title\":\"** Teachey DT, Lacey SF, Shaw PA, Melenhorst JJ, Maude SL, Frey N, et al. (June 2016). [\\\"Identification of Predictive Biomarkers for Cytokine Release Syndrome after Chimeric Antigen Receptor T-cell Therapy for Acute Lymphoblastic Leukemia\\\"](https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5448406). _Cancer Discovery_. **6** (6): 664â€“79\\\\. [doi](Doi_\\\\(identifier\\\\) \\\"Doi \\\\(identifier\\\\)\\\"):[10.1158/2159-8290.CD-16-0040](https://doi.org/10.1158%2F2159-8290.CD-16-0040). [PMC](PMC_\\\\(identifier\\\\) \\\"PMC \\\\(identifier\\\\)\\\") [5448406](https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5448406). [PMID](PMID_\\\\(identifier\\\\) \\\"PMID \\\\(identifier\\\\)\\\") [27076371](https://pubmed.ncbi.nlm.nih.gov/27076371).\",\"description\":\"11. **^** Teachey DT, Lacey SF, Shaw PA, Melenhorst JJ, Maude SL, Frey N, et al. (June 2016). [\\\"Identification of Predictive Biomarkers for Cytokine Release Syndrome after Chimeric Antigen Receptor T-cell Therapy for Acute Lymphoblastic Leukemia\\\"](https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5448406). _Cancer Discovery_. **6** (6): 664â€“79\\\\. [doi](Doi_\\\\(identifier\\\\) \\\"Doi \\\\(identifier\\\\)\\\"):[10.1158/2159-8290.CD-16-0040](https://doi.org/10.1158%2F2159-8290.CD-16-0040). [PMC](PMC_\\\\(identifier\\\\) \\\"PMC \\\\(identifier\\\\)\\\") [5448406](https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5448406). [PMID](PMID_\\\\(identifier\\\\) \\\"PMID \\\\(identifier\\\\)\\\") [27076371](https://pubmed.ncbi.nlm.nih.gov/27076371).\",\"url\":\"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5448406\",\"favicon\":\"\"},{\"id\":\"12\",\"title\":\"** Hay KA, Hanafi LA, Li D, Gust J, Liles WC, Wurfel MM, et al. (November 2017). [\\\"Kinetics and biomarkers of severe cytokine release syndrome after CD19 chimeric antigen receptor-modified T-cell therapy\\\"](https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5701525). _Blood_. **130** (21): 2295â€“2306\\\\. [doi](Doi_\\\\(identifier\\\\) \\\"Doi \\\\(identifier\\\\)\\\"):[10.1182/blood-2017-06-793141](https://doi.org/10.1182%2Fblood-2017-06-793141). [PMC](PMC_\\\\(identifier\\\\) \\\"PMC \\\\(identifier\\\\)\\\") [5701525](https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5701525). [PMID](PMID_\\\\(identifier\\\\) \\\"PMID \\\\(identifier\\\\)\\\") [28924019](https://pubmed.ncbi.nlm.nih.gov/28924019).\",\"description\":\"12. **^** Hay KA, Hanafi LA, Li D, Gust J, Liles WC, Wurfel MM, et al. (November 2017). [\\\"Kinetics and biomarkers of severe cytokine release syndrome after CD19 chimeric antigen receptor-modified T-cell therapy\\\"](https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5701525). _Blood_. **130** (21): 2295â€“2306\\\\. [doi](Doi_\\\\(identifier\\\\) \\\"Doi \\\\(identifier\\\\)\\\"):[10.1182/blood-2017-06-793141](https://doi.org/10.1182%2Fblood-2017-06-793141). [PMC](PMC_\\\\(identifier\\\\) \\\"PMC \\\\(identifier\\\\)\\\") [5701525](https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5701525). [PMID](PMID_\\\\(identifier\\\\) \\\"PMID \\\\(identifier\\\\)\\\") [28924019](https://pubmed.ncbi.nlm.nih.gov/28924019).\",\"url\":\"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5701525\",\"favicon\":\"\"},{\"id\":\"13\",\"title\":\"** Barrett DM, et al. (2016). [\\\"Interleukin 6 Is Not Made By Chimeric Antigen Receptor T Cells and Does Not Impact Their Function\\\"](https://ashpublications.org/blood/article/128/22/654/99086/Interleukin-6-Is-Not-Made-By-Chimeric-Antigen). _Blood_. **128** (22): 654. [doi](Doi_\\\\(identifier\\\\) \\\"Doi \\\\(identifier\\\\)\\\"):[10.1182/blood.V128.22.654.654](https://doi.org/10.1182%2Fblood.V128.22.654.654).\",\"description\":\"13. **^** Barrett DM, et al. (2016). [\\\"Interleukin 6 Is Not Made By Chimeric Antigen Receptor T Cells and Does Not Impact Their Function\\\"](https://ashpublications.org/blood/article/128/22/654/99086/Interleukin-6-Is-Not-Made-By-Chimeric-Antigen). _Blood_. **128** (22): 654. [doi](Doi_\\\\(identifier\\\\) \\\"Doi \\\\(identifier\\\\)\\\"):[10.1182/blood.V128.22.654.654](https://doi.org/10.1182%2Fblood.V128.22.654.654).\",\"url\":\"https://ashpublications.org/blood/article/128/22/654/99086/Interleukin-6-Is-Not-Made-By-Chimeric-Antigen\",\"favicon\":\"\"},{\"id\":\"14\",\"title\":\"_**a**_ _**b**_ Sentman ML, Murad JM, Cook WJ, Wu MR, Reder J, Baumeister SH, et al. (December 2016). [\\\"Mechanisms of Acute Toxicity in NKG2D Chimeric Antigen Receptor T Cell-Treated Mice\\\"](https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5136298). _Journal of Immunology_. **197** (12): 4674â€“4685\\\\. [doi](Doi_\\\\(identifier\\\\) \\\"Doi \\\\(identifier\\\\)\\\"):[10.4049/jimmunol.1600769](https://doi.org/10.4049%2Fjimmunol.1600769). [PMC](PMC_\\\\(identifier\\\\) \\\"PMC \\\\(identifier\\\\)\\\") [5136298](https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5136298). [PMID](PMID_\\\\(identifier\\\\) \\\"PMID \\\\(identifier\\\\)\\\") [27849169](https://pubmed.ncbi.nlm.nih.gov/27849169).\",\"description\":\"14. ^ _**a**_ _**b**_ Sentman ML, Murad JM, Cook WJ, Wu MR, Reder J, Baumeister SH, et al. (December 2016). [\\\"Mechanisms of Acute Toxicity in NKG2D Chimeric Antigen Receptor T Cell-Treated Mice\\\"](https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5136298). _Journal of Immunology_. **197** (12): 4674â€“4685\\\\. [doi](Doi_\\\\(identifier\\\\) \\\"Doi \\\\(identifier\\\\)\\\"):[10.4049/jimmunol.1600769](https://doi.org/10.4049%2Fjimmunol.1600769). [PMC](PMC_\\\\(identifier\\\\) \\\"PMC \\\\(identifier\\\\)\\\") [5136298](https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5136298). [PMID](PMID_\\\\(identifier\\\\) \\\"PMID \\\\(identifier\\\\)\\\") [27849169](https://pubmed.ncbi.nlm.nih.gov/27849169).\",\"url\":\"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5136298\",\"favicon\":\"\"},{\"id\":\"15\",\"title\":\"_**a**_ _**b**_ Drazen JM, Cecil RL, Goldman L, Bennett JC (2000). [_Cecil Textbook of Medicine_](https://archive.org/details/ceciltextbookofm00ceci) (21st ed.). Philadelphia: W.B. Saunders. [ISBN](ISBN_\\\\(identifier\\\\) \\\"ISBN \\\\(identifier\\\\)\\\") 978-0-7216-7996-9.\",\"description\":\"15. ^ _**a**_ _**b**_ Drazen JM, Cecil RL, Goldman L, Bennett JC (2000). [_Cecil Textbook of Medicine_](https://archive.org/details/ceciltextbookofm00ceci) (21st ed.). Philadelphia: W.B. Saunders. [ISBN](ISBN_\\\\(identifier\\\\) \\\"ISBN \\\\(identifier\\\\)\\\") 978-0-7216-7996-9.\",\"url\":\"https://archive.org/details/ceciltextbookofm00ceci\",\"favicon\":\"\"},{\"id\":\"16\",\"title\":\"** Wadman M, Couzin-Frankel J, Kaiser J, Matacic C (April 2020). [\\\"A rampage through the body\\\"](https://doi.org/10.1126%2Fscience.368.6489.356). _Science_. **368** (6489): 356â€“360\\\\. [Bibcode](Bibcode_\\\\(identifier\\\\) \\\"Bibcode \\\\(identifier\\\\)\\\"):[2020Sci...368..356W](https://ui.adsabs.harvard.edu/abs/2020Sci...368..356W). [doi](Doi_\\\\(identifier\\\\) \\\"Doi \\\\(identifier\\\\)\\\"):[10.1126/science.368.6489.356](https://doi.org/10.1126%2Fscience.368.6489.356). [PMID](PMID_\\\\(identifier\\\\) \\\"PMID \\\\(identifier\\\\)\\\") [32327580](https://pubmed.ncbi.nlm.nih.gov/32327580). [S2CID](S2CID_\\\\(identifier\\\\) \\\"S2CID \\\\(identifier\\\\)\\\") [216110951](https://api.semanticscholar.org/CorpusID:216110951).\",\"description\":\"16. **^** Wadman M, Couzin-Frankel J, Kaiser J, Matacic C (April 2020). [\\\"A rampage through the body\\\"](https://doi.org/10.1126%2Fscience.368.6489.356). _Science_. **368** (6489): 356â€“360\\\\. [Bibcode](Bibcode_\\\\(identifier\\\\) \\\"Bibcode \\\\(identifier\\\\)\\\"):[2020Sci...368..356W](https://ui.adsabs.harvard.edu/abs/2020Sci...368..356W). [doi](Doi_\\\\(identifier\\\\) \\\"Doi \\\\(identifier\\\\)\\\"):[10.1126/science.368.6489.356](https://doi.org/10.1126%2Fscience.368.6489.356). [PMID](PMID_\\\\(identifier\\\\) \\\"PMID \\\\(identifier\\\\)\\\") [32327580](https://pubmed.ncbi.nlm.nih.gov/32327580). [S2CID](S2CID_\\\\(identifier\\\\) \\\"S2CID \\\\(identifier\\\\)\\\") [216110951](https://api.semanticscholar.org/CorpusID:216110951).\",\"url\":\"https://doi.org/10.1126%2Fscience.368.6489.356\",\"favicon\":\"\"},{\"id\":\"17\",\"title\":\"** Zhang C, Wu Z, Li JW, Zhao H, Wang GQ (March 2020). [\\\"The cytokine release syndrome (CRS) of severe COVID-19 and Interleukin-6 receptor (IL-6R) antagonist Tocilizumab may be the key to reduce the mortality\\\"](https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7118634). _International Journal of Antimicrobial Agents_. **55** (5): 105954. [doi](Doi_\\\\(identifier\\\\) \\\"Doi \\\\(identifier\\\\)\\\"):[10.1016/j.ijantimicag.2020.105954](https://doi.org/10.1016%2Fj.ijantimicag.2020.105954). [PMC](PMC_\\\\(identifier\\\\) \\\"PMC \\\\(identifier\\\\)\\\") [7118634](https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7118634). [PMID](PMID_\\\\(identifier\\\\) \\\"PMID \\\\(identifier\\\\)\\\") [32234467](https://pubmed.ncbi.nlm.nih.gov/32234467).\",\"description\":\"17. **^** Zhang C, Wu Z, Li JW, Zhao H, Wang GQ (March 2020). [\\\"The cytokine release syndrome (CRS) of severe COVID-19 and Interleukin-6 receptor (IL-6R) antagonist Tocilizumab may be the key to reduce the mortality\\\"](https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7118634). _International Journal of Antimicrobial Agents_. **55** (5): 105954. [doi](Doi_\\\\(identifier\\\\) \\\"Doi \\\\(identifier\\\\)\\\"):[10.1016/j.ijantimicag.2020.105954](https://doi.org/10.1016%2Fj.ijantimicag.2020.105954). [PMC](PMC_\\\\(identifier\\\\) \\\"PMC \\\\(identifier\\\\)\\\") [7118634](https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7118634). [PMID](PMID_\\\\(identifier\\\\) \\\"PMID \\\\(identifier\\\\)\\\") [32234467](https://pubmed.ncbi.nlm.nih.gov/32234467).\",\"url\":\"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7118634\",\"favicon\":\"\"},{\"id\":\"18\",\"title\":\"** Rezk SA, Zhao X, Weiss LM (September 2018). \\\"Epstein-Barr virus (EBV)-associated lymphoid proliferations, a 2018 update\\\". _Human Pathology_. **79** : 18â€“41\\\\. [doi](Doi_\\\\(identifier\\\\) \\\"Doi \\\\(identifier\\\\)\\\"):[10.1016/j.humpath.2018.05.020](https://doi.org/10.1016%2Fj.humpath.2018.05.020). [PMID](PMID_\\\\(identifier\\\\) \\\"PMID \\\\(identifier\\\\)\\\") [29885408](https://pubmed.ncbi.nlm.nih.gov/29885408). [S2CID](S2CID_\\\\(identifier\\\\) \\\"S2CID \\\\(identifier\\\\)\\\") [47010934](https://api.semanticscholar.org/CorpusID:47010934).\",\"description\":\"18. **^** Rezk SA, Zhao X, Weiss LM (September 2018). \\\"Epstein-Barr virus (EBV)-associated lymphoid proliferations, a 2018 update\\\". _Human Pathology_. **79** : 18â€“41\\\\. [doi](Doi_\\\\(identifier\\\\) \\\"Doi \\\\(identifier\\\\)\\\"):[10.1016/j.humpath.2018.05.020](https://doi.org/10.1016%2Fj.humpath.2018.05.020). [PMID](PMID_\\\\(identifier\\\\) \\\"PMID \\\\(identifier\\\\)\\\") [29885408](https://pubmed.ncbi.nlm.nih.gov/29885408). [S2CID](S2CID_\\\\(identifier\\\\) \\\"S2CID \\\\(identifier\\\\)\\\") [47010934](https://api.semanticscholar.org/CorpusID:47010934).\",\"url\":\"Doi_\\\\(identifier\\\\\",\"favicon\":\"\"},{\"id\":\"19\",\"title\":\"** E. GÃ¶hring: _Active Fever Therapy with MBV â€“ Coley's Toxins: The Perfect Storm of Cytokines_ , Epubli, Berlin 2019, [ISBN](ISBN_\\\\(identifier\\\\) \\\"ISBN \\\\(identifier\\\\)\\\") 978-3748530596.\",\"description\":\"19. **^** E. GÃ¶hring: _Active Fever Therapy with MBV â€“ Coley's Toxins: The Perfect Storm of Cytokines_ , Epubli, Berlin 2019, [ISBN](ISBN_\\\\(identifier\\\\) \\\"ISBN \\\\(identifier\\\\)\\\") 978-3748530596.\",\"url\":\"ISBN_\\\\(identifier\\\\\",\"favicon\":\"\"},{\"id\":\"20\",\"title\":\"** [\\\"Common Terminology Criteria for Adverse Events (CTCAE) Version v4.03\\\"](https://web.archive.org/web/20170830073206/https://evs.nci.nih.gov/ftp1/CTCAE/CTCAE_4.03_2010-06-14_QuickReference_5x7.pdf#page=67) (PDF). National Institutes of Health and National Cancer Institute. June 14, 2010. p. 66\\\\. Archived from [the original](https://evs.nci.nih.gov/ftp1/CTCAE/CTCAE_4.03_2010-06-14_QuickReference_5x7.pdf) (PDF) on August 30, 2017. Retrieved October 16, 2017.\",\"description\":\"20. **^** [\\\"Common Terminology Criteria for Adverse Events (CTCAE) Version v4.03\\\"](https://web.archive.org/web/20170830073206/https://evs.nci.nih.gov/ftp1/CTCAE/CTCAE_4.03_2010-06-14_QuickReference_5x7.pdf#page=67) (PDF). National Institutes of Health and National Cancer Institute. June 14, 2010. p. 66\\\\. Archived from [the original](https://evs.nci.nih.gov/ftp1/CTCAE/CTCAE_4.03_2010-06-14_QuickReference_5x7.pdf) (PDF) on August 30, 2017. Retrieved October 16, 2017.\",\"url\":\"https://web.archive.org/web/20170830073206/https://evs.nci.nih.gov/ftp1/CTCAE/CTCAE_4.03_2010-06-14_QuickReference_5x7.pdf#page=67\",\"favicon\":\"\"},{\"id\":\"21\",\"title\":\"** [\\\"Guidance for Industry: Immunogenicity Assessment for Therapeutic Protein Products\\\"](https://web.archive.org/web/20191213233706/https://www.fda.gov/media/85017/download) (PDF). FDA. August 2014. Archived from [the original](https://www.fda.gov/media/85017/download) on December 13, 2019.\",\"description\":\"21. **^** [\\\"Guidance for Industry: Immunogenicity Assessment for Therapeutic Protein Products\\\"](https://web.archive.org/web/20191213233706/https://www.fda.gov/media/85017/download) (PDF). FDA. August 2014. Archived from [the original](https://www.fda.gov/media/85017/download) on December 13, 2019.\",\"url\":\"https://web.archive.org/web/20191213233706/https://www.fda.gov/media/85017/download\",\"favicon\":\"\"},{\"id\":\"22\",\"title\":\"** Fletcher EA, Eltahir M, Lindqvist F, Rieth J, TÃ¶rnqvist G, Leja-Jarblad J, Mangsbo SM (January 2018). [\\\"Extracorporeal human whole blood in motion, as a tool to predict first-infusion reactions and mechanism-of-action of immunotherapeutics\\\"](https://doi.org/10.1016%2Fj.intimp.2017.10.021). _International Immunopharmacology_. **54** : 1â€“11\\\\. [doi](Doi_\\\\(identifier\\\\) \\\"Doi \\\\(identifier\\\\)\\\"):[10.1016/j.intimp.2017.10.021](https://doi.org/10.1016%2Fj.intimp.2017.10.021). [PMID](PMID_\\\\(identifier\\\\) \\\"PMID \\\\(identifier\\\\)\\\") [29100032](https://pubmed.ncbi.nlm.nih.gov/29100032).\",\"description\":\"22. **^** Fletcher EA, Eltahir M, Lindqvist F, Rieth J, TÃ¶rnqvist G, Leja-Jarblad J, Mangsbo SM (January 2018). [\\\"Extracorporeal human whole blood in motion, as a tool to predict first-infusion reactions and mechanism-of-action of immunotherapeutics\\\"](https://doi.org/10.1016%2Fj.intimp.2017.10.021). _International Immunopharmacology_. **54** : 1â€“11\\\\. [doi](Doi_\\\\(identifier\\\\) \\\"Doi \\\\(identifier\\\\)\\\"):[10.1016/j.intimp.2017.10.021](https://doi.org/10.1016%2Fj.intimp.2017.10.021). [PMID](PMID_\\\\(identifier\\\\) \\\"PMID \\\\(identifier\\\\)\\\") [29100032](https://pubmed.ncbi.nlm.nih.gov/29100032).\",\"url\":\"https://doi.org/10.1016%2Fj.intimp.2017.10.021\",\"favicon\":\"\"},{\"id\":\"23\",\"title\":\"** Zelalem T, Charles B, Jason B, Christopher P, Claudia L, Colleen K, Vincent M, Robert O, Victoria C, William A, Cameron D, Dale C, Omar A, Gabrielle C, Andrew B (December 2021). [\\\"Lenzilumab in hospitalised patients with COVID-19 pneumonia (LIVE-AIR): a phase 3, randomised, placebo controlled trial\\\"](https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8109186). _Lancet Respiratory Medicine_. **9** (12): 237â€“246\\\\. [doi](Doi_\\\\(identifier\\\\) \\\"Doi \\\\(identifier\\\\)\\\"):[10.1016/S2213-2600(21)00494-X](https://doi.org/10.1016%2FS2213-2600%2821%2900494-X). [PMC](PMC_\\\\(identifier\\\\) \\\"PMC \\\\(identifier\\\\)\\\") [8109186](https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8109186). [PMID](PMID_\\\\(identifier\\\\) \\\"PMID \\\\(identifier\\\\)\\\") [33972949](https://pubmed.ncbi.nlm.nih.gov/33972949).\",\"description\":\"23. **^** Zelalem T, Charles B, Jason B, Christopher P, Claudia L, Colleen K, Vincent M, Robert O, Victoria C, William A, Cameron D, Dale C, Omar A, Gabrielle C, Andrew B (December 2021). [\\\"Lenzilumab in hospitalised patients with COVID-19 pneumonia (LIVE-AIR): a phase 3, randomised, placebo controlled trial\\\"](https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8109186). _Lancet Respiratory Medicine_. **9** (12): 237â€“246\\\\. [doi](Doi_\\\\(identifier\\\\) \\\"Doi \\\\(identifier\\\\)\\\"):[10.1016/S2213-2600(21)00494-X](https://doi.org/10.1016%2FS2213-2600%2821%2900494-X). [PMC](PMC_\\\\(identifier\\\\) \\\"PMC \\\\(identifier\\\\)\\\") [8109186](https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8109186). [PMID](PMID_\\\\(identifier\\\\) \\\"PMID \\\\(identifier\\\\)\\\") [33972949](https://pubmed.ncbi.nlm.nih.gov/33972949).\",\"url\":\"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8109186\",\"favicon\":\"\"},{\"id\":\"24\",\"title\":\"** Temesgen, Zelalem; Burger, Charles; Baker, Jason; Polk, Christopher; Libertin, Claudia; Kelley, Colleen; Marconi, Vincent; Orenstein, Robert; Catterson, Victoria; Aronstein, William; Durrant, Cameron; Chappell, Dale; Chappell, Gabrielle; Ahmed, Omar; Badley, Andrew (2021). [\\\"C-Reactive Protein as a Biomarker for Improved Efficacy of Lenzilumab in Patients with Covid-19: Results from the Live-Air Trial\\\"](https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8503207). _Chest_. **160** (4): A2522 â€“ A2524. [doi](Doi_\\\\(identifier\\\\) \\\"Doi \\\\(identifier\\\\)\\\"):[10.1016/j.chest.2021.08.029](https://doi.org/10.1016%2Fj.chest.2021.08.029). [PMC](PMC_\\\\(identifier\\\\) \\\"PMC \\\\(identifier\\\\)\\\") [8503207](https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8503207). [S2CID](S2CID_\\\\(identifier\\\\) \\\"S2CID \\\\(identifier\\\\)\\\") [238585501](https://api.semanticscholar.org/CorpusID:238585501).\",\"description\":\"24. **^** Temesgen, Zelalem; Burger, Charles; Baker, Jason; Polk, Christopher; Libertin, Claudia; Kelley, Colleen; Marconi, Vincent; Orenstein, Robert; Catterson, Victoria; Aronstein, William; Durrant, Cameron; Chappell, Dale; Chappell, Gabrielle; Ahmed, Omar; Badley, Andrew (2021). [\\\"C-Reactive Protein as a Biomarker for Improved Efficacy of Lenzilumab in Patients with Covid-19: Results from the Live-Air Trial\\\"](https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8503207). _Chest_. **160** (4): A2522 â€“ A2524. [doi](Doi_\\\\(identifier\\\\) \\\"Doi \\\\(identifier\\\\)\\\"):[10.1016/j.chest.2021.08.029](https://doi.org/10.1016%2Fj.chest.2021.08.029). [PMC](PMC_\\\\(identifier\\\\) \\\"PMC \\\\(identifier\\\\)\\\") [8503207](https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8503207). [S2CID](S2CID_\\\\(identifier\\\\) \\\"S2CID \\\\(identifier\\\\)\\\") [238585501](https://api.semanticscholar.org/CorpusID:238585501).\",\"url\":\"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8503207\",\"favicon\":\"\"},{\"id\":\"25\",\"title\":\"** Nishimoto N, Terao K, Mima T, Nakahara H, Takagi N, Kakehi T (November 2008). [\\\"Mechanisms and pathologic significances in increase in serum interleukin-6 (IL-6) and soluble IL-6 receptor after administration of an anti-IL-6 receptor antibody, tocilizumab, in patients with rheumatoid arthritis and Castleman disease\\\"](https://ashpublications.org/blood/article/112/10/3959/24657/Mechanisms-and-pathologic-significances-in). _Blood_. **112** (10): 3959â€“64\\\\. [doi](Doi_\\\\(identifier\\\\) \\\"Doi \\\\(identifier\\\\)\\\"):[10.1182/blood-2008-05-155846](https://doi.org/10.1182%2Fblood-2008-05-155846). [PMID](PMID_\\\\(identifier\\\\) \\\"PMID \\\\(identifier\\\\)\\\") [18784373](https://pubmed.ncbi.nlm.nih.gov/18784373).\",\"description\":\"25. **^** Nishimoto N, Terao K, Mima T, Nakahara H, Takagi N, Kakehi T (November 2008). [\\\"Mechanisms and pathologic significances in increase in serum interleukin-6 (IL-6) and soluble IL-6 receptor after administration of an anti-IL-6 receptor antibody, tocilizumab, in patients with rheumatoid arthritis and Castleman disease\\\"](https://ashpublications.org/blood/article/112/10/3959/24657/Mechanisms-and-pathologic-significances-in). _Blood_. **112** (10): 3959â€“64\\\\. [doi](Doi_\\\\(identifier\\\\) \\\"Doi \\\\(identifier\\\\)\\\"):[10.1182/blood-2008-05-155846](https://doi.org/10.1182%2Fblood-2008-05-155846). [PMID](PMID_\\\\(identifier\\\\) \\\"PMID \\\\(identifier\\\\)\\\") [18784373](https://pubmed.ncbi.nlm.nih.gov/18784373).\",\"url\":\"https://ashpublications.org/blood/article/112/10/3959/24657/Mechanisms-and-pathologic-significances-in\",\"favicon\":\"\"},{\"id\":\"26\",\"title\":\"** Santomasso BD, Park JH, Salloum D, Riviere I, Flynn J, Mead E, et al. (August 2018). [\\\"Clinical and Biological Correlates of Neurotoxicity Associated with CAR T-cell Therapy in Patients with B-cell Acute Lymphoblastic Leukemia\\\"](https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6385599). _Cancer Discovery_. **8** (8): 958â€“971\\\\. [doi](Doi_\\\\(identifier\\\\) \\\"Doi \\\\(identifier\\\\)\\\"):[10.1158/2159-8290.CD-17-1319](https://doi.org/10.1158%2F2159-8290.CD-17-1319). [PMC](PMC_\\\\(identifier\\\\) \\\"PMC \\\\(identifier\\\\)\\\") [6385599](https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6385599). [PMID](PMID_\\\\(identifier\\\\) \\\"PMID \\\\(identifier\\\\)\\\") [29880584](https://pubmed.ncbi.nlm.nih.gov/29880584).\",\"description\":\"26. **^** Santomasso BD, Park JH, Salloum D, Riviere I, Flynn J, Mead E, et al. (August 2018). [\\\"Clinical and Biological Correlates of Neurotoxicity Associated with CAR T-cell Therapy in Patients with B-cell Acute Lymphoblastic Leukemia\\\"](https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6385599). _Cancer Discovery_. **8** (8): 958â€“971\\\\. [doi](Doi_\\\\(identifier\\\\) \\\"Doi \\\\(identifier\\\\)\\\"):[10.1158/2159-8290.CD-17-1319](https://doi.org/10.1158%2F2159-8290.CD-17-1319). [PMC](PMC_\\\\(identifier\\\\) \\\"PMC \\\\(identifier\\\\)\\\") [6385599](https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6385599). [PMID](PMID_\\\\(identifier\\\\) \\\"PMID \\\\(identifier\\\\)\\\") [29880584](https://pubmed.ncbi.nlm.nih.gov/29880584).\",\"url\":\"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6385599\",\"favicon\":\"\"},{\"id\":\"27\",\"title\":\"** Sterner RM, Sakemura R, Cox MJ, Yang N, Khadka RH, Forsman CL, et al. (February 2019). [\\\"GM-CSF inhibition reduces cytokine release syndrome and neuroinflammation but enhances CAR-T cell function in xenografts\\\"](https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6376281). _Blood_. **133** (7): 697â€“709\\\\. [doi](Doi_\\\\(identifier\\\\) \\\"Doi \\\\(identifier\\\\)\\\"):[10.1182/blood-2018-10-881722](https://doi.org/10.1182%2Fblood-2018-10-881722). [PMC](PMC_\\\\(identifier\\\\) \\\"PMC \\\\(identifier\\\\)\\\") [6376281](https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6376281). [PMID](PMID_\\\\(identifier\\\\) \\\"PMID \\\\(identifier\\\\)\\\") [30463995](https://pubmed.ncbi.nlm.nih.gov/30463995).\",\"description\":\"27. **^** Sterner RM, Sakemura R, Cox MJ, Yang N, Khadka RH, Forsman CL, et al. (February 2019). [\\\"GM-CSF inhibition reduces cytokine release syndrome and neuroinflammation but enhances CAR-T cell function in xenografts\\\"](https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6376281). _Blood_. **133** (7): 697â€“709\\\\. [doi](Doi_\\\\(identifier\\\\) \\\"Doi \\\\(identifier\\\\)\\\"):[10.1182/blood-2018-10-881722](https://doi.org/10.1182%2Fblood-2018-10-881722). [PMC](PMC_\\\\(identifier\\\\) \\\"PMC \\\\(identifier\\\\)\\\") [6376281](https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6376281). [PMID](PMID_\\\\(identifier\\\\) \\\"PMID \\\\(identifier\\\\)\\\") [30463995](https://pubmed.ncbi.nlm.nih.gov/30463995).\",\"url\":\"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6376281\",\"favicon\":\"\"}],\"images\":[],\"fixedIssues\":[{\"criticality\":\"Critical\",\"issueType\":\"Mechanism/Specification Error\",\"problematicText\":\"\\\"It refers to [cytokine storm](Cytokine_storm \\\"Cytokine storm\\\") syndromes (CSS)[4]\\\"\",\"explanation\":\"CRS is a specific subset or form of cytokine storm syndrome (CSS), not something that \\\"refers to\\\" CSS; this misrepresents the hierarchical relationship where CSS is an umbrella term encompassing CRS and related conditions like hemophagocytic lymphohistiocytosis.\",\"fixedText\":\"Revise to: \\\"CRS is a type of cytokine storm syndrome (CSS)\\\"\",\"evidenceSource\":\"Ref 4: Behrens EM, Koretzky GA (2017)\"},{\"criticality\":\"Critical\",\"issueType\":\"Source/Citation Mismatch\",\"problematicText\":\"\\\"Immediate-onset CRS is a cytokine storm,[7]\\\"\",\"explanation\":\"Ref 7 distinguishes cytokine storm as the immediate-onset (minutes to hours) reaction independent of tumor targeting, while CRS specifically denotes the delayed-onset (days to weeks) response in contexts like CAR-T therapy; labeling the immediate form as \\\"CRS\\\" mismatches the source's precise terminology.\",\"fixedText\":\"Revise to: \\\"Immediate-onset reactions associated with some therapies are termed cytokine storms,[7] in contrast to the delayed CRS\\\"\",\"evidenceSource\":\"Ref 7: Porter D, et al. (2018)\"},{\"criticality\":\"Critical\",\"issueType\":\"Missing Information\",\"problematicText\":\"No specific mention\",\"explanation\":\"The intro lacks key context on CRS's prominence in recent contexts like severe infections (e.g., COVID-19), which expanded its recognition beyond immunotherapy; this creates a knowledge gap in scope and impact, as COVID-19 cases highlighted CRS-like responses globally from 2020 onward.\",\"fixedText\":\"Add: \\\"CRS gained widespread attention during the COVID-19 pandemic due to its role in severe cases.[16][17]\\\"\",\"evidenceSource\":\"Refs 16, 17\"},{\"criticality\":\"Critical\",\"issueType\":\"Source/Citation Mismatch\",\"problematicText\":\"\\\"[factor I deficiency](Complement_factor_I \\\"Complement factor I\\\") and excessive bleeding\\\"\",\"explanation\":\"The term \\\"factor I deficiency\\\" is incorrectly linked to complement factor I, but in CRS context, it refers to hypofibrinogenemia (deficiency of coagulation factor I, fibrinogen), which predisposes to bleeding diathesis. This misattribution confuses the coagulation mechanism involved in CRS complications.\",\"fixedText\":\"Replace with \\\"hypofibrinogenemia and excessive bleeding\\\" without the incorrect link.\",\"evidenceSource\":\"[5]\"},{\"criticality\":\"Critical\",\"issueType\":\"Missing Information\",\"problematicText\":\"The laboratory findings list omits key diagnostic markers.\",\"explanation\":\"The section fails to mention elevated C-reactive protein (CRP) and ferritin levels, which are standard laboratory indicators used to assess CRS presence and severity, representing a significant knowledge gap in clinical monitoring.\",\"fixedText\":\"Add \\\"elevated C-reactive protein (CRP) and ferritin\\\" to the list of laboratory findings.\",\"evidenceSource\":\"[5]\"},{\"criticality\":\"Critical\",\"issueType\":\"Source/Citation Mismatch\",\"problematicText\":\"including graft-versus-host disease (GVHD), coronavirus disease 2019 (COVID-19), acute respiratory distress syndrome (ARDS), sepsis, Ebola, avian influenza, smallpox, and systemic inflammatory response syndrome (SIRS).[15]\",\"explanation\":\"Reference 15 (Cecil Textbook of Medicine, 2000) predates the identification of COVID-19 (2019) and likely does not discuss CRS in the context of COVID-19, Ebola (major outbreaks post-2000), or avian influenza (H5N1 prominence post-2000). The textbook may cover general SIRS or early CRS from therapies like OKT3, but not this specific list of modern infectious diseases. This mismatches the source's scope and date.\",\"fixedText\":\"Remove COVID-19 from the list (covered separately with [16][17]). Reassess and cite appropriately for other diseases, or rephrase to focus on well-supported examples like sepsis and GVHD, using more recent sources for infections (e.g., ref 9 for influenza, ref 6 for general). Change \\\"diseases\\\" to \\\"conditions\\\" to include syndromes like ARDS and SIRS.\",\"evidenceSource\":\"Ref 15; web search confirms CRS history from 1990s (OKT3), but 2000 textbook unlikely covers post-2000 diseases.\"},{\"criticality\":\"Critical\",\"issueType\":\"Scope/Applicability Misstatement\",\"problematicText\":\"severe CRS or cytokine reactions can occur in a number of infectious and non-infectious diseases including ... systemic inflammatory response syndrome (SIRS).[15]\",\"explanation\":\"The article intro defines CRS as a form of SIRS, so stating CRS occurs \\\"in\\\" SIRS creates a logical loop or misstatement of scope. SIRS is the broader syndrome, not a context where CRS occurs separately.\",\"fixedText\":\"Remove SIRS from the list or clarify that CRS is a manifestation within SIRS triggered by these factors.\",\"evidenceSource\":\"Page intro: \\\"cytokine release syndrome (CRS) is a form of systemic inflammatory response syndrome (SIRS)\\\"\"},{\"criticality\":\"Critical\",\"issueType\":\"Source/Citation Mismatch\",\"problematicText\":\"CRS has also arisen with biotherapeutics such as COVID-19 vaccines (Frontiers of Immunology 2022 13: 967226)\",\"explanation\":\"The cited article reports \\\"cytokine storm\\\" (not explicitly CRS) in four fatal cases post-vaccination, based on RNA sequencing suggesting immune dysregulation. It does not conclusively establish causality and emphasizes vaccination benefits. Using \\\"CRS\\\" misaligns with the source's terminology, especially given the article's distinction between CRS and cytokine storm.\",\"fixedText\":\"Rephrase to \\\"cytokine storm\\\" or \\\"CRS-like reactions\\\" if supported, and add context of rarity/no causality. Format as proper inline citation [](https://doi.org/10.3389/fimmu.2022.967226). If not central, omit to avoid overstating rare events.\",\"evidenceSource\":\"Article: https://www.frontiersin.org/journals/immunology/articles/10.3389/fimmu.2022.967226/full (uses \\\"cytokine storm\\\"; no definitive causality for CRS).\"},{\"criticality\":\"Critical\",\"issueType\":\"Missing Information\",\"problematicText\":\"[No specific quote; overall section on infections]\",\"explanation\":\"The section attributes infection-induced events to CRS, but many sources (e.g., for smallpox, Ebola) describe \\\"cytokine storm\\\" rather than CRS, which is more therapy-specific. Missing distinction aligns with intro but gaps in precision for historical/modern contexts up to 2025. No mention of recent associations like monkeypox (2022 outbreak linked to cytokine storm).\",\"fixedText\":\"Add note: \\\"In infections, this is often termed cytokine storm.\\\" Include monkeypox as example if space, with citation [](https://doi.org/10.1016/j.cyto.2024.104063) for recency as of 2024.\",\"evidenceSource\":\"Web search: Cytokine storm common in poxviruses (e.g., https://pubmed.ncbi.nlm.nih.gov/17228320/); monkeypox cytokine storm (https://www.sciencedirect.com/science/article/abs/pii/S1043466624000632).\"},{\"criticality\":\"Critical\",\"issueType\":\"Timeliness/Currency\",\"problematicText\":\"As of 2015, differential diagnoses depended on the judgement of doctors, as there were no objective tests.[5]\",\"explanation\":\"The statement is outdated; since 2016, objective biomarkers such as elevated levels of IL-6, IFN-Î³, CRP, and ferritin have been identified for diagnosing and predicting CRS severity. Recent 2024 studies confirm key cytokines like IL-2, IL-10 as predictive. This misrepresents current diagnostic capabilities, potentially affecting clinical practice.\",\"fixedText\":\"Update to: \\\"Differential diagnosis involves distinguishing CRS from underlying disease symptoms or other adverse effects, such as tumor lysis syndrome. Objective biomarkers, including elevated IL-6, CRP, ferritin, and others like IFN-Î³ and IL-10, aid in diagnosis and severity assessment as of 2024.\\\"\",\"evidenceSource\":\"Ref [11], [12]; [](https://www.frontiersin.org/journals/immunology/articles/10.3389/fimmu.2024.1450173/full); [](https://link.springer.com/article/10.1007/s44272-025-00044-0)\"},{\"criticality\":\"Critical\",\"issueType\":\"Timeliness/Currency\",\"problematicText\":\"CRS is a form of [systemic inflammatory response syndrome](Systemic_inflammatory_response_syndrome \\\"Systemic inflammatory response syndrome\\\") and is an [adverse effect](Adverse_effect \\\"Adverse effect\\\") of some drugs.[5]\",\"explanation\":\"This is accurate but cited to 2014 ref; however, it's not the critical part. The subsection as a whole uses outdated classification.\",\"fixedText\":\"Retain but integrate into updated classification description.\",\"evidenceSource\":\"Ref [5]\"},{\"criticality\":\"Critical\",\"issueType\":\"Figures/Tables/Data Presentation\",\"problematicText\":\"The [Common Terminology Criteria for Adverse Events](Common_Terminology_Criteria_for_Adverse_Events \\\"Common Terminology Criteria for Adverse Events\\\") classifications for CRS as of version 4.03 issued in 2010 were:[5][20] [followed by the table]\",\"explanation\":\"The CTCAE v4.03 (2010) grading is outdated; CTCAE v5.0 (2017) updated CRS criteria, and for CRS in immune effector cell therapies (key context for the article), the 2019 ASTCT consensus grading is the standard, focusing on fever, hypotension, and hypoxia. Using the old table could lead to incorrect severity assessment and management.\",\"fixedText\":\"Replace with ASTCT consensus grading table as of 2019, noting it's the current standard for immunotherapy-related CRS. Provide markdown table with criteria.\",\"evidenceSource\":\"Ref [5], [20]; [](https://dctd.cancer.gov/research/ctep-trials/for-sites/adverse-events/ctcae-v5-5x7.pdf); [](https://doi.org/10.1016/j.bbmt.2018.12.758)\"},{\"criticality\":\"Critical\",\"issueType\":\"Missing Information\",\"problematicText\":\"[Entire section lacks current biomarkers and grading updates]\",\"explanation\":\"Missing key factual details on current diagnostic tools (biomarkers) and the preferred grading system (ASTCT 2019), which are essential for accuracy in a medical article on CRS, especially given the focus on immunotherapy in the intro and structure.\",\"fixedText\":\"Add description of biomarkers and update to ASTCT grading in the rewritten section.\",\"evidenceSource\":\"[](https://www.frontiersin.org/journals/immunology/articles/10.3389/fimmu.2024.1450173/full); [](https://doi.org/10.1016/j.bbmt.2018.12.758)\"},{\"criticality\":\"Critical\",\"issueType\":\"Source/Citation Mismatch\",\"problematicText\":\"Severe CRS caused by some drugs can be prevented by using lower doses, infusing slowly, and administering [anti-histamines](Anti-histamine \\\"Anti-histamine\\\") or [corticosteroids](Corticosteroid \\\"Corticosteroid\\\") before and during administration of the drug.[5]\",\"explanation\":\"The cited source [5] (Lee et al., 2014) focuses on diagnosis and management of CRS in CAR T-cell therapy contexts and does not discuss preventive strategies such as lower doses, slow infusion, or pre-administration of antihistamines or corticosteroids. These approaches are more relevant to monoclonal antibody infusions where they help mitigate infusion-related reactions including CRS, but prophylactic corticosteroids are generally avoided in CAR T-cell therapy to preserve efficacy.\",\"fixedText\":\"Replace citation [5] with [1], which supports premedication with antihistamines and corticosteroids, as well as slow infusion for preventing infusion reactions (encompassing CRS) in monoclonal antibody therapies. Rephrase slightly for clarity and remove wiki links to maintain plain text.\",\"evidenceSource\":\"Ref [5]: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4093680/\"},{\"criticality\":\"Non-Critical\",\"issueType\":\"Missing Information\",\"problematicText\":\"No specific text; overall section\",\"explanation\":\"The section focuses on drug-induced CRS prevention but lacks mention of context-specific strategies, such as step-up dosing for bispecific antibodies like blinatumomab or avoidance of prophylactic steroids in CAR T-cell therapies to prevent interference with antitumor activity. This gap could lead to incomplete understanding, though not critically erroneous.\",\"fixedText\":\"Add a brief sentence clarifying differences for CAR T-cell vs. monoclonal antibody therapies, citing ref [3] or a new source if needed.\",\"evidenceSource\":\"Ref [3]: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6003181/ and recent guidelines (e.g., ASH 2023 consensus)\"},{\"criticality\":\"Critical\",\"issueType\":\"Timeliness/Currency\",\"problematicText\":\"Although frequently used to treat severe CRS in people with [ARDS](ARDS \\\"ARDS\\\"), [corticosteroids](Corticosteroids \\\"Corticosteroids\\\") and [NSAIDs](NSAID \\\"NSAID\\\") have been evaluated in [clinical trials](Clinical trials \\\"Clinical trials\\\") and have shown no effect on lung mechanics, gas exchange, or beneficial outcome in early established ARDS.[15]\",\"explanation\":\"The reference [15] is from 2000 and predates key trials like DEXA-ARDS (2020) showing mortality benefits. Current 2024 ATS/SCCM guidelines conditionally recommend corticosteroids for moderate-to-severe ARDS (moderate certainty evidence), reducing 28-day mortality (RR 0.82). This outdated claim misleads on current standard care, potentially affecting health decisions in CRS-associated ARDS.\",\"fixedText\":\"Revise to: \\\"Corticosteroids are recommended in guidelines for moderate-to-severe ARDS associated with CRS, based on evidence of improved outcomes; NSAIDs lack supporting evidence from trials.\\\"\",\"evidenceSource\":\"ATS 2024 Guideline: [](https://www.atsjournals.org/doi/10.1164/rccm.202311-2011ST); SCCM 2024 Update: [](https://www.sccm.org/clinical-resources/guidelines/guidelines/use-of-corticosteroids-in-sepsis-ards-cap)\"},{\"criticality\":\"Critical\",\"issueType\":\"Source/Citation Mismatch\",\"problematicText\":\"Additionally, as a soluble cytokine blockade, it will not increase serum levels of GM-CSF (a phenomenon seen with [tocilizumab](Tocilizumab \\\"Tocilizumab\\\") and IL-6).[25]\",\"explanation\":\"Reference [25] discusses increased serum IL-6 and soluble IL-6R with tocilizumab but does not address GM-CSF or lenzilumab's effects on GM-CSF levels. No provided evidence supports the comparison for GM-CSF.\",\"fixedText\":\"Remove the unsupported parenthetical claim about serum levels.\",\"evidenceSource\":\"[25] Nishimoto et al. (2008)\"},{\"criticality\":\"Critical\",\"issueType\":\"Scope/Applicability Misstatement\",\"problematicText\":\"[Lenzilumab](Lenzilumab \\\"Lenzilumab\\\"), an anti-GM-CSF monoclonal antibody, is also clinically proven to be effective at managing cytokine release by reducing activation of myeloid cells and decreasing the production of IL-1, IL-6, MCP-1, MIP-1, and IP-10. [23][24]\",\"explanation\":\"References [23] and [24] report results from the LIVE-AIR phase 3 trial in COVID-19 pneumonia (a CRS-like condition), showing improved survival without ventilation. However, lenzilumab is not FDA-approved for CRS (EUA rejected in 2021), remains investigational for therapy-induced CRS (e.g., CAR-T), and is not a standard management option like tocilizumab. Claiming it as generally \\\"clinically proven\\\" overstates applicability beyond the specific COVID context.\",\"fixedText\":\"Qualify as: \\\"Lenzilumab, an investigational anti-GM-CSF monoclonal antibody, showed efficacy in reducing cytokine release in a phase 3 trial for COVID-19-associated CRS-like symptoms by...\\\" or remove if not essential to general management.\",\"evidenceSource\":\"LIVE-AIR Trial: [](https://pmc.ncbi.nlm.nih.gov/articles/PMC8109186/); FDA Status: [](https://www.genengnews.com/news/humanigen-lenzilumab/)\"},{\"criticality\":\"Critical\",\"issueType\":\"Missing Information\",\"problematicText\":\"\",\"explanation\":\"Section lacks mention of alternative approved IL-6 blockers like siltuximab for CRS refractory to tocilizumab, per guidelines. No update on evolved management post-2014 consensus (e.g., ASTCT 2019 grading influencing therapy escalation). As of 2025, biosimilars of tocilizumab (e.g., tocilizumab-anoh) are approved for CRS, expanding access.\",\"fixedText\":\"Add: \\\"Siltuximab is an alternative anti-IL-6 agent for cases refractory to tocilizumab. As of 2025, tocilizumab biosimilars are also approved for CRS management.\\\"\",\"evidenceSource\":\"ASTCT Consensus: [](https://www.astctjournal.org/article/S1083-8791(18)31292-0/fulltext); FDA Biosimilar: [](https://www.targetedonc.com/view/fda-expands-approval-for-tocilizumab-biosimilar-to-treat-crs)\"},{\"criticality\":\"Critical\",\"issueType\":\"Source/Citation Mismatch | Timeliness/Currency\",\"problematicText\":\"Severe CRS is rare. Minor and moderate CRS are common side effects of immune-modulating antibody therapies and CAR-T therapies.[6]\",\"explanation\":\"Reference 6 (2017) supports rarity of severe CRS primarily for monoclonal antibody therapies (e.g., ~1-2% serious events), but describes it as \\\"less common but significant\\\" in early CAR-T therapies with higher reported rates (up to 40-80% for components like hypotension). Recent meta-analyses indicate grade 3+ (severe) CRS incidence in CAR-T at approximately 9.6% (range 6-13%), which is higher than typical \\\"rare\\\" thresholds (\u0026lt;5%) in adverse event classification, though lower than early trials due to improved management. The undifferentiated claim across therapies lacks temporal context, potentially misleading on current epidemiology as of 2025.\",\"fixedText\":\"Revise to differentiate incidence by therapy type: Severe CRS is rare in immune-modulating antibody therapies (incidence \u0026lt;5%) but occurs in 5-15% of CAR-T cases depending on product. Minor and moderate CRS are common in both (50-90% for CAR-T, variable for antibodies). Cite recent source for CAR-T data and date claims.\",\"evidenceSource\":\"Reference 6; [](https://www.sciencedirect.com/science/article/pii/S2589537025001993)\"},{\"criticality\":\"Critical\",\"issueType\":\"Missing Information\",\"problematicText\":\"No quantitative claims present.\",\"explanation\":\"An epidemiology section requires key metrics like incidence/prevalence rates across main triggers (therapies and infections). Current text is vague without specifics, omitting variation by therapy type, patient population, or non-therapy causes (e.g., infections like severe COVID-19, where CRS-like syndromes affected ~20-30% of critically ill patients in 2020 peaks). This gap hinders comprehensive understanding of occurrence and risk factors.\",\"fixedText\":\"Add summarized incidence data: e.g., In CAR-T therapy, any-grade CRS occurs in 50-100% of patients, severe (grade â‰¥3) in 5-15% as of 2023 reviews. For monoclonal antibodies, severe CRS \u0026lt;5%. In infections, CRS contributes to ~25% of severe sepsis cases, notably during COVID-19 pandemics.\",\"evidenceSource\":\"References 3,5,6,16,17; [](https://www.nejm.org/doi/full/10.1056/NEJMra2026131)\"},{\"criticality\":\"Critical\",\"issueType\":\"Source/Citation Mismatch\",\"problematicText\":\"\\\"thus driving the cytokine across the blood brain barrier (BBB) and worsening neurotoxicity.[26]\\\"\",\"explanation\":\"The cited source [26] confirms that tocilizumab increases serum IL-6 levels due to receptor saturation and notes a suboptimal response to neurotoxicity (e.g., 56.3% of severe cases peaked after administration), but does not explicitly state or provide evidence that this drives IL-6 across the BBB or worsens neurotoxicity. While other literature (e.g., 2024 reviews) suggests a possible association with worsening neurotoxicity due to paradoxical IL-6 increase in the CNS, the specific citation does not support this causal mechanism.\",\"fixedText\":\"Revise to: \\\"it has been shown to increase serum levels of IL-6 by saturating the receptor.[26] However, tocilizumab may not fully resolve neurotoxicity and has been associated in some studies with paradoxical worsening due to increased IL-6 signaling in the CNS.[](https://www.sciencedirect.com/science/article/pii/S2473952924003604)\\\" or remove the unsupported causal link and cite appropriately for the association.\",\"evidenceSource\":\"[26] Santomasso et al. (2018)\"},{\"criticality\":\"Critical\",\"issueType\":\"Missing Information\",\"problematicText\":\"No specific text; overall section lacks recency.\",\"explanation\":\"The section cites research up to 2019, but as of 2025, there are recent developments in CRS research, including novel targets like inhibition of IL-6 translation (e.g., using metoprolol, a beta-blocker, shown in 2023 studies to mitigate CRS without affecting CAR-T efficacy) and ongoing clinical trials for GM-CSF blockade with lenzilumab (Phase 2/3 as of 2021, with continued evaluation). This creates a knowledge gap in timeliness/currency for a \\\"Research\\\" section.\",\"fixedText\":\"Add a sentence or paragraph summarizing recent advances, e.g., \\\"More recent research (as of 2023) has identified IL-6 translation as a therapeutic target, with metoprolol demonstrating potential to reduce CRS in human models.[](https://pmc.ncbi.nlm.nih.gov/articles/PMC10432851/) Lenzilumab remains under investigation in clinical trials for preventing CRS and neurotoxicity in CAR-T therapy.\\\"\",\"evidenceSource\":\"[](https://pmc.ncbi.nlm.nih.gov/articles/PMC10432851/) (2023 J Exp Med); ongoing trials per clinical sources.\"}],\"slug\":\"Cytokine_release_syndrome\",\"title\":\"Cytokine release syndrome\",\"content\":\"$1f\",\"description\":\"Cytokine release syndrome\\n\\n| Attribute | Details |\\n|--------------------|-------------------------------------------------------------------------|\\n| Other names | Infusion-related reaction (IRR),...\",\"metadata\":{\"categories\":[\"CRS\",\"Cytokine storm\"],\"lastModified\":\"1761552986\",\"contentLength\":\"15698\",\"version\":\"1.0\",\"lastEditor\":\"system\",\"language\":\"en\",\"isRedirect\":false,\"redirectTarget\":\"\",\"isWithheld\":false},\"stats\":{\"totalViews\":\"40738\",\"recentViews\":\"40738\",\"dailyAvgViews\":1357.933349609375,\"qualityScore\":1,\"lastViewed\":\"1761886731\"},\"linkedPages\":null},\"found\":true},\"dataUpdateCount\":1,\"dataUpdatedAt\":1761886731573,\"error\":null,\"errorUpdateCount\":0,\"errorUpdatedAt\":0,\"fetchFailureCount\":0,\"fetchFailureReason\":null,\"fetchMeta\":null,\"isInvalidated\":false,\"status\":\"success\",\"fetchStatus\":\"idle\"},\"queryKey\":[\"page\",\"Cytokine_release_syndrome\"],\"queryHash\":\"[\\\"page\\\",\\\"Cytokine_release_syndrome\\\"]\"}]},\"children\":\"$L20\"}]\n"])</script><script nonce="ZTYwMmJhNmYtNzA2Mi00ODJjLTkyZWMtZTEyMjYyYjIxODZj">self.__next_f.push([1,"c:{\"metadata\":[[\"$\",\"title\",\"0\",{\"children\":\"Cytokine release syndrome\"}],[\"$\",\"meta\",\"1\",{\"name\":\"description\",\"content\":\"In immunology, cytokine release syndrome (CRS) is a form of systemic inflammatory response syndrome (SIRS) that can be triggered by a variety of factors such as infections and certain drugs.[3] CRS is a type of cytokine storm syndrome (CSS)[4] and occurs when large numbers of white blood cells are activated and release inflammatory cytokines, which in turn activate yet more white blood cells. CRS is also an adverse effect of some monoclonal antibody medications, as well as adoptive T-cell...\"}],[\"$\",\"meta\",\"2\",{\"name\":\"author\",\"content\":\"system\"}],[\"$\",\"link\",\"3\",{\"rel\":\"manifest\",\"href\":\"/manifest.webmanifest\",\"crossOrigin\":\"$undefined\"}],[\"$\",\"meta\",\"4\",{\"name\":\"keywords\",\"content\":\"CRS, Cytokine storm\"}],[\"$\",\"meta\",\"5\",{\"name\":\"robots\",\"content\":\"index, follow\"}],[\"$\",\"meta\",\"6\",{\"name\":\"googlebot\",\"content\":\"index, follow, max-snippet:-1\"}],[\"$\",\"link\",\"7\",{\"rel\":\"canonical\",\"href\":\"https://grokipedia.com/page/Cytokine_release_syndrome\"}],[\"$\",\"meta\",\"8\",{\"property\":\"og:title\",\"content\":\"Cytokine release syndrome\"}],[\"$\",\"meta\",\"9\",{\"property\":\"og:description\",\"content\":\"In immunology, cytokine release syndrome (CRS) is a form of systemic inflammatory response syndrome (SIRS) that can be triggered by a variety of factors such as infections and certain drugs.[3] CRS is a type of cytokine storm syndrome (CSS)[4] and occurs when large numbers of white blood cells are activated and release inflammatory cytokines, which in turn activate yet more white blood cells. CRS is also an adverse effect of some monoclonal antibody medications, as well as adoptive T-cell...\"}],[\"$\",\"meta\",\"10\",{\"property\":\"og:url\",\"content\":\"https://grokipedia.com/page/Cytokine_release_syndrome\"}],[\"$\",\"meta\",\"11\",{\"property\":\"og:site_name\",\"content\":\"Grokipedia\"}],[\"$\",\"meta\",\"12\",{\"property\":\"og:locale\",\"content\":\"en\"}],[\"$\",\"meta\",\"13\",{\"property\":\"og:image\",\"content\":\"https://grokipedia.com/icon-512x512.png\"}],[\"$\",\"meta\",\"14\",{\"property\":\"og:image:width\",\"content\":\"512\"}],[\"$\",\"meta\",\"15\",{\"property\":\"og:image:height\",\"content\":\"512\"}],[\"$\",\"meta\",\"16\",{\"property\":\"og:image:alt\",\"content\":\"Cytokine release syndrome\"}],[\"$\",\"meta\",\"17\",{\"property\":\"og:type\",\"content\":\"article\"}],[\"$\",\"meta\",\"18\",{\"property\":\"article:modified_time\",\"content\":\"1970-01-21T09:19:12.986Z\"}],[\"$\",\"meta\",\"19\",{\"name\":\"twitter:card\",\"content\":\"summary\"}],[\"$\",\"meta\",\"20\",{\"name\":\"twitter:creator\",\"content\":\"@Grokipedia\"}],[\"$\",\"meta\",\"21\",{\"name\":\"twitter:title\",\"content\":\"Cytokine release syndrome\"}],[\"$\",\"meta\",\"22\",{\"name\":\"twitter:description\",\"content\":\"In immunology, cytokine release syndrome (CRS) is a form of systemic inflammatory response syndrome (SIRS) that can be triggered by a variety of factors such as infections and certain drugs.[3] CRS is a type of cytokine storm syndrome (CSS)[4] and occurs when large numbers of white blood cells are activated and release inflammatory cytokines, which in turn activate yet more white blood cells. CRS is also an adverse effect of some monoclonal antibody medications, as well as adoptive T-cell...\"}],[\"$\",\"meta\",\"23\",{\"name\":\"twitter:image\",\"content\":\"https://grokipedia.com/icon-512x512.png\"}],[\"$\",\"link\",\"24\",{\"rel\":\"icon\",\"href\":\"/favicon.ico\",\"type\":\"image/x-icon\",\"sizes\":\"16x16\"}],[\"$\",\"$L21\",\"25\",{}]],\"error\":null,\"digest\":\"$undefined\"}\n"])</script><script nonce="ZTYwMmJhNmYtNzA2Mi00ODJjLTkyZWMtZTEyMjYyYjIxODZj">self.__next_f.push([1,"11:\"$c:metadata\"\n"])</script><script nonce="ZTYwMmJhNmYtNzA2Mi00ODJjLTkyZWMtZTEyMjYyYjIxODZj">self.__next_f.push([1,"22:I[61172,[\"8739\",\"static/chunks/63f0ec43-8ee6a76d70472249.js\",\"2254\",\"static/chunks/8208b75a-a48e5a4507a0de91.js\",\"4684\",\"static/chunks/24cf1b50-159cca90b09285e0.js\",\"1829\",\"static/chunks/9ffa21ba-c069766d809bd4c7.js\",\"7670\",\"static/chunks/7670-7326298c9856172b.js\",\"282\",\"static/chunks/282-691fffb366e24ca5.js\",\"7515\",\"static/chunks/7515-336759ef5dad2b52.js\",\"5497\",\"static/chunks/5497-ab85ef3ea59dd353.js\",\"7720\",\"static/chunks/7720-3a1e7e411adba2d3.js\",\"6281\",\"static/chunks/6281-c6e84786dade3614.js\",\"7086\",\"static/chunks/7086-1f1c4891d766e04f.js\",\"600\",\"static/chunks/600-9a9fcafaaa6c1c4c.js\",\"5002\",\"static/chunks/5002-9735c25beda556ba.js\",\"5448\",\"static/chunks/5448-2a3cfd853d899c9a.js\",\"5855\",\"static/chunks/5855-243eeca8f0e4cabd.js\",\"4393\",\"static/chunks/4393-1c8dff25ec904469.js\",\"9214\",\"static/chunks/9214-a10614844a67ba31.js\",\"8\",\"static/chunks/8-8ca70ca619d8e099.js\",\"4789\",\"static/chunks/4789-2080f6497f78b5b6.js\",\"6304\",\"static/chunks/app/page/%5Bslug%5D/page-540a27b6839afde5.js\"],\"PageEditorProvider\"]\n"])</script><script nonce="ZTYwMmJhNmYtNzA2Mi00ODJjLTkyZWMtZTEyMjYyYjIxODZj">self.__next_f.push([1,"23:I[63493,[\"8739\",\"static/chunks/63f0ec43-8ee6a76d70472249.js\",\"2254\",\"static/chunks/8208b75a-a48e5a4507a0de91.js\",\"4684\",\"static/chunks/24cf1b50-159cca90b09285e0.js\",\"1829\",\"static/chunks/9ffa21ba-c069766d809bd4c7.js\",\"7670\",\"static/chunks/7670-7326298c9856172b.js\",\"282\",\"static/chunks/282-691fffb366e24ca5.js\",\"7515\",\"static/chunks/7515-336759ef5dad2b52.js\",\"5497\",\"static/chunks/5497-ab85ef3ea59dd353.js\",\"7720\",\"static/chunks/7720-3a1e7e411adba2d3.js\",\"6281\",\"static/chunks/6281-c6e84786dade3614.js\",\"7086\",\"static/chunks/7086-1f1c4891d766e04f.js\",\"600\",\"static/chunks/600-9a9fcafaaa6c1c4c.js\",\"5002\",\"static/chunks/5002-9735c25beda556ba.js\",\"5448\",\"static/chunks/5448-2a3cfd853d899c9a.js\",\"5855\",\"static/chunks/5855-243eeca8f0e4cabd.js\",\"4393\",\"static/chunks/4393-1c8dff25ec904469.js\",\"9214\",\"static/chunks/9214-a10614844a67ba31.js\",\"8\",\"static/chunks/8-8ca70ca619d8e099.js\",\"4789\",\"static/chunks/4789-2080f6497f78b5b6.js\",\"6304\",\"static/chunks/app/page/%5Bslug%5D/page-540a27b6839afde5.js\"],\"default\"]\n"])</script><script nonce="ZTYwMmJhNmYtNzA2Mi00ODJjLTkyZWMtZTEyMjYyYjIxODZj">self.__next_f.push([1,"20:[\"$\",\"$L22\",null,{\"children\":[\"$\",\"$L23\",null,{\"slug\":\"Cytokine_release_syndrome\"}]}]\n"])</script></body></html>